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CXCL10, an IFN-γ-induced chemokine, is required for the development of depigmentation in
a mouse model of vitiligo
M Rashighi,1 P Agarwal,1 TH Harris,2 A Deng,1 CA Hunter2 and JE Harris1 1 University of
Massachusetts Medical School, Worcester, MA and 2 University of Pennsylvania, Philadelphia,
PA
Our goal was to determine how the cytokine IFN-γ promotes depigmentation in vitiligo. Vitiligo is
an autoimmune disease that results in depigmentation of the epidermis and is caused by CD8+ T
cell destruction of melanocytes. IFN-γ is expressed in lesional skin from patients with vitiligo, lead-
ing to the hypothesis that IFN-γ was required for disease pathogenesis. To test this hypothesis, we
developed a new mouse model of vitiligo through adoptive T cell transfer that develops focused epi-
dermal depigmentation. We found that IFN-γ was critical for depigmentation and for autoreactive
T cell accumulation in the skin. Chemokines are secreted proteins that promote immune cell migra-
tion to peripheral tissues. RT-PCR on lesional skin from mice with vitiligo revealed a >50-fold induc-
tion of the IFN-γ-dependent chemokines, CXCL9 and CXCL10. CXCR3, their common receptor, is
expressed on melanocyte-specific CD8+ T cells in the blood. Eliminating expression in these cells
using CXCR3 knockout mice reduced the severity of vitiligo by 4-fold (p =0.0007), and reduced the
ability of T cells to migrate to the skin by 5-fold (p = 0.01), however total numbers of these cells
were equal to wild-type (WT) T cells in skin-draining lymph nodes (p = 0.87). When CXCL10-defi-
cient mice were used as hosts for vitiligo induction, depigmentation did not occur (score of 0),
compared to a score of 9.6 in WT control hosts (p = 0.0003). In parallel, CXCL10 neutralizing anti-
body treatment starting 2 weeks after vitiligo induction in WT hosts reduced the vitiligo score 4-
fold compared to controls (p = 0.002). CXCL9 appeared to play a less-critical role. Importantly,
CXCL9 and CXCL10 are expressed in lesional skin from patients with vitiligo, and CXCR3 is expressed
on T cells that infiltrate affected skin. These findings reveal a critical role for the IFN-γ-chemokine
axis in the pathogenesis of vitiligo, and support a strategy of targeting this axis for the development
of new treatments.
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Cutaneous expression of neutrophil elastase in relation to IgG autoantibodies to desmogleins
1 and 3 in pemphigus foliaceus and pemphigus vulgaris
M Dmochowski,1 J Gornowicz-Porowska,1 A Seraszek-Jaros,2 E Kaczmarek,2 PP Pietkiewicz1 and
M Bowszyc-Dmochowska1 1 Dermatology, University of Medical Sciences, Poznan, Poland
and 2 Bioinformatics & Computational Biology, University of Medical Sciences, Poznan,
Poland
Pemphigus foliaceus (PF) together with mucosal-dominant and mucocutaneous varieties of pem-
phigus vulgaris (PV) form, imaginably, a continuum within autoimmunity-mediated acantholytic
dermatoses. Inflammation seems to play certain role in their cutaneous pathology albeit its degree
varies substantially among individual PF/PV cases. Here, we examined whether in PF/PV lesional
skin the expression of neutrophil elastase (NE), chosen as a biomarker of cutaneous inflammation,
is related to IgG autoantibodies to desmoglein 1 (DSG1) and desmoglein 3 (DSG3). Altogether, 28
PF/PV patients, as well as 24 dermatitis herpetiformis (DH) and 27 bullous pemphigoid (BP) con-
trol patients were studied. The intensity of NE expression, visualized with immunohistochemical
streptavidin-peroxidase technique on paraffin-embedded sections, was measured using quantita-
tive digital morphometry and levels of serum IgG autoantibodies to DSG1 (IgG DSG1) and DSG3
(IgG DSG3) were evaluated with ELISA. The mean intensity of expression of NE in both PF/PV and
BP was significantly lower than that in DH (both p=0.001), but it was not significantly different in
PF/PV and BP. There were no significant correlations between intensity of expression of NE and lev-
els of either IgG DSG1 or IgG DSG3 in PF/PV. There was no significant correlation between levels
of IgG DSG1 and IgG DSG3 in PV. Thus, it seems that in PV IgG DSG1 and IgG DSG3 are produced
in an uncoordinated way. Our results corroborate the notion that in PF/PV the role of NE-releasing
cutaneous neutrophils, activation of which conceivably might be unrelated to PF/PV-type autoim-
munity, has lesser pathologic importance compared to DH. Taking together, this NE expression com-
parative study further implies that not only inflammatory processes in PF/PV but also in BP, in
which an intra-lamina lucida separation is forming like in DH, are distinct from those in DH.
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Decreased expression of acetylcholine esterase in cholinergic urticaria
Y Sawada,1 M Nakamura,1 R Kubo,1 R Hino,1 M Kobayashi,1 T Bito2 and Y Tokura3 1 Department
of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan, 2
Division of Dermatology, Department of Clinical Molecular Medicine, Faculty of Medicine,
Kobe University Graduate School of Medicine, Kobe, Japan and 3 Department of
Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Cholinergic urticaria is a rare condition clinically characterized by pinpoint-sized, highly pruritic
wheals and is typically provoked by stimulation such as exercise. We have recently reported that
the expression of the cholinergic receptor M3 is decreased in sweat glands in cholinergic urticaria
with hypohidrosis. However, the degradation condition of acetylcholine remains unclear in this
disease. In 12 patients with cholinergic urticarial, we investigated the expression of acetylcholine
esterase, an acetylcholine degrading enzyme, in nerves around sweat glands. Intradermal acetyl-
choline injections induced both sweating and wheals in all 12 patients. Biopsy specimens taken
from the exercise-induced urticarial site showed infiltration of a mixture of CD4+ and CD8+ T cells
around eccrine glands. Immunohistochemical study demonstrated that the expression of acetyl-
choline esterase by nerves around sweat glands decreased in the exercise-induced urticarial site as
compared to the non-urticarial site, whereas the production of monocyte chemotactic protein-1
(MCP-1) increased around sweat glands. Real-time PCR analysis revealed the reduction of acetyl-
choline esterase mRNA in the urticarial lesions compared to the non-affected lesions. Our results
suggest that acetylcholine overflows from adjacent nerve-eccrine gland complex due to the decreased
production of acetylcholine esterase, leading to histamine release and wheal induction. The increased
production of chemokines, such as MCP-1, around eccrine glands may induce the lymphocytic infil-
tration, which might downmodulate the expression of acetylcholine esterase.
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Genome-wide analyses of generalized vitiligo identify 31 loci that define an interacting net-
work of melanocyte-specific and immunoregulatory proteins
RA Spritz Human Medical Genetics and Genomics Program, University of Colorado School
of Medicine, Aurora, CO
Generalized vitiligo is a complex disease in which patches of depigmented skin and hair result
from autoimmune destruction of epidermal melanocytes, epidemiologically associated with several
other autoimmune diseases. By genome-wide linkage and genome-wide association studies of
generalized vitiligo, we have identified 31 loci that contribute to vitiligo susceptibility, accounting
for ~14% of total risk. Most of these genes encode immunoregulatory proteins, several of which are
also associated with other autoimmune diseases. However, a few vitiligo susceptibility genes, includ-
ing TYR, OCA2, and MC1R, encode melanocyte components. DNA re-sequencing and functional
analyses of causal variants indicate that TYR, OCA2, and HLA-A likely mediate vitiligo susceptibil-
ity, and opposite genetic susceptibulity to melanoma, by modulating immune recognition and tar-
geting of melanocytes, whereas NLRP1 mediates vitiligo susceptibility by modulating inflammatory
responses. Most of the 31 vitiligo susceptibility loci thus far identified comprise an functional inter-
action network that stretches from the melanocyte to the immune system. Whereas dysregulation
of this system results in autoimmune destruction of melanocytes in vitiligo, the same system may
serve a normal role in immune surveillance of malignant melanoma.
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Visfatin enhances human β-defensin-2, human β-defensin-3, LL-37, and S100A7 production
in human keratinocytes and murine skin
N Kanda,1 CS Hau,2 Y Tada,2 S Sato2 and S Watanabe1 1 Dermatology, Teikyo University School
of Medicine, Tokyo, Japan and 2 Dermatology, Faculty of Medicine, University of Tokyo,
Tokyo, Japan
Psoriasis patients are frequently associated with metabolic syndromes, indicating the involvement
of adipokines in the pathogenesis of psoriasis. We recently found that visfatin (an adipokine) enhances
TNF-α-induced chemokine production in keratinocytes via activation of NF-κB and STAT3. In pso-
riasis lesions, the expression of antimicrobial peptides is enhanced, which may promote the devel-
opment of psoriasis. We herein investigated the effects of visfatin on antimicrobial peptide expres-
sion in human keratinocytes and murine imiquimod-induced psoriasis-like skin inflammation. Visfatin
in vitro enhanced basal and TNF-α-induced LL-37 secretion and cathelicidin (LL-37 precursor) mRNA
levels, and enhanced TNF-α-induced human β-defensin (hBD)-2, hBD-3, and S100A7 secretion and
mRNA levels in human keratinocytes. siRNA against C/EBPα suppressed the visfatin or visfatin plus
TNF-α-induced production of LL-37; siRNAs against NF-κB p65 and STAT3 suppressed the visfatin
plus TNF-α-induced production of hBD-2; siRNAs against c-Jun and STAT3 suppressed the visfatin
plus TNF-α-induced production of hBD-3; siRNAs against p65 and STAT3 suppressed the visfatin
plus TNF-α-induced production of S100A7. Visfatin enhanced basal and TNF-α-induced C/EBP tran-
scriptional activities and C/EBPα phosphorylation, which were suppressed by p38 MAPK inhibitor.
Visfatin did not alter basal or TNF-α-induced AP-1 activities. Visfatin enhanced basal and TNF-α-
induced p38 MAPK phosphorylation. Intraperitoneal injection of visfatin increased mRNA and
protein levels of cathelicidin, mDEFB4, mDEFB14, mS100A15, murine homologs of cathelicidin,
hBD-2, hBD-3, and S100A7, respectively, in imiquimod-treated back skin of mice. These results
suggest that visfatin enhances LL-37, hBD-2, hBD-3, and S100A7 production in human keratinocytes
and homologous antimicrobial peptide production in murine imiquimod-treated skin. Visfatin may
link metabolic syndromes to psoriasis via induction of antimicrobial peptides.
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IL-36 cytokines are over-expressed in psoriasis, induce keratinocyte chemokine expression
and alter antigen-presenting cell phenotype and function
CS Chen, AM Guzman, PM Al-Attar, AM Foster, X Xing, M Riblett, JE Gudjonsson and A Johnston
Dermatology, University of Michigan, Ann Arbor, MI
The new IL-1 family members IL-36α (IL-1F6), IL-36β (IL-1F8) and IL-36γ (IL-1F9) and the receptor
antagonist IL-36Ra (IL-1F5) constitute a novel signaling system that is poorly understood. We have
recently demonstrated that expression of IL-36α, IL-36β, IL-36γ and IL-36Ra were increased 2-3
orders of magnitude in plaque psoriasis vs. symptomless skin and treatment of psoriasis led to sig-
nificantly decreased IL-36α (p<0.0001), IL-36β (p<0.0001) and IL-36γ (p<0.0001) mRNAs, con-
comitant with clinical improvement. We now show that these cytokines have profound effects on
the skin immune system. Treatment of normal human keratinocytes with IL-36α or IL-36β signifi-
cantly increased the expression of CCL3 (112-fold increased with IL-36α, p<0.05), CCL4 (309-,
p<0.001), CCL5 (137-, p<0.001), CCL20 (615-, p<0.01), CXCL1 (55-, p<0.01), CXCL9 (9-, p<0.05),
CXCL10 (280-, p<0.01) and CXCL11 (55-fold, p<0.05), potent chemotactic agents for activated T
cells and monocytes. Blood monocytes expressed IL-36R and expressed IL-1A, IL-1B and IL-6 mRNA
and secreted IL-6 protein in response to IL-36 cytokines. In contrast, no direct effects of IL-36 on
resting or activated CD4+ or CD8+ blood T cells could be demonstrated. Monocyte-derived den-
dritic cells (MO-DC) expressed 6-fold more IL-36R mRNA than precursor monocytes (p<0.05), and
in response to IL-36α, upregulated their surface expression of HLA-DR (1.7-fold, p=0.008) and CD86
(2.9-fold, p=0.019), two molecules crucial for antigen presentation to T-cells. Further, when cul-
tured with allogeneic CD4+ T cells, IL-36α-matured MO-DC enhanced T cell proliferation, demon-
strating that IL-36 can stimulate the maturation and functional capacity of DC. These data support
the view that IL-36 cytokines actively propagate skin inflammation by recruiting inflammatory cells
into skin via keratinocyte chemokine expression and activating antigen presenting cells and, indi-
rectly, T cells leading to a pro-inflammatory environment in skin.
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A natural biotechnological active ingredient dedicated to skin troubles management
C Baudouin, S Leclere-Bienfait, S Garnier, J Rocheteau, S Bredif, S Debrock, A Saunois and
P Msika Innovation R&D, Laboratoires Expanscience, Epernon, France
The Proteinase-Activated Receptor-2 (PAR-2) is a G-protein coupled receptor that can be activated
by a variety of proteinases (endogenous or produced by allergens and pathogens). PAR-2 is abun-
dantly expressed in the skin. Over time, numerous studies and data allowed to confirm the role of
PAR-2 in skin physiology but also in skin pathology and suggest that PAR-2 might be a potent ther-
apeutic target. We have developed specific peptides from an original vegetal source of protein,
Quinoa – Chenopodium quinoa. This active ingredient was developed according a biotechnologi-
cal process, in compliance with our sustainable policy. The final and patented ingredient is secured
and optimised containing a high peptides concentration at specific molecular weights distribution.
As gene expression of PAR-2 was reduced by these natural patented peptides, their in vitro effects
on cutaneous inflammation were investigated. Quinoa peptides were able to significantly reduce
aspecific inflammatory mediators in inflamed-keratinocytes model: IL1alpha (basal level), IL8 (-
61%), PGE2 (-94%), VEGF (-49%) and NF-kappaB (translocation inhibition) and to limit neuro-
genic inflammation in mast cells (histamine; -84%). Secondly we have evaluated the Quinoa pep-
tides activity on skin barrier and especially by following gene expression of differentiation and
cornified envelope markers, corneodesmosomes and also by measuring moisturizing factors. In ker-
atinocytes treated with Quinoa peptides, gene expression of K1, K10 (X7, X3.5), loricrin, involucrin
(X2.8, X2.3) and desmoglein-1 were significantly stimulated and hyaluronic acid (+149%) and GAGs
production were highly enhanced. Patented Quinoa peptides from natural biotechnology have shown
a specific and wide spectrum of activity on inflammation and skin barrier. Thus they could be of
interest in the management of skin troubles involving PAR-2 such as pruritus, skin hyperreactivity
and allergy, atopic dermatitis, acne, hyperpigmentation.
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Inhibition of the SDF-1/CXCR4 axis alleviates chronic and acute skin inflammation
S Zgraggen, R Huggenberger, A Ochsenbein and M Detmar Institute of Pharmaceutical
Sciences, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland
Recent studies indicate that the SDF-1/CXCR4 axis may be involved in the pathogenesis of several
inflammatory diseases. However, it is not known whether this chemokine axis also plays a role in
inflammatory skin diseases. This study was aimed at evaluating the relevance of the SDF-1/CXCR4
interaction in the initiation or maintenance of chronic and acute cutaneous inflammation. We found
that CXCR4 and SDF-1 were significantly up-regulated during inflammation in the established ker-
atin 14 (K14) VEGF-A transgenic (tg) mouse model of chronic cutaneous inflammation and that
CXCR4 is expressed on different inflammatory cells in the inflamed ear skin, including dendritic
cells and macrophages. To investigate the functional importance of the SDF-1/CXCR4 axis in vivo,
we inhibited CXCR4 signaling by AMD3100, a specific CXCR4 antagonist, and by a neutralizing
anti-SDF-1 antibody in the K14-VEGF-A tg mice. Both treatments significantly reduced inflamma-
tory edema formation and inflammatory cell infiltration in the inflamed ear skin. Moreover, we found
that in the inflamed ear skin, CXCR4 was only expressed on blood vessels but not on lymphatic
vessels and that inflammatory angiogenesis was significantly reduced by inhibiting CXCR4 signal-
ing. Furthermore, incubation with AMD3100 or anti-SDF-1 antibody inhibited SDF-1 induced chemo-
taxis of CD11b+ splenocytes in vitro. Finally, we investigated the role of the SDF-1/CXCR4 axis in
acute skin inflammation using FVB wild-type mice. Shortly after the induction of an oxazolone-
induced skin inflammation, AMD3100 treatment was started. Inhibition of the CXCR4 signaling
significantly limited acute skin inflammation with a reduction in dermal edema formation. Taken
together, these results demonstrate that inhibition of the CXCR4/SDF-1 axis might serve as a novel
strategy to treat patients with inflammatory skin disorders such as psoriasis.
009
Antibodies against desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foli-
aceus are mostly against the precursor molecule
A Toumi,1 MA Saleh,2,3 J Yamagami,2 O Abida,1 M Kallel,1 A Masmoudi,5 S Makni,4 H Turki,5
T Hachiya,6 K Kuroda,6 JR Stanley,7 H Masmoudi1 and M Amagai2 1 Immunology, Habib
Bourguiba Hospital, Sfax, Tunisia, 2 Dermatology, Keio. Univ., Tokyo, Japan, 3 Dermatology,
Cairo. Univ., Cairo, Egypt, 4 Immunology, Rabta Hospital, Tunis, Tunisia, 5 Dermatology, Hédi
Chaker Hospital, Sfax, Tunisia, 6 MBL Co. Ltd., Nagoya, Japan and 7 Dermatology, Univ. of
Penn, Philadelphia, PA
Desmoglein 1 (Dsg1), pemphigus foliaceus (PF) antigen, is produced as a precursor form (preDsg1)
and is transported to the cell surface as the mature form (matDsg1). Recent studies have found
preDsg1-specific B cell clones, but not antibodies, in people without PF. However, in Tunisia, where
PF is endemic, anti-Dsg1 IgGs are frequently detected in healthy individuals by ELISA (which detects
both preDsg1 and matDsg1 antibodies) but not immunofluorescence (IF). We hypothesized that
these anti-Dsg1 antibodies are directed against preDsg1, which would account for their negative
cell surface staining by IF and would be consistent with a preclinical phase of PF in this endemic
area. We tested this idea by immunoprecipiation/immunoblotting against preDsg1 and matDsg1
with sera from healthy Tunisians and PF patients, and characterized their epitopes using domain-
swapped Dsg1/Dsg2 molecules. Normal Tunisians with anti-Dsg1 IgGs (n=16) reacted to preDsg1
alone (8/16) or more strongly to preDsg1 than to matDsg1 (7/16), while those from all Tunisian PF
patients (n=9) and Japanese non-endemic PF patients (n=9) reacted similarly to preDsg1 and matDsg1,
or preferentially to matDsg1. The epitopes recognized by anti-preDsg1 IgGs from normal Tunisians
were more frequently found in the C-terminal extracellular domains (EC3 to EC5) of Dsg1, while
those in Tunisian PF patients were widely distributed throughout the extracellular domain, suggesting
IgGs against EC1 and EC2 developed during disease progression. These findings suggest that devel-
opment of anti-preDsg1 antibodies may be an early step in PF disease progression.
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Preclinical anti-inflammatory activity of SIG1311, a candidate for the topical treatment of
atopic dermatitis
JR Fernandez,1 E Perez,1 M Voronkov,1,2 K Rouzard,2,1 M Stock,2,1 JS Gordon1 and B Shroot1 1
Argyle Therapeutics, Monmouth Junction, NJ and 2 Signum Biosciences, Monmouth Junction,
NJ
There is a need for safe and effective therapeutic agents for the treatment of atopic dermatitis (AD),
whose prevalence is increasing. We have previously shown (SID 2011 Poster #57) cytokine signal-
ing through G-Protein Coupled Receptor (GPCR) and Toll-Like Receptor (TLR) signaling is markedly
inhibited by isoprenylcysteine (IPC) analogs, structural mimics of the lipidated C-termini of the
Gγsubunit of all heterotrimeric G-proteins and small G-proteins. G-proteins elicit the release of
pro-inflammatory mediators, and the migration and activation of inflammatory cells. We propose
the use of the novel IPC analog SIG1311 in AD in the light of its activity in multiple cell-based assays
targeting key pro-inflammatory cytokines that drive AD pathogenesis. In a mixed human T-Cells
system (PBMCs) we show SIG1311 inhibits Th2 and Th17 cytokine release elicited by CD3/CD28
activation. Furthermore, SIG1311 abrogates a nickel (Ni2+)-TLR4 response in endothelial cells as
estimated by inhibition of IL-6 and IL-8. Lastly, in keratinocytes (NHEKs), SIG1311 inhibits chemi-
cally-induced release of two key mediators of dermal inflammation (IL-8 and TNFα). These data are
supported in vivo as we demonstrate dose dependant anti- inflammatory activity of SIG1311 in the
mouse ear TPA inflammation model, and two delayed type hypersensitivity (DTH) mouse models
(oxazolone (OXA) and dinitrofluorobenzene (DNFB) sensitization). Based on these findings, we have
selected SIG1311 as a development candidate and plan to commence preclinical safety evaluations
towards an investigational new drug (IND) submission for treatment of AD.
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Signaling through the P2X7 receptor for ATP induces psoriasis-like inflammation: A human
skin model
AR Mathers,1,2 ME Killeen,1 L Ferris1 and L Falo, Jr.1 1 Dermatology, University of Pittsburgh Sch.
of Med., Pittsburgh, PA and 2 Immunology, University of Pittsburgh Sch. of Med., Pittsburgh,
PA
Current therapeutics for psoriasis includes the use of systemic acting immuno-suppressive drugs;
however, long-term effects of these treatments remain a concern. A better understanding of the mech-
anism(s) involved in psoriasis pathogenesis is highly relevant for developing refined therapeutics.
However, the immunological processes that perpetuate psoriatic lesions from non lesional skin are
not well known. It is likely that alarmins, such as ATP, play a pivotal role in the pathogenesis by
positive-feedback inflammatory mechanisms that break immunological self-tolerance and perpet-
uate immune responses. We have demonstrated the increased presence of P2X7R, an ATP recep-
tor, in lesional and non lesional psoriatic skin, suggesting a principal difference in skin of psoriasis
patients and not just a change due to inflammation. Mechanistically, utilizing human cutaneous
models, we determined that signaling via P2X7R initiates psoriasis-like inflammation in skin by
mechanisms that include inflammatory innate immunity, DC17 differentiation, and the induction
of Th17 biased responses. Furthermore, our results define a prospective role for P2X7R signaling in
perpetuating psoriasis lesions by stimulating the mir-21/VEGF pathway. In conclusion, we have
begun to describe a potential mechanism of psoriasis lesional formation in humans, which will con-
tribute to understanding the pathogenesis of psoriasis and lead to the development of refined ther-
apeutics.
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The in vitro effects of neuropeptides and bicyclic monoterpene diol on the inflammatory path-
way using primary human keratinocytes
CY Ding, Y Ee, AR Shalita and WS Lee Dermatology, SUNY-Downstate Medical Ctr., Brooklyn,
NY
Substance P (SP) has been suggested to be a critical player and modulator of itch in atopic dermatitis
(AD) via its receptor NK-1. IL-31, a T cell cytokine, has also been shown to induce pruritis in those
with AD via its main receptor IL-31RA, while the downstream pathway of the receptor remains
unclear. Previous data showed that bicyclic monoterpene diols (BMTd) and SP both upregulate iNOS
levels and are also known to increase skin vascular temperature. The objective of this study is to
further examine the possible roles and relationship of BMTd and neuropeptides (NP) in inflamma-
tory processes using human primary keratinocytes (NHEK). NHEKs were treated with BMTd, SP, and
calcitonin-gene related protein (CGRP) with or without BMTd for 48 hours. Cytoplasmic levels of
NK-1, IL-31RA, and NF-κΒ p105 were assessed using Western blot and NIH Image J. The levels of
LTB4, IL-1α, IL-1β, IL-8 and TNF-α were analyzed via ELISA. Our preliminary data indicated that
BMTd caused a ten-fold decrease in the measurable density of IL-31RA, with similar decreases
seen in NK-1 and NF-κΒ p105 levels. Interestingly, when treated with BMTd and moderate doses
of NPs, its effects are returned to baseline. There were notable increases in IL-1α, IL-1β, and TNF-
α levels of 25%, 50%, and 45%, respectively, when treated with a combination of BMTd and SP.
We observed similar changes in IL-8 and LTB4 when treated with the combination of CGRP+BMTd.
The data suggests that BMTd may play a role in modulating cytokine levels in the skin by working
in conjunction with NPs present in skin. BMTd showed a specific modulating effect on the activa-
tion of the NF-κB transcription pathway, which has been associated with the pathogenesis of many
inflammatory diseases including AD. We conclude that BMTd may be a therapeutic molecule that
might have an anti-pruritic and anti-inflammatory effect by modifying the inflammatory signal
pathway related to its effect on NK-1, NF-κΒ, or IL-31RA. These findings pave the way for future
applications of BMTd as a modulator of the inflammatory response.
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IL-4 up-regulates epidermal IL-19 expression in atopic dermatitis
L Bao,1 J Alexander,1 VY Shi1 and LS Chan1,2,3 1 Dermatology, University of Illinois at Chicago,
Chicago, IL, 2 Microbiology/Immunology, University of Illinois at Chicago, Chicago, IL and 3
Medical Service, Jesse Brown VA Med Center, Chicago, IL
IL-19 plays an important role in the pathogenesis of asthma by inducing Th2 cytokines from acti-
vated T cells. Interestingly, IL-4 and IL-13 also up-regulate IL-19 expression in airway epithelia, thus
forming a positive feedback loop. In atopic dermatitis (AD), another Th2 disease closely related to
asthma, IL-19 was reported to be up-regulated in the skin. We aimed to use IL-4 transgenic (Tg)
mice, a well established AD animal model, as well as HaCat cells, a keratinocyte line, to delineate
the molecular mechanisms involved in the up-regulation of IL-19 in AD. Consistent with the clini-
cal findings in human AD, we found that IL-19 is up-regulated in the skin of IL-4 Tg mice as com-
pared to non-Tg littermates. Next we treated HaCat cells with various concentrations of IL-4 and
performed real-time PCR to examine IL-19 expression. IL-4 up-regulates IL-19 expression in a dose
dependent manner. Interestingly, the up-regulation was suppressed by Jak kinse inhibitors, suggesting
that Jak kinases may play roles in the regulation of IL-19 by IL-4 in keratinocytes. Eight IL-19 pro-
moters, different in length, were cloned into the upstream of a firefly luciferase and were used to
transfect HaCat cells. Renilla luciferase was used as an internal reference to normalize transfection
efficiency. Seventeen hours after transfection, the transfected cells were treated with IL-4 or vehi-
cle. Our data located the IL-4 response elements between -2500 and -2000 bp of the IL-19 pro-
moter. Subsequent mutagenesis studies will delineate the exact location of the IL-4 response ele-
ments. Taken together, we have found that IL-19 is up-regulated in the skin of IL-4 Tg mice and that
IL-4 activates IL-19 expression at the transcriptional level through Jak kinases in keratinocytes.
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Identification of cytotoxic T cell epitopes in alopecia areata
E Wang,1 JP Dutz,1,2 J Shapiro2 and KJ McElwee1 1 Dermatology and Skin Science, University
of British Columbia, Vancouver, BC, Canada and 2 Dermatology and Skin Science, Vancouver
General Hospital, Vancouver, BC, Canada
Alopecia areata (AA), a non-scarring, inflammatory hair loss disease, is believed to involve an autoim-
mune mechanism. Both human studies and rodent models have shown that CD4 T cells and cyto-
toxic CD8 T cells (CTLs) play a crucial role in the onset and progression of AA. It is suspected that
antigen epitopes originating in hair follicle (HF) keratinocytes and/or melanocytes may be CTL tar-
gets. However, the exact epitopes targeted by auto-reactive CTLs in AA have not yet been identi-
fied. We investigated the potential of a panel of epitopes expressed by human HF keratinocytes and
melanocytes to induce activation of CTLs. Peripheral blood mononuclear cell (PBMC) populations
were isolated from AA affected and healthy subjects with HLA-A2 serotypes. CTLs were cultured
with synthesized peptides designed for HLA-A2 specificity with specific sequences for trichohyalin,
cytokeratin 16 (K16), tyrosinase, tyrosinase related protein, melanin, MELAN-A, and GP100. The
frequency of CTL activation in the PBMC population was measured using an enzyme-linked
immunosorbent spot (ELISpot) assay where reactive interferon gamma (IFNg) secreting cells are vis-
ible as spots. Specific epitopes derived from trichohyalin induced significantly greater responses in
human AA CTLs compared to healthy controls. Investigation into the reactivity of AA affected C3H/HeJ
mouse lymph node cells to an equivalent panel of mouse antigen epitopes was carried out in par-
allel. All AA mouse CTL samples displayed significantly increased responses against K16 epitopes
in addition to trichohyalin while no responses were observed from healthy controls’ CTLs, a poten-
tial indication of multiple CTL targets in AA. The data indicate that AA affected subjects present
with an increased frequency of CTLs responsive to antigen epitopes originating from keratinocytes.
Whether these are primary targets in AA remains to be determined.
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Elevated EphA2 in the psoriatic epidermis provides a molecular target for restoring keratinocyte
differentiation
JE Gudjonsson,2 H Blatt,1 K Gordon,1 J Kochkodan,2 A Johnston,2 S Lin,1 P Hoover,1 BJ Schlosser,1
JT Elder2 and S Getsios1 1 Dermatology, Northwestern U., Chicago, IL and 2 Dermatology, U.
Michigan, Ann Arbor, MI
EphA2 is a receptor tyrosine kinase (RTK) that triggers keratinocyte differentiation once it is engaged
by membrane-associated ephrin-A ligands on adjacent cells. Ligand binding of EphA2 leads to kinase
activation and subsequent receptor down-regulation, which occur during normal differentiation.
The objective for this study was to determine if the EphA2/ephrin-A1 signaling axis was altered in
psoriasis, an inflammatory skin condition where keratinocyte differentiation is abnormal. Microar-
ray analysis of 58 paired lesional and non-lesional skin biopsies revealed increased mRNA tran-
scripts for several members of this largest family of RTKs in psoriatic plaques, including the EphA
subtypes most prominently expressed by keratinocytes (i.e. EphA1/2/4). Of these, EphA2 showed
the greatest up-regulation (2.42 fold change; P< 5.04 E-106), a finding that was confirmed by quan-
titative RT-PCR (n=10; P<0.001) and IHC (n=3) analysis. In contrast, psoriatic lesions exhibited
reduced ephrin-A1 ligand expression. Moreover, exposure of primary human keratinocytes or 3-D
raft cultures of human epidermis to a combination of growth factors and/or cytokines elevated in
psoriasis (e.g. EGF+IL-1α, TNFα+IL-17) recapitulated the increase in EphA2 and decrease in ephrin-
A1 levels while also disrupting differentiation and inducing S100A7 expression. We reasoned that
pharmacological delivery of ephrin-A1 ligand might be used to target the enhanced EphA2 in pso-
riatic lesions in order to down-regulate this RTK and normalize differentiation. Accordingly, treat-
ment of keratinocytes with a soluble ephrin-A1-Fc peptidomimetic restored the differentiated phe-
notype of cells exposed to cytokines as assessed by an increase in epidermal proteins expressed in
the suprabasal layers (i.e. keratin 10, desmoglein 1 and loricrin). These findings suggest that ephrin-
A1-mediated regulation of EphA2 signaling can drive keratinocytes into a terminal differentiation
pathway to help overcome cytokine insults.
016
Vaspin as a possible link of obesity and psoriasis
K Vester,1 A Saalbach,1 K Rall,1 J Tremel,1,4 U Anderegg,1 M Averbeck,1 M Bodendorf,1 M Ziemer,1
AG Beck-Sickinger,2,4 M Blüher3,4 and JC Simon1,4 1 Department of Dermatology, Venerology
and Allergology, University of Leipzig, Leipzig, Germany, 2 Institute of Biochemistry, Faculty of
Life Sciences, Pharmacy and Psychology, University of Leipzig, Leipzig, Germany, 3
Department of Medicine, University of Leipzig, Leipzig, Germany and 4 LIFE –Leipzig
Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany
There is a known link of psoriasis with obesity, the metabolic syndrome and the serum levels of
adipokines. Vaspin, a serine proteinase inhibitor of the serpin family, is an adipokine originally
described in adipose tissue of fatty rats at the age when obesity reached the maximum. An exertion
of anti-inflammatory effects of vaspin by inhibiting the expression of the proinflammatory adipokines
and of TNF-α in murine white adipose tissue could be shown. The impact of vaspin on inflamma-
tory skin diseases such as psoriasis is so far unknown. We studied the role of vaspin in psoriasis by
analyzing vaspin serum levels by ELISA as well as vaspin mRNA by RT-PCR and protein expression
by immunohistochemistry in the skin. Within the total study population there were no differences
in serum vaspin levels between healthy controls and psoriatic patients. A correlation was found
between vaspin serum levels and body mass index (BMI) in healthy individuals. Interestingly, no
correlation of vaspin and BMI was detected in psoriatic patients. Furthermore, vaspin serum level
did not correlate with disease activity. Keratinocytes could be identified as the major cell type express-
ing vaspin mRNA in skin. Vaspin protein expression was only detected in the epidermis of healthy
and psoriatic skin. In healthy skin a clear increase of staining intensity was seen during differentia-
tion of keratinocytes. The expression pattern of vaspin was changed in psoriatic skin. Considering
vaspin as a suggested inhibitor of serine proteases, the fine tuned balance of proteases and inhibitors
involved in the desquamation process as well as in the regulation of inflammation may be dis-
turbed in psoriasis and thus, altered vaspin expression might contribute to the maintenance of pso-
riasis.
014
IgG4 as a potential therapeutic target for disease-specific antibodies in pemphigus
L Lunardon,1 T Funakoshi,3 AR Nagler,1 CE O’Leary,1 DM Allman2 and AS Payne1 1 Dermatology,
University of Pennsylvania, Philadelphia, PA, 2 Pathology and Laboratory Medicine, University
of Pennsylvania, Philadelphia, PA and 3 Dermatology, Keio University, Tokyo, Japan
Previous studies have suggested an IgG4 > IgG1 predominance of pathogenic autoantibodies in
pemphigus, a potentially fatal blistering disease of the skin and mucous membranes. IgG4 is induced
by conditions of chronic cutaneous antigen stimulation, such as in beekeepers and those undergo-
ing allergic desensitization therapy. We hypothesized that chronic autoantigen stimulation could
occur with persistent skin blistering, and therefore IgG4 itself could serve as a therapeutic target for
disease-specific autoantibodies in pemphigus. IgG4 is an attractive target for therapy as it is the
least prevalent subclass of serum IgG, and selective IgG4 deficiency does not appear to result in
significant immune deficiency. Total serum IgG4, but not other IgG subclasses, was elevated in 27
pemphigus vulgaris and 16 pemphigus foliaceus patients, compared to unaffected individuals
(p=0.035 and p=0.005, respectively). Using a novel anti-desmoglein subclass ELISA to calculate the
percent of total IgG that is antigen-specific, we found that desmoglein-specific antibodies comprised
a median of 7.1% versus 0.5% of total IgG4 and IgG1 in pemphigus vulgaris patients (p<0.0001),
with desmoglein-specific IgG4 exceeding desmoglein-specific IgG1 in 44% of patients. Patients with
recurrent disease after B cell depletion were enriched for surface-IgG4 positive memory B cells com-
pared to unaffected individuals. IgG4 depletion of PV sera blocked pathogenicity in a keratinocyte
dissociation assay and showed that affinity-purified IgG4 is more pathogenic than other serum IgG
fractions. By preferentially targeting autoimmune rather than beneficial immune antibodies, IgG4-
targeted therapies may offer safer treatment options for pemphigus, and potentially other autoanti-
body-mediated diseases.
018
Social stress prevents the development of psoriasis in modified transgenic K14/VEGF mice
O Vegas,1 B Poligone,2 J VanBuskirk2 and F Tausk2,3 1 Psychology, Basque Country University,
San Sebastián, Spain, 2 Dermatology, University of Rochester, Rochester, NY and 3 Psychiatry,
University of Rochester, Rochester, NY
Although numerous retrospective human studies have suggested the deleterious effects of stress in
the course of psoriasis, this report shows that contrary to expectations, exposure to chronic social
stressors prevents development of the psoriasis phenotype in six week old mice genetically deter-
mined to spontaneously express lesions (“modified” K14/VEGF) in 95% of litters. For 21 days, 25
mice were co- housed in cages containing a CD1 mouse extensively trained to express aggression,
separated by an acrylic perforated panel that was lifted for 3 minutes daily (sensory contact social
stress model) with careful monitoring to avoid injuries during the confrontations. Non-stressed con-
trol mice were housed similarly with a non-aggressive cohort. No mice showed psoriasiform signs
of at baseline. Serum corticosterone in stressed mice remained markedly elevated between days
one (mean 232 ng/ml) and 21 (mean 265 ng/ml) compared to non-stressed controls (39 and 34 ng/ml
respectively)(p<0.0001), returning to baseline 10 days post stress (mean12 ng/ml). Ear thickness was
tracked as a measure of psoriasiform inflammation. At baseline, all mice had ear thickness meas-
ures of 0.22±0.03 mm. Data showed a very significant thickening in non-stressed mice (0.64±0.2*mm)
compared to the stressed animals (0.34±0.09*mm) at day 21 (p<0.0001) and 10 days later (p<0.0001).
Behavioral assessments such as the defensive withdrawal test, elevated plus maze, forced swim test
and novel preference test, all showed a significant level of distress in the stressed mice compared
to controls. This study demonstrates that unexpectedly, stress prevents the development of the pso-
riasis phenotype in this mouse model. This protection may be mediated by the elevation of endoge-
nous corticosteroids. These findings may support the observation that patients whose psoriasis wors-
ens under stress suffer from a blunted cortisol response to acute stressors.
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Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation
of naïve T cells into cytokine-producing mature T cells
K Yamanaka, K Tsuda, H Kitagawa, T Akeda, M Naka, K Niwa, T Nakanishi, M Kakeda and
H Mizutani Dermatology, Mie University, Graduate School of Medicine, Tsu, Japan
T cells have been classified as belonging to the Th1 or Th2 subsets according to the production of
defining cytokines such as IFN-γ and IL-4. The discovery of the Th17 lineage and regulatory T cells
shifted the simple concept of the Th1/Th2 balance into a 4-way mechanistic pathway of local and
systemic immunological activity. Clinically, the blockage of cytokine signals or non-specific sup-
pression of cytokine predominance by immunosuppressants is the first-line treatment for inflam-
matory T cell-mediated disorders. Cyclosporine A (CsA) and Tacrolimus (Tac) are commonly used
immunosuppressants for the treatment of autoimmune disease, psoriasis, and atopic disorders. Many
studies have shown that these compounds suppress the activation of the calcium-dependent phos-
phatase calcineurin, thereby inhibiting T-cell activation. Although CsA and Tac are frequently uti-
lized, their pharmacological mechanisms have not yet been fully elucidated. In the present study,
we focused on the effects of CsA and Tac on cytokine secretion from purified human memory
CD4T cells and the differentiation of naïve T cells into cytokine-producing memory T cells. CsA or
Tac significantly inhibited IFN-γ, IL-4, and IL-17 production from memory T cells. These compounds
also inhibited T cell differentiation into the Th1, Th2, and Th17 subsets, even when used at a low
concentration. This study provided critical information regarding the clinical efficacies of CsA and
Tac as immunosuppressants.
020
Effect of Liang Xue Huo Xue Capsules on mice psoriasis-like lesions induced by Imiquimod
P Li1,2 and T Di2,1 1 Department of Pathophysiology, Beijing Institute of Traditional Chinese
Medicine, Beijing, China and 2 Capital Medical University, Beijing, China
Psoriasis is an immune-mediated chronic inflammatory disease. Topical Imiquimod could induce
psoriasis-like murine lesions. On the basis, this study observes the effects of Liang Xue Huo Xue
(LXHX) Capsules on mice psoriasis-like lesions induced by Imiquimod (IMQ). Balb/c female mice
(n=48) were randomly assigned to six groups: Normal control group(topical using vaseline on the
back and NS oral administration once a day for 8 days ), Model group(topical 4% Imiquimod (IMQ)
42mg and NS oral administration once a day for 8 days), LXHX Capsules high, medium and low
dose groups(2mg/kg,1mg/kg,0.5mg/kg LXHX Capsules solutions oral administration, with topical
IMQ as Model group), Tripterygium glycosides group (GTW, 10mg/kg GTW solutions oral admin-
istration, with topical IMQ as Model group). At day 8 d, skin lesions were cut for pathological exam-
ination. The lesions were evaluated according to the Psoriasis area and severity index (PASI). The
histology and epidermal thicknesses were observed by light microscope. Proliferating cell nuclear
antigen (PCNA) expression was investigated by immunohistochemical staining. Meanwhile, CD3,
CD11c, F4/80, CD31 and Gr-1 positive expression were counted by immunohistochemical stain-
ing for inflammatory infiltrations of T lymphocytes, dendritic cells, macrophages, neutrophils and
monocytes. Compared with Model group, the cutaneous symptoms of the LXHX Capsules groups
were alleviated, with PASI scores decreased, epidermal parakeratosis and epidermal over-prolifer-
ation relived, the numbers of dermal T lymphocytes, dendritic cells, macrophages, neutrophils and
monocytes reduced significantly. LXHX Capsules improved imiquimod-induced murine psoriasis-
like lesions probably by inhibiting keratinocytes over-proliferation, parakeratosis, inflammatory infil-
tration and angiogenisisinhibiting mediated by T lymphocyte activation.
021
The alpha adrenergic receptor agonist oxymetazoline inhibits temperature-induced vasodi-
lation and LL-37-induced skin inflammation
E Hsia, M Tian, E Santori, D Mistry and D Gil Biological Sciences, Allergan, Irvine, CA
Of the various subtypes, erythematotelengiactatic rosacea (ETR) is the most prevalent and also the
most difficult to treat. At the molecular level, rosacea is thought to be caused by increased levels
of LL-37 cathelicidin which promote vascular changes and chronic inflammation. The alpha adren-
ergic receptor agonists oxymetazoline (OXY) and brimonidine are currently in clinical development
as promising new therapies for the treatment of ETR. These compounds are thought to reduce ery-
thema through vasoconstriction of cutaneous blood vessels, but direct evidence to support this
contention is limited. Here we demonstrate that OXY not only inhibits temperature-induced cuta-
neous vasodilation, but also that it inhibits LL-37-induced skin inflammation. To investigate the
effects of OXY on cutaneous blood flow, the hind footpads of rats were dosed unilaterally with OXY
or vehicle, and blood flow in response to heating and cooling intervals was recorded using a laser
doppler microvascular perfusion monitor. Heat-induced vasodilation was decreased by 36% com-
pared to vehicle control, following 30 min pre-treatment with a single topical dose of 0.5% OXY
(p < 0.05). Interestingly, brimonidine was not as effective as OXY, with only a 21% reduction at 30
min using twice the concentration (1%) as that of OXY. In addition to its expected effects on vas-
cular responses, OXY has also been reported to have anti-inflammatory properties. To investigate
the effects of OXY on rosacea-like skin inflammation, ears of mice were pre-dosed topically with
0.5% OXY and following intradermal injection of LL-37 peptide, ear swelling was measured as an
indicator of inflammation. OXY significantly inhibited LL-37-induced ear swelling, and this was evi-
dent as early as 2 hrs post-LL-37 injection (p < 0.05). Taken together, these data suggest that OXY
has both vasoconstrictive and anti-inflammatory properties, both of which would be desirable for
the treatment of rosacea.
022
Functional interaction between complement and the proinflammatory cytokine TNF-α in
experimental bullous pemphigoid
L Heimbach,1,2 M Zhao,1 N Li,1 J Fan,3 J Fairley,4 LA Diaz1 and Z Liu1,2 1 Dermatology, University
of North Carolina at Chapel Hill, Chapel Hill, NC, 2 Microbiology and Immunology,
University of North Carolina at Chapel Hill, Chapel Hill, NC, 3 Pediatrics, Medical College of
Wisconsin, Milwaukee, WI and 4 Dermatology, University of Iowa, Iowa City, IA
Bullous pemphigoid (BP) is a chronic inflammatory skin blistering disease characterized by autoan-
tibodies against two hemidesmosomal proteins, BP230 and BP180. Previous studies using an IgG
passive transfer mouse model of experimental BP (eBP) demonstrated that anti-BP180 antibodies
trigger dermal-epidermal separation and subepidermal blistering via a process that depends on com-
plement, mast cell (MC) degranulation, and neutrophil (PMN) infiltration. In human BP patients,
high levels of TNF-α are found in the serum and blister fluid, and anti-TNF-α therapies reduce sever-
ity of clinical disease. In this study, we examined the relationship between complement activation
and TNF-α in eBP. Pathogenic anti-BP180 antibodies trigger sharp, MC-dependent increases in TNF-
α levels in mouse skin and blister fluid. Mice lacking TNF-α (TNF-α-/-) or MCs (MC-/-) fail to recruit
PMNs to the skin and do not develop clinical blisters; disease susceptibility in both TNF-α-/- and
MC-/- mice is restored by reconstitution with WT MCs. Mice lacking C5a receptor (C5aR-/-) are
resistant to eBP and do not exhibit elevated skin TNF-α levels. Blister formation and skin TNF-α lev-
els are restored in C5aR-/- mice by reconstitution with C5aR+/+ MCs, but not C5aR-/- MCs. TNF-α
receptor 1 (TNFR1) expression on MCs is required for eBP, suggesting that TNF-α released from MCs
acts in an autocrine manner. Together with our previous work showing that C5a interaction with
the C5aR on MCs is required for MC degranulation, these data support a model for the pathogen-
esis of eBP in which (1) pathogenic anti-BP180 antibodies activate complement and generate C5a
molecules, which (2) interact with C5aR on MCs to initiate MC degranulation and release of TNF-
α, which (3) mediates PMN infiltration by acting in an autocrine fashion on the TNFR1 on MCs.
023
Whole tissue molecular profiling identifies unique cytokine-related gene sets of disease pro-
gression and response to therapy
GK Perera,1 C Ainali,2 C Hundhausen,1 G Barinaga,1 D Kassen,1 A Williams,1 M Miirza,3 S Tsoka,2
W Ouyang4 and FO Nestle1 1 St. John’s Institute of Dermatology, King’s College London,
London, United Kingdom, 2 Department of Informatics, King’s College London, London,
United Kingdom, 3 Genomics Facility, Biomedical Research Centre, King’s College London,
London, United Kingdom and 4 Department of Immunology, Genentech Inc., South San
Francisco, CA
The identification of biomarkers of human disease and those predictive of response to therapy is an
ideal of personalised medicine. The translation of key steps in disease pathogenesis, accrued from
in vitro and non-human model systems, to the subsequent identification of biomarkers with clini-
cal applicability are fraught with inconsistencies. We report a novel network medicine-based approach
in the identification of psoriasis-relevant cytokine-related biomarkers capable of predicting disease
progression and response to therapy. Using humanised xenotransplantation mouse models we define
unique IL-22 and IL-17A molecular signatures in normal human skin, and in psoriasis development
and progression. We established IL-22 and IL-17A-related biomarkers or gene sets associated with
severe psoriasis and generate a therapeutic-response gene set by using selective anti-cytokine mon-
oclonal antibodies. We suggest that the integration of experimental human-relevant model systems
with computational biology is a new technology platform approach for human skin-related bio-
marker discovery and for the validation of cytokines as putative therapeutic targets.
024
Successful engraftment of human skin and T cells in NOD-scid-IL2γr null mice for the inves-
tigation of human inflammatory skin responses
P Agarwal,1 WJ Racki,1 A Cuthbert,1 MS Brehm,1 LD Shultz,2 DL Greiner1 and JE Harris1 1
Medicine, University of Massachusetts Medical School, Worcester, MA and 2 Jackson
Laboratories, Bar Harbor, ME
The goal of this study was to determine whether a functional human skin graft and immune system
could be established in a severely immunocompromised mouse strain, resulting in a humanized
mouse model of inflammatory skin diseases. While animal models of human disease facilitate the
study of basic mechanisms, many do not fully reflect human disease, and numerous therapies devel-
oped in animals have not been successfully translated to humans. Previous studies report success-
ful skin grafting onto immunodeficient mice, however efficient immune reconstitution in these strains
has not been successful, and therefore investigation of human T cell responses in human skin has
not been possible. The NOD-scid-IL2γrnull (NSG) is a unique strain of mice that accepts most human
tissues, including skin, tumors, thymus, liver, etc., as well as human T cells. Our study uses NSG
mice, discarded human skin from panniculectomy surgery, and human peripheral blood leuko-
cytes (PBLs) to investigate human T cell responses in human skin. We report that NSG mice engraft
with both human skin and human T cells in a physiologic CD4:CD8 ratio in the blood. When skin
and PBLs from the same patient (autologous) are used for engraftment, the skin graft heals, contin-
ues to produce human involucrin and vimentin, and becomes populated with human CD45+ cells.
When skin and PBLs are taken from different donors (allogeneic), the skin is fully rejected through
an allogeneic T cell response within 14 days. Future studies using skin-localized infection and con-
tact dermatitis will measure the functionality of autologous skin and T cells within this model. A
fully developed humanized mouse model of inflammatory skin disease using the immunodeficient
NSG mouse strain holds promise for investigation of fully human T cell-skin responses, including
vaccination/T cell memory, contact dermatitis, and autoimmunity, as well as acting as a preclinical
bridge to test newly developed treatments.
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Autoantibodies vs. desmogleins (Dsg) 1 or 3 do not represent tissue-specific disease ampli-
fiers in subjects with discoid or systemic lupus erythematosus (LE)
L Tseng, LA Matthews, KB Yancey and BF Chong Dermatology, University of Texas
Southwestern, Dallas, TX
Immune complex deposition in LE leads to tissue damage that may be enhanced by tissue-specific
autoantibodies (autoabs). This hypothesis has been supported by the demonstration that MRL lpr/lpr
lupus-prone mice with skin lesions have autoabs against Dsg3 and that levels of anti-Dsg3 IgA highly
correlate with skin disease severity in this murine model (Proc Nat’l Acad Sci USA 103:3292, 2006).
To determine if comparable findings exist in man, we studied sera from subjects with discoid and
systemic LE (DLE and SLE, respectively) for evidence of IgG vs. Dsg3 or Dsg1 by ELISA, and IgG or
IgA autoabs vs. monkey esophagus by indirect immunofluorescence (IF) microscopy. Age- and gen-
der-matched SLE subjects without DLE (SLE+/DLE-) (N=18), SLE subjects with DLE (SLE+/DLE+)
(N=17), DLE subjects without SLE (DLE+/SLE-) (N=23), and healthy control subjects (N=22) were
studied. In the ELISA studies, 1 SLE+/DLE+ subject and 1 healthy control showed evidence of anti-
Dsg1 or anti-Dsg3 IgG, respectively, while the other 78 subjects were negative. Similarly, indirect
IF microscopy studies found IgG vs. plasma membranes of epithelial cells in 2 healthy controls, IgA
vs. epithelial basement membrane in 1 healthy control, IgA vs. basal keratinocytes in 2 healthy
controls and 2 DLE+/SLE- subjects, and no evidence of IgG or IgA tissue-specific autoabs against
plasma or basement membranes of epithelial cells in monkey esophagus in the remaining 73 sub-
jects. Three and 4 of 22 healthy controls, 1 and 1 of 23 DLE+/SLE- subjects, 6 and 5 of 17 SLE+/DLE+
subjects, and 11 and 7 of 18 SLE+/DLE- subjects showed evidence of IgG or IgA anti-nuclear autoabs,
respectively. These studies show that, in notable contrast to MRL lpr/lpr mice, IgG and/or IgA autoabs
vs. Dsg1 and 3 are not present in a large cohort of subjects with various forms of LE. The identifi-
cation and characterization of skin-specific autoantigens that amplify skin injury in LE patients still
holds potential relevance to the understanding of this complex disease.
027
Regulation of IL-33 expression by interferon-γ and tumor necrosis factor-α in normal human
epidermal keratinocytes
J Meephansan,1 H Tsuda,1 M Komine,1,2 M Karakawa,1 S Tominaga2 and M Ohtsuki1 1
Dermatology, Jichi Medical University, Shimotsuke, Japan and 2 Biochemistry, Jichi Medical
University, Shimotsuke, Japan
Interleukin (IL)-33, a member of the IL-1 family, is implicated in Th2 immune reactions. We inves-
tigated the effect of Th-1 and Th-2 cytokines on IL-33 expression in normal human epidermal ker-
atinocytes (NHEKs). IFN-γ dose- and time-dependently induced IL-33 expression in protein and
mRNA; this was dependent on extracellular signal-regulated kinase (ERK), p38, and epidermal growth
factor receptor (EGFR) phosphorylation. Combined treatment with IFN-γ and TNF-α induced expres-
sion of a 20-kDa band corresponding to mature IL-33, which was abolished by addition of calpain
inhibitor. Addition of calpain inhibitor to IFN-γ and TNF-α-stimulated cells also induced strong
expression of a 25-kDa band. Small interference (si)RNA for IL-33 abolished expression of the smaller
bands and the 30-kDa IL-33 band, suggesting that all these IL-33 forms were IL-33 transcription
products. These results indicate that NHEKs can produce 30-kDa, 25-kDa, and 20-kDa IL-33 after
stimulation with IFN-γ and TNF-α, and cleavage of pro-IL-33 to mature IL-33 is dependent on cal-
pain. IL-4 also induced IL-33 expression but the potency was less than IFN-γ. Immunohistochem-
istry demonstrated that epidermis of lichen planus expressed IL-33 with more frequency and with
higher level compared to that of atopic dermatitis. Recombinant IL-33 induced IL-8 production from
NHEKs with NF kappa B activation. These results suggest that IL-33 induced by IFNg and TNFa could
work autocrinely and is involved in the formation of cutaneouse lesions in inflammatory skin dis-
eases.
029
Regulation of immune responses by kurarinone through the JAK/STAT and TCR-mediated sig-
naling
B Kim and T Kim Dermatology, College of Medicine, The Catholic University of Korea, Seoul,
Republic of Korea
Sophora flavescens is a medicinal herb that contains flavonoids and quinolizidine alkaloids and
has a wide range of biological activities due to its anti-inflammatory, anti-bacterial, and anti-can-
cer properties. We isolated a series of flavonoids (1-14) from the roots of Sophora flavescens and
examined their ability to inhibit immune responses. Among the flavonoids, kurarinone exhibited
the strongest inhibitory effect on immune responses. Kurarinone suppressed the differentiation of
CD4+ T cells by inhibiting the expression of T-cell lineage-specific master regulators and cytokines.
These events implicated that kurarinone directly suppressed the cytokine-induced Janus kinase/sig-
nal transducer and activator of transcription (JAK/STAT), nuclear factor-kappaB (NF-κB), and Src fam-
ily kinase pathways. In two established animal models of skin diseases by IL-23 injection and
2,4,6-trinitrochlorobenzene (TNCB) painting, kurarinone ameliorated psoriasis-like skin disease and
down-regulated delayed-type hypersensitivity by inhibiting the expression of not only cytokines and
chemokines but also inflammatory mediators in mice ears. This study provides new evidences that
kurarinone may ameliorate chronic skin diseases through the suppression of pathogenic CD4+ T
cell differentiation and the overall immune response.
028
Loss of hTid-1S expression and aberrant actin cytoskeleton organization in lesional psoriatic
skin
J Choi and C Joe KAIST, Daejeon, Republic of Korea
The biochemical mechanism by which hTid-1S interferes with actin cytoskeleton organization in
keratinocytes of human skin epidermis was investigated. We found that hTid-1, specifically hTid-
1S, interacts with MK5, a p38-regulated/activated protein kinase, and inhibits the protein kinase
activity of MK5 that phosphorylates heat shock protein HSP27 in cultured HeLa cells. Phosphory-
lation of HSP27 has been known to play important roles in F-actin polymerization, actin cytoskele-
ton organization and subsequent actin dynamics. The connection between MK5/HSP27 signaling
and hTid-1S expression was supported by results showing the inhibition of HSP27 phosphorylation
and MK5 activity in HeLa cells in response to hypoxia during which hTid-1S expression was down-
regulated. Overexpression of hTid-1S resulted in the inhibition of HSP27 phosphorylation, F-actin
polymerization, actin cytoskeleton organization and cell migration in transfected HeLa cells and
transduced HaCaT keratinocytes. This study further proposes that the enhanced HSP27 phospho-
rylation and the aberrant actin cytoskeleton organization in the epidermis of lesional psoriatic skin
correlates with the loss of hTid-1Sexpression in the basal layer.
026
Early detection and therapy of hemophagocytic lymphohistiocytosis improves patient out-
come
TT Farsani, W Tsiaras and AP Saavedra Dermatology, Brigham and Women’s Hospital, Boston,
MA
A 64-year-old male with IgGk myeloma s/p chemotherapy was admitted for malaise, fever and
rash. He denied new medications. Exam revealed a morbilliform exanthem of the trunk, groin, and
proximal extremities. Labs revealed pancytopenia, elevated levels of ferritin, triglycerides, ALT,
AST, soluble IL-2, CRP, with normal ESR and fibrinogen. Imaging was positive for hepatosplenomegaly
(HSM) and retroperitoneal lymphadenopathy (LAD). Infectious work-up was negative. Bone mar-
row biopsy (BMB) showed phagocytosis of the nucleated marrow elements including erythrocytes.
Therapy with steroids and intravenous immunoglobulin (IVIG) resulted in improvement. HLH is a
rare, life-threatening syndrome that occurs in the setting of systemic infection, malignancy, or immun-
odeficiency. It results from overactive histiocytes and lymphocytes and presents with fever, HSM,
pancytopenia, LAD, and rash. The two forms include: 1) the inherited type, or familial ery-
throphagocytic lymphohistiocytosis, and 2) the secondary type, or acquired HLH. Overactivation
of T-cells and histiocytes in the setting of decreased natural killer cell activity results in proliferation
and autophagocytosis of cells (ie erythrocytes and white blood cells). Diagnosis requires five of the
eight criteria: 1) fever, 2) cytopenia, 3) hypertriglyceridemia, 4) hyperferritinemia (>500microg/L),
5) evidence of hemophagocytosis, 6) elevated IL-2-receptor, 7) decreased NK cell activity, and 8)
HSM. Up to 65% of patients present with erythroderma, purpura, or a morbilliform skin eruption.
Laboratory markers may be notable for elevated CRP with low ESR levels. Diagnosis is confirmed
via BMB, but may be non-diagnostic in up to two thirds. Treatment includes high dose corticos-
teroids, IVIG and chemotherapy. Regardless of treatment, there is a 50% mortality rate. Given the
poor prognosis and aggressive course of HLH, it should be considered in the differential of patients
with fever and rash in the setting of malignancy, cytopenia, and HSM. Labs and BMB may help
confirm diagnosis. Early diagnosis is crucial, as therapy can be life-saving.
030
Mapping conformational epitopes on the ectodomain of desmoglein 1 for Fogo Selvagem
IgG4 autoantibodies by proteolytic footprinting
F Evangelista,1,3 A Roth,2 Z Liu,1,3 DG Klapper3 and LA Diaz1 1 Dermatology, UNC School of
Medicine, Chapel Hill, NC, 2 Pathology and Laboratory Medicine, UNC School of Medicine,
Chapel Hill, NC and 3 Microbiology & Immunology, UNC School of Medicine, Chapel Hill,
NC
Fogo Selvagem (FS) is a disease mediated by pathogenic, predominantly IgG4 subclass autoanti-
bodies against Desmoglein-1(Dsg1). Subclass switching and epitope spreading within the Dsg1
ectodomain may initiate FS. However, the fine epitope specificity of these IgG4 autoantibodies to
Dsg1 remains elusive. In this study, the IgG4 fraction from each of ten FS patients’ sera was puri-
fied by affinity chromatography using a 12kD camelid antibody fragment that specifically recog-
nizes human IgG4. The IgG4 fraction (97% pure) from each patient was pathogenic in the neona-
tal mouse model. Each IgG4 fraction was immobilized on CNBr-activated Sepharose and then
incubated with recombinant human Dsg1 ectodomain. A proteolytic footprinting of the bound Dsg1
was performed using chymotrypsin and trypsin, in which the antibody (IgG4) protects from diges-
tion the sequence of interest. Then, the IgG4-bound Dsg1 peptides were dissociated and the sequences
were identified by Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS/MS).
The following conformational epitopes were identified by IgG4 autoantibodies from ten FS patients:
residues 129A-144R in EC-1 (90% of sera), residues 201Q-213R in EC-2 (100%) and residues
41W-45R in the propeptide sequence (80%). IgG4 purified from healthy human serum did not rec-
ognize any Dsg1 epitopes by this method. Digestion of Dsg1 by chymotrypsin and trypsin prior to
incubation with IgG4-Sepharose completely obliterated the binding of IgG4 to any epitopes, indi-
cating that these autoantibodies bind and protect conformational epitopes on Dsg1. This novel study
sheds light on the conformational epitopes bound by pathogenic IgG4 anti-Dsg1 autoantibodies
from FS and may provide targets for the development of preventative and improved therapeutic
strategies for this and other autoantibody mediated diseases.
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Facial pseudolymphoma responsive to pulsed-dye-laser therapy
TT Farsani, CF Yang and AP Saavedra Dermatology, Brigham and Women’s Hospital, Boston,
MA
A 42-year-old female presented with a 4-year history of multiple 2-4mm deeply pink papules on
the face and upper chest, initially diagnosed as rosacea. However, treatments were unsuccessful.
Biopsy revealed a B-cell infiltrate with germinal centers. Review of systems was negative, and she
denied new meds. Serologies and imaging were unrevealing for connective tissue, vascular, or
neoplastic disease. After multiple unsuccessful attempts with topical and systemic treatments, she
declined further systemic medications. We therefore began a trial of pulsed-dye-laser (PDL) to the
area. Cutaneous pseudolymphoma (CPL) refers to a group of reactive T- or B-cell lymphoprolifera-
tive processes that mimic cutaneous lymphomas clinically and histologically but have benign bio-
logic behavior. Our patient was found to have cutaneous B-cell pseudolymphoma (CBPL). CBPL
may be induced by several factors including insect bites, B. burgdorferi, trauma, vaccinations, injec-
tions, and tattoos. In most cases, the inciting stimulus is not identified. Treatments include penicillin,
corticosteroids, radiotherapy, topical nitrogen mustard, chemotherapy, excision, and cryotherapy.
Three reports demonstrated improvement after treatment with topical 5-ALA-based PDT and another
with use of the Argon laser. Pulsed-dye-laser (PDL) therapy is used to treat vascular lesions, angiofi-
bromas, verrucae, basal cell carcinoma, psoriasis, and discoid lupus. It utilizes selective pho-
tothermolysis to target oxyhemoglobin in vessels, resulting in red blood cell coagulation with fib-
rin and thrombi formation. Given previously reported success with Argon laser, we treated with PDL
therapy, which has a wavelength close to that of Argon, yet penetrates deeper. CPL is characterized
by a reddish-purple color, presumably with increased vascularity. PDL may induce regression of
CPL lesions by its thermal effects on blood vessels. After 7 treatments, our patient demonstrated sig-
nificant improvement of her lesions. PDL may be beneficial in treating CPL in those refractory to
topical treatment, since it is free of the side effects of systemic therapies or radiation.
032
A key role for the polyclonal nature of pemphigus vulgaris IgG in p38 MAPK-dependent loss
of keratinocyte adhesion
M Saito,1,3 CY Caughman,1 DK Tucker,1 X Mao,4 SN Stahley,1 AS Payne,4 M Amagai3 and
AP Kowalczyk1,2 1 Cell Biology, Emory University, Atlanta, GA, 2 Dermatology, Emory
University, Atlanta, GA, 3 Dermatology, Keio University, Tokyo, Japan and 4 Dermatology,
University of Pennsylvania, Philadelphia, PA
Pemphigus vulgaris (PV) is an autoimmune disease caused by autoantibodies to the desmosomal
cadherin desmoglein 3 (Dsg3). PV IgG cause the loss of keratinocyte cell adhesion, resulting in skin
blisters and mucosal erosions. The pathomechanism of PV is not well understood. Dsg3 endocyto-
sis, steric hindrance, and the induction of cell signaling have been proposed to explain PV IgG path-
ogenic activity. Here, we provide evidence that a substantial component of PV IgG pathogenicity
can be attributed to the polyclonal nature of patient antibodies. In primary human keratinocytes,
PV IgG, but not a pathogenic monoclonal anti-Dsg3 antibody (AK23), caused clustering and endo-
cytosis of cell surface Dsg3. Electron microscopy revealed that PV IgG disrupted normal desmo-
some organization, whereas AK23 caused loss of adhesion without an obvious effect on desmo-
some ultrastructure. Furthermore, clustering and loss of cell surface Dsg3 caused by PV IgG could
be mimicked by using a combination of Dsg3 mAbs. Interestingly, PV IgG-induced clustering, loss
of cell surface Dsg3, and loss of adhesion were prevented by the tyrosine kinase inhibitor genistein
and the p38 MAPK inhibitor SB202190. Genistein and SB202190 also prevented loss of adhesion
caused by PV IgG when injected into human skin ex-vivo. Importantly, the pathogenic activity of
AK23 was resistant to inhibition of either tyrosine kinases or p38 MAPK both in vitro and ex-vivo.
These findings suggest that AK23 pathogenic mAb primarily disrupts adhesion by steric hindrance.
In contrast, a major pathogenic mechanism of PV patient IgG is due to clustering of Dsg3, result-
ing in Dsg3 endocytosis and disorganization of desmosomes in a tyrosine kinase and p38 MAPK-
dependent manner. This work highlights the importance of studying PV patient IgG to evaluate PV
pathomechanisms and therapies.
033
Cathelicidin anti-microbial peptide is expressed and secreted from adipocytes – a novel mech-
anism for fat cells in the innate immune system
L Zhang, A Coda, T Hata and R Gallo Dermatology, University of California, San Diego, San
Diego, CA
Adipose tissue functions for energy storage but recent studies reveal that it also secretes various
cytokines and regulates metabolic pathways. Although an elevated Body Mass Index (BMI) associ-
ates with several immune disorders, the role of adipocytes in innate immunity remains unknown.
Cathelicidin is essential for resistance to infection and also may participate in the pathophysiology
of immunological diseases such as psoriasis. Here we show for the first time that cathelicidin is
expressed and inducible in adipocytes. qPCR analyses found increased expression of Camp mRNA
(85-fold +/-9) in murine adipocytes after differentiation from primary 3T3 preadipocytes. This level
of expression was greater (112-fold +/-12) than in primary murine keratinocytes. In contrast, the
expression of other major antimicrobial peptides (Defa3/5/17 and Defb1/2/3/4/14) were low and
not induced in adipocytes. Abundant cathelicidin protein was detected by western blot in cultured
adipocyte supernatants, and the majority of cell associated cathelicidin was proteolytically processed
to its mature active peptide form which was seen by immunohistochemistry to localize at or within
the nucleus. Western blot also detected cathelicidin from extracts of subcutaneous and omental fat
collected from adult mice. In normal human serum, cathelicidin (LL37) concentrations were higher
in patients with high BMI>25 (37.35+/-22.92 ng/ml) compared to normal BMI<25; (6.258 +/-3.086
ng/ml, p<0.2, n=6 for each group), and in atopic patients cathelicidin was 126.7+/-29 ng/ml at
BMI>25 but significantly less in BMI<25 (16.41+/-5.9 ng/ml, p<.001, n=6 for each group), sug-
gesting that increased adipose tissue contributes to elevated circulating LL37. These results demon-
strate that cathelicidin antimicrobial peptide is expressed and secreted by adipocytes, may provide
an unexpected role in host defense, and may provide a mechanism to explain the association of
obesity with autoimmune disorders.
034
Cynaropicrin, an extract from artichoke, inhibits UVB-induced oxidative stress in cultured
human keratinocytes
G Tsuji,1 M Takahara,1 X Yan,2 A Hachiya,1 H Uchi,1 S Takeuchi,1 F Yasukawa,1 K Takei,1 Y Moroi1
and M Furue1 1 Dermatology, Graduate School of Medical Sciences, Kyushu University,
Fukuoka, Japan and 2 P&G Design Center Godo Kaisha, Kobe, Japan
Cynaropicrin, a bioactive extract from artichoke, has been reported to have a potent anti-inflam-
matory activity, however, the precise mechanism remains unclear. Several studies have shown that
some phytochemicals modulate aryl hydrocarbon receptor (AhR) signaling, which results in inhi-
bition of reactive oxygen species (ROS) production in vitro and vivo. Further, we have demon-
strated that AhR signaling regulates ROS production via Nrf2 and SIRT1 activation, which turns on
a redox machinery against ROS-induced oxidative stress in human keratinocytes. Therefore, we
examined whether cynaropicrin exerts its anti-inflammatory effect via AhR-mediated Nrf2 and SIRT1
activation in human keratinocytes. Cultured normal human epidermal keratinocytes (NHEKs) were
treated with cynaropicrin (100nM-10μM). We found 1) that cynaropicrin upregulated CYP1a1, Nrf2,
Nqo1 and SIRT1 mRNA expression in real-time PCR assay, 2) that cynaropicrin induced nuclear
translocation of AhR and Nrf2 in confocal microscopic analysis, and 3) that knockdown of AhR
using siRNA transfection cancelled cynaropicrin-induced CYP1a1, Nrf2 and Nqo1 mRNA upregu-
lation in real-time PCR assay. Taken together, we have revealed that cynaropicrin is an AhR-Nrf2
signal activator in NHEKs. Furthermore, to examine its anti-inflammatory effect, NHEKs were exposed
to ultraviolet (UV) B radiation which produces ROS attributing to skin aging, inflammation and car-
cinogenesis. As UVB has been reported to induce skin inflammation via AhR-mediated COX-2
expression, we hypothesized that cynaropicrine might prevent UVB-induced AhR activation antag-
onistically. We found that cynaropicrin (1μM) inhibited UVB-induced ROS and inflammatory cytokine
(IL-1a, IL-6, IL-8 and TNF-a) production in NHEKs. In conclusion, these findings indicate that cynaropi-
crin may be a useful agent for preventing the UVB-induced skin aging, inflammation and carcino-
genesis via AhR-Nrf2-mediated mechanism.
035
RNASeq reveals new insights into psoriasis biology
LC Tsoi,1 B Li,1 RP Nair,2 J Ding,1 JE Gudjonsson,2 PE Stuart,2 JJ Voorhees,2 T Tejasvi,2 HM Kang,1
GR Abecasis1 and JT Elder2,3 1 Biostatistics, Univ of Michigan, Ann Arbor, MI, 2 Dermatology,
Univ of Michigan, Ann Arbor, MI and 3 VA Hospital, Ann Arbor, MI
To further our understanding of the biology of psoriasis, we utilized high-throughput RNA sequenc-
ing technology (RNASeq) to assay the transcriptomes of lesional and normal skin. We sequenced
92 lesional and 82 normal punch biopsy samples of human skin, each with an average of ~38 mil-
lion single-end 80-bp reads. Comparison of 42 samples examined by both RNASeq and microar-
ray (MA) showed dramatic differences in gene expression, particularly for transcripts with low expres-
sion levels. We identified 3,577 differentially expressed genes between the two tissues by RNASeq,
with those identified only by RNASeq having markedly lower expression than those identified by
both MA and RNASeq. RNASeq identified many more differentially-expressed transcripts involved
in heuristically-identified biological pathways than did MA, such as cytokine-cytokine receptor inter-
action and immune system processes, and included key transcripts such as IFNG, IL17, IL22 and
IL24. Weighted gene co-expression network analysis revealed a normal skin co-expression module
containing IL6, IL8, CXCL1, IL17, IL19, and IL24 along with multiple SPRR, S100A7-A12, and DEFB4
transcripts, demonstrating a link between inflammatory signals and abnormal differentiation in
normal skin. Performing variant calling using the RNASeq data, we found that 33%, 49%, and 53%
of the nonsynonymous, synonymous, and nonsense polymorphisms overlapped with those found
in dbSNP. Ts/Tv ratios were very similar for the known and novel variants, suggesting high accuracy
for the novel variants. Comparing individual genotypes we obtained a 98.4% average concordance
rate with previous GWAS data, further indicative of high accuracy. The increased resolution and
power provided by RNASeq will allow a more comprehensive view of global gene regulation in
psoriasis, and the ability to identify novel disease-associated expressed variants may provide new
insights into its pathogenesis.
036
Newly developed enzyme-linked immunosorbent assays using eukaryotic recombinant pro-
teins of desmocollins (Dsc) are highly sensitive and revealed Dsc2 and Dsc3 as autoantigens
specific for paraneoplastic pemphigus
N Ishii,1,2 S Fukuda,1,2 K Teye,1,2 A Tsuchisaka,1,2 T Hamada,1,2 D Tsuruta,1,2 T Dainichi1,2 and
T Hashimoto1,2 1 Department of Dermatology, Kurume University School of Medicine,
Fukuoka, Japan and 2 Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan
We previously reported that IgG and IgA autoantibodies to desmocollins (Dsc) are detected fre-
quently in sera of pemphigus herpetiformis (PH), pemphigus vegetans (PVeg) and paraneoplastic
pemphigus (PNP) by cDNA transfection method using COS-7 cells, but not by enzyme-linked
immunosorbent assays (ELISA) using baculovirus-produced recombinant proteins (RPs). In this study,
we examined sera from 87 PNP, 28 PH, 20 PVeg, 16 pemphigus foliaceus (PF), 20 pemphigus vul-
garis (PV) cases and 33 normal controls by newly developed ELISAs using eukaryotic human Dsc1-
3RPs. By these ELISAs, Dsc1, Dsc2, and Dsc3 were detected by 16.1%, 37.9% and 59.8% of PNP
sera, by 14.3%, 14.3% and 25.0% of PH sera and by 5%, 15% and 25% of PVeg sera, respectively,
whereas Dsc1-3 were detected only by 6.3%, 6.3% and 18.8% of PF sera, by 9.1%, 13.6% and
4.5% of PV sera and by 0%, 3% and 3% of normal control sera, respectively. Most Dsc-positive PH
and PVeg sera showed very high OD values. Immunoprecipitation-immunoblotting using culture
media containing the same RPs showed similar results, confirming the ELISA results. That some Dsc-
positive sera did not react with desmogleins (Dsgs) by ELISA further indicated pathogenic role of
anti-Dsc antibodies. Our study indicates that the new ELISAs using eukaryotic RPs are highly sen-
sitive and specific to detect anti-Dsc1-3 antibodies, and that Dsc2 and Dsc3 (less Dsc1) are autoanti-
gens specific for atypical pemphigus, particularly PNP. That Dsc2 was reacted mostly by PNP sera
is interesting, because Dsc2 is expressed in various visceral epithelia and PNP occasionally shows
internal diseases. This study also indicates that the epitopes for anti-Dsc antibodies can be produced
in eukaryotic cells (but not in insect cells) and are different from those for anti-Dsg antibodies.
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Increased serum VEGF levels correlate with therapeutic responsiveness to biologics in patients
with psoriasis
T Shimauchi, S Hirakawa, T Suzuki, A Yasuma, T Ito and Y Tokura Department of Dermatology,
Hamamatsu University School of Medicine, Hamamatsu, Japan
Although biologic therapies are highly efficient in the treatment of psoriasis, some patients poorly
respond to the therapies and may develop even paradoxical adverse effects. The mechanisms under-
lying the unresponsiveness remain unknown. The aim of this study is to clarify the psoriasis-asso-
ciated biomarkers that are different between the responders and non-responders of biologics. In
this retrospective study, 13 patients with psoriasis (7 psoriasis vulgaris, 5 psoriasis arthropathica,
and one pustular psoriasis) and 4 normal healthy controls were enrolled. The number of patients
treated with each biologic and the therapeutic durations were as follows: 5 infliximab (12 to 14
weeks), 3 adalimumab (12 weeks), and 5 ustekinumab (16 weeks). Three patients were classified
as high-responders, which showed >50% reduction of Psoriasis Area and Severity Index (PASI) score,
and 2 patients were moderate-responders showing <50% reduction. Three patients were non-respon-
ders with PASI score elevation. Before and after the treatments, the serum levels of IL-22 and vas-
cular endothelial growth factor (VEGF) were measured by ELISA. We found that the serum level of
VEGF at the baseline was significantly higher in the high-responder and moderate-responder groups
than the non-responder group (796.6 ± 344.1 pg/mL vs. 148.9 ± 117.9 pg/mL, p=0.022, Student’s
t-test). In addition, serum IL-22 and VEGF levels positively correlated with PASI score (IL-22 vs. PASI,
p=0.027, VEGF vs. PASI, p=0.0216, IL-22 vs. PASI, p=0.035, Spearman’s rank test). After the treat-
ment, the high-responder and moderate-responder groups showed significant decreases in serum
VEGF (796.6 ± 344.1 pg/mL vs. 565.4 ± 257.5 pg/mL, p=0.031, paired t-test) as well as IL-22 (47.9
± 58.3 pg/mL vs. 34.3 ± 64.4 pg/mL, p=0.080). While, serum IL-22 was elevated after treatment in
the non-responders (10.3 ± 9.2 pg/mL vs. 20.5 ± 6.0 pg/mL, p=0.09). These results suggest that serum
VEGF levels are predictive for the responsiveness to biologics and a good monitoring marker for
psoriasis.
039
Host genetics play a role in controlling skin bacterial species and autoimmune blistering skin
disease
G Srinivas,1,2 S Moeller,1 R Ludwig,1 S Kuenzel,2 D Zillikens,1 J Baines2 and S Ibrahim1 1
Dermatology, University of Luebeck, Luebeck, Germany and 2 Max Planck Institute for
Evolutionary Biology, Ploen, Germany
Establishing the relationship between the host-genome and skin microbiota is key to understand-
ing the genetic basis for skin autoimmune diseases. To study this, a cohort of mice from the G4 pop-
ulation of an advanced intercross line originating from 4 strains partially susceptible to epidermol-
ysis bullosa acquisita (EBA) was used. We have previously shown that EBA susceptibility is associated
with the MHC haplotype (H2s, H2k) with additional contribution of non-MHC genes. To identify
EBA-non-MHC genes 250 mice were genotyped using a 1400-SNP Illumina microarray and their
EBA disease scores were determined. Disease onset was associated with several quantitative trait
loci (QTLs) located on chr. 9, 12, 14 and 19, while maximum disease severity was linked to QTLs
on chr. 1, 15 and 19. Pyrosequecing was then used to quantitatively measure the skin microbiota
of the same mice. Sequences were classified to species level Operational Taxonomic Units (OTUs)
(using a 97% threshold). Measurable Microbiota (MM), defined as those species level OTUs that
quantitatively varied across the animal population, in total 134 OTUs, was tested for co-segrega-
tion against the genotype. 335 overlapping host QTLs (LOD scores ≥ 3.9) were identified for 97
MM-OTUs. Using the unweighted UniFrac metric, highly significant species differences between
healthy and EBA mice were observed (Monte Carlo permutation test, n=1000 permutations, P=0.001).
This further led to identifying common QTLs for EBA disease and species level OTUs, resulting in
19 QTLs for 18 species. Eleven out of these 18 species were significantly more enriched in healthy
mice. This data is currently being confirmed using knockout mice of candidate quantitative trait
genes mapping within the common microbial/EBA QTLs. Our findings show that the host QTL con-
trolling EBA disease also controls certain skin bacterial species, suggesting that host-genetics plays
a role in controlling microbiota and disease.
041
IL-17 Receptor A subunit is a central hub for inflammatory signaling in human psoriasis
CB Russell,1 K Kerkof,1 J Bigler,1 M Timour,1 RL Diaz,2 A Symons,2 H Rand,1 JG Krueger3 and
DA Martin1 1 Medical Sciences, Amgen, Inc., Seattle, WA, 2 Inflammation Research, Amgen,
Inc., Seattle, WA and 3 Investigative Dermatology, Rockefeller University, Seattle, WA
The IL-17 family ligands IL-17A, IL-17C, and IL-17F are overexpressed in psoriatic lesional skin and
stimulate inflammatory gene expression in keratinocytes. These IL-17 ligands all act through het-
eromeric IL-17 receptor complexes that include the IL-17RA subunit. Blockade of IL-17RA by AMG
827 resulted in broad normalization of the psoriatic gene expression phenotype in advance of lesional
clearance. Most transcripts were affected within one week and normalized to non-lesional levels
within two weeks after a single dose of AMG 827 with ongoing decreases in infiltrating T cell and
dermal DC counts extending beyond two weeks. Among the fastest responses to treatment were
changes in the keratinocyte functions including reduced proliferation, as measured by Ki67, and
reduced expression of keratinocyte genes including KRT16 and DEFB4. Slower responses to AMG
827 were observed for some lymphocyte expressed genes including IL22, IFNG, and IL17A itself.
Notably, Ki67 cell counts were rapidly reduced to the range of non-lesional skin while IL22 and
IFNG transcripts remained above non-lesional levels, suggesting that neither of these cytokines is
a major driver for keratinocyte hyperplasia in the absence of IL-17 signaling. Control of IL-17
driven gene expression in human keratinocytes was investigated by siRNA knockdown experiments.
While the genes induced by IL-17A were attenuated by siRNA against IL17RA, individual genes
were differentially attenuated by siRNA against genes encoding IL-17 receptor accessory proteins
such as IKKi and Act-1, suggesting complex branching of signaling immediately downstream of IL-
17RA. These data provide insights into how blockade of IL-17RA by AMG 827 generates rapid
pleiotropic effects, suggesting that IL-17RA on keratinocytes acts as a major signaling hub in psori-
asis, through which signals from multiple IL-17 ligands converge, and from which multiple down-
stream signals diverge.
040
Effective prevention and treatment of CD8 T cell-mediated Graft-versus-host-like disease
(GvHD) using a JAK inhibitor
N Okiyama,1 Y Furumoto,2 V Villarroel,1 J Gutermuth,1 K Ghoreschi,2 M Gadina2 and SI Katz1 1
Dermatology Branch, NCI, NIH, Bethesda, MD and 2 NIAMS, NIH, Bethesda, MD
A small molecule Janus kinase (JAK) inhibitor, tofacitinib (tofa), inhibits JAK 1, 2 and 3 of some
cytokine receptor pathways and is being tested in more than 20 clinical trials of autoimmune dis-
eases. Preclinical work has demonstrated beneficial effect in CD4+ T cell-dependent models. To
determine if tofa affects CD8+ T cells, we analyzed its effect on a CD8+ T-cell-dependent murine
model of GvHD (OT-I T cell transfer into Tg mice expressing ovalbumin (OVA) in skin and mucosae.)
Tofa at 50 or 25 mg/kg/day (mkd) p.o. completely prevented GvHD development in our model
with final weights: -0.6%±5.6 (50 mkd), +5.3%±4.7 (25 mkd) and -15.4%±4.1 (vehicle) 13 days
post OT-I cell transfer (p<0.05 each pairing; 2-way ANOVA). At 13 days post OT-I transfer, clinical
scores of tofa-treated mice were reduced to 0 vs.7.3±0.52 in the vehicle group (p<0.01; U test).
Tofa at 12.5 mkd had only a partial, but significant, beneficial effect (p<0.01; 2-way ANOVA). We
also assessed a treatment protocol in which treatment with 50 mkd of tofa started on diseased mice
at day 5 and this completely abrogated GvHD. FACS analysis demonstrated reduced expression of
OVA-specific TCR and reduced activation markers (CD62L and CD25) of OT-I cells in skin-drain-
ing lymph nodes after transfer of GFP/OT-I cells and treatment with 50 and 12.5 mkd of tofa. Tofa
also inhibited proliferation of OT-I cells stimulated by SIINFEKL (OVA peptide) in vitro. qRT-PCR
showed increased expression of IFN-γ-induced chemokine mRNA, CXCL9; 39-fold and CXCL1010;
22-fold, in the epidermis of vehicle-treated mice vs. 50 mkd tofa-treated mice 4 days post OT-I cell
transfer. Effects of tofa in this model may reflect inhibition of JAK signaling in IL-2 and IL-15 recep-
tor-pathways in OT-I cells and in IFN-γ receptor-pathways in keratinocytes. Tofa may be efficacious
in CD8 T cell-mediated skin diseases, including GVHD, lichen planus and discoid lupus erythe-
matosus.
038
Bullous pemphigoid is characterized by a reduction of skin-homing/circulating FOXP3+ Tregs
and by a down-regulation of the IL-10 pathway
P Quaglino,1 E Antiga,2 M Novelli,1 T Nardò,1 P Fava,1 R Ponti,1 S Osella-Abate,1 M Caproni,2
P Fabbri2 and M Bernengo1 1 Dermatologic Clinic, University of Turin, Torino, Italy and 2
Department of Dermatologic Sciences, University of Florence, Firenze, Italy
Few and controversial data are reported as to regulatory T-cells (Tregs) in bullous pemphigoid (BP).
Some authors failed to demonstrate Treg differences between BP and controls, whilst more recently
a significant reduction of FOXP3+ skin infiltrating T-cells was demonstrated. The objective is to ana-
lyze expression and distribution of naturally-occurring FOXP3+ Tregs, “antigen-induced” IL-10 and
TGF-beta producing Tregs, and CD8+CD28- Tregs in both lesional skin and blood of BP patients.
Skin and blood samples were taken from 23 BP patients at first diagnosis before treatment; blood
samples were collected also at the resolution of disease after therapy. Chronic dermatoses (psoria-
sis,PSO, and atopic dermatitis, AD) and healthy subjects (HC) were used as controls. Treg distribu-
tion was investigated using immuno-histochemistry, flow-cytometry (circulating levels of
CD4+CD25brightFOXP3+ and CD8+CD28- subsets), ELISA (IL-10 and TGF-beta serum levels) and
RT-PCR (blood FOXP3 expression). The FOXP3+/CD4+ ratio and the IL-10+/CD4+ ratio were sig-
nificantly lower in BP skin lesions compared to HC, psoriasis, and AD (p=0.001). The frequency of
circulating CD25brightFOXP3+ within the CD4+ subset was significantly reduced in PB (median:
1.5% vs 3.5% in HC (p=0.0005). The resolution of cutaneous lesions was paralleled by an increase
in CD25brightFOXP3+ cell subset up to HC values. No differences in CD8+CD28- cells were found
between BP and HC or before and after treatment. TGF-beta and IL-10 serum concentrations were
similar in BP patients and HC. After the disease resolution, BP patients showed significantly higher
IL-10 serum levels. Our findings show a reduction of skin-homing and circulating FOXP3+ Tregs
together with a down-regulation of IL-10 pathway, in BP patients. The increase of circulating Treg
and IL-10 serum levels after steroid treatment suggest an alternative action mechanism of these
drugs.
042
Dermal mesenchymal stem cells suppress CD8+ T lymphocyte derived from vitiligo patients
M Zhou,1 J Wu,1 F Lin,1 X Wu,1 Y Wan2 and A Xu1 1 The Third Hospital of Hangzhou,
Hangzhou, China and 2 Providence College, Providence, RI
It has been suggested that cytotoxic T cells infiltrating the perilesional margin are involved in the
pathogenesis of vitiligo, while the mechanisms remain elusive. Skin-derived precursor (SKP) cells
have been proven as a population of MSCs which are functional in immune suppression or tolero-
genic mechanisms. Preliminary studies have demonstrated that SKP cells separated from the der-
mis of foreskin are positive for CD44, CD73, CD90, CD105 but negative for CD11b, CD19, CD34,
CD45, and can be differentiated into osteoblasts and adipocytes in special conditional medium. To
understand the function of those cells on modulation of immunoreaction that depend on CD8+ T
lymphocyte in vitiligo patients, we co-cultured SKP cells with CD8+ T lymphocyte derived from the
perilesional margin of vitiligo patients. The proliferation and apoptosis of CD8+ T lymphocytes were
assessed by cell counter and flow cytometry respectively. We found that after co-culture with human
dermal mesenchymal stem cells with ratio of 1:1, 1:2, 1:5, 1:10, the proliferation of CD8+ T lym-
phocyte was inhibited significantly (1.1 fold/3d, 1.26 fold/3d, 1.3 fold/3d, 1.36 fold/3d, P<0.001),
compared with control group (2.8 fold/3d). After co-culture with human dermal mesenchymal
stem cells with ratio of 1:1, 1:2, the apoptosis rate of CD8+ T lymphocyte also increased remark-
ably (9.6±1.5%, 6.6±1.3%, P<0.01), compared with control group (3.2±0.6%). We conclude that
skin-derived precursor cells suppress CD8+ T lymphocyte of vitiligo patients, and may play impor-
tant roles in immune modulation in vitiligo patients.
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Immunization with MOG fused to a novel single chain fragment variable (scFv) for murine
DEC-205 suppresses allergic experimental encephalomyelitis (EAE) in mice
S Ring, A Enk and K Mahnke Dermatology, Ruprecht-Karls-University, Heidelberg, Germany
The antigenreceptor DEC-205 is expressed by Dendritic cells (DC) and greatly increases antigen
presentation. We have shown that in vivo loading of DC with antigen via anti-DEC-205:antigen con-
jugates induces immunosuppressive regulatory T-cells (Treg). Therefore we set out to create single
chain fragment variables (scFv) specific for DEC-205 fused with the EAE antigen MOG, to target
non-activated DC for induction of tolerance to EAE in vivo. A non-binding anti-b-gal scFv:MOG was
created as control. ScFv:MOG fusions proteins were expressed and purified, and immunohisto-
chemical staining of cytospins from isolated CD11c+ cells displayed a positive staining for DEC-
scFv, colocalizing with MHC class II. For functional testing DEC-scFv:MOG was injected into
mice. Lymph node DC were isolated thereafter and cocultivated with MOG-specific (2D2) T-cells.
Strong T-cell proliferation was induced by DC from mice injected with DEC-scFv:MOG in contrast
to controls. When analyzing the T-cell populations in DEC-scFv:MOG injected mice, we found
enhanced numbers of CD4+CD25+FoxP3+ Treg (16% of CD4) as compared to control animals (10%
of CD4). Most importantly, when EAE was induced in either DEC-scFv-MOG-injected or in control
mice, none of the DEC-scFv:MOG injected mice developed EAE symptoms. In contrast, all animals
in the control group developed a severe EAE. Thus, these data indicate that targeting of MOG to
steady state DC in vivo prevents EAE by a Treg-driven mechanism.
044
Perilesional CD8+ T cells from vitiligo patients that fail in transplantation induce autologous
melanocyte apoptosis
J Wu,1 M Zhou,1 D Liu,1 F Lin,1 X Luo,1 Y Li,1 D Zhao,1 Y Wan2 and A Xu1 1 The Third Hospital
of Hangzhou, Hangzhou, China and 2 Providence College, Providence, RI
Vitiligo, a depigmenting disorder of the skin characterized by achromic macules due to the absence
of melanocytes, is thought to result from an autoimmune mediated destruction of melanocytes in
the epidermis. Cytotoxic T cells infiltrating the perilesional margin are suggested to be involved in
the pathogenesis of this disease. Surgical interventions are still considered useful when lesions are
clinically stable, while partial failure to repigment is observed. To improve the therapeutic efficacy,
we investigated the local microenvironment of recipient area. T cells obtained from perilesional skin
biopsies from vitiligo patients who failed in transplantation at least twice were cultured and expanded
in vitro. Flow cytometry data revealed an increased levels of expression in perilesional T cells com-
pared to peripheral CD8+T cell by measuring the expression of CD69 and CD137. The former is
65.98% and 46.18%, whereas the latter is 22.70% and 25.48%. We co-cultured perilesional T
cells and autologous melanocyte and then assessed melanocytes apoptosis by flow cytometry. The
results showed that the apoptosis rate of co-cultured melanocytes is significantly higher than that
of single melanocyte culture. The apoptosis rate is 18.45%, 15.83%, 19.08% respectively when the
ratio of MC:TC is 1:1, 1:2 and 1:5, while the apoptosis rate of single MC culture is 6.45%. This
result suggests that activated CD8+T cells in the recipient area may be attributable to the failure of
transplantation. Treatments aimed at reducing CD8+T cells in the local area may improve thera-
peutic effects.
045
Dysregulation of the Th17 pathway in alopecia areata
MM Van Acker,1 K Andrews,2 K Seiffert-Sinha2 and AA Sinha2 1 Michigan State University
College of Osteopathic Medicine, East Lansing, MI and 2 Dermatology, University at Buffalo
and Roswell Park Cancer Institute, Buffalo, NY
Recently, a new subset of IL17 secreting T helper cells, Th17, has been shown to be important in
certain autoimmune conditions, but has not been well evaluated in Alopecia areata (AA). We
investigated the extent to which cytokines associated with the Th17 pathway are differentially
expressed in patients with AA and its clinical subtypes in comparison to healthy relatives and unre-
lated controls. Serum samples were collected from 64 AA patients, 16 healthy relatives, and 16
healthy blood donors with no family history of autoimmune disease. AA patients were divided into
disease subtypes based on the National Alopecia Areata Foundation classification. A comprehen-
sive set of Th17 related cytokines was evaluated by ELISA: i) cytokines that promote Th17 differen-
tiation in naive T cells (IL1β, IL6, IL21, IL23, and TGFβ1), and ii) cytokines produced by Th17 cells
(IL6, IL10, IL17A, IL21, IL22, and TNFα). Additionally, we evaluated the Th1 hallmark cytokine IFNγ.
Differences between individual groups were assessed by Kruskal Wallis test (p < 0.05). We found
a significant elevation in the Th17 products IL17A (p=0.00) and TNFα (p=0.04), and the Th17 inducer
IL23 (P=0.03) in AA patients regardless of disease subtype compared to controls. Of note, healthy
family members grouped together with patients in terms of elevated Th17 related cytokines, distinct
from unrelated controls. The same inheritance specific upregulation was also seen for IFNγ. No sig-
nificant differences were detected between disease subgroups. The elevation of Th17 cytokines in
healthy controls related to AA patients indicates Th17 dysregulation in AA may be genetically based.
Of note, one unrelated control displayed elevated levels of IL17A and IL23 similar to those detected
in patients. One year after initial blood draw two well-circumscribed 1x1 cm persistent areas of
beard hair loss consistent with the diagnosis of AA were reported by this individual, indicating that
the elevation in Th17 related cytokines may have predictive value.
046
Scurfy mice reveal strong autoimmune skin inflammation with Th2-deviation of skin-infil-
trating CD4+ T cells and high epidermal expression of thymic stromal lymphopoietin (TSLP)
EN Hadaschik, B Heckmann and AH Enk Dermatology, University of Heidelberg, Heidelberg,
Germany
Scurfy mice lack functional regulatory T cells (Treg) due to a mutation in the foxP3 gene encoding
a transcription factor crucial for the development and function of Treg. Scurfy mice spontaneously
develop autoimmune inflammation in multiple organs including the skin and this disease has been
shown to be CD4+ T cell-mediated. We analyzed the inflammatory infiltrate in Scurfy skin and the
cytokine profile of skin-infiltrating autoreactive CD4+ T cells particularly with regard to Thymic Stro-
mal Lymphopoietin (TSLP) as potential differentiation factor. FACS-analysis revealed CD4+ T cells
and granulocytes as the predominant cells in inflamed skin. After isolation of CD4+ T cells from
inflamed Scurfy skin these cells secreted high levels of Th2-cytokines (IL-4 and IL-5) and low levels
of the Th1-cytokine interferon-γ as determined by intracellular FACS-analysis after in vitro restimu-
lation with PMA/Ionomycin. We then analyzed the expression of TSLP, a soluble factor known to
mediate Th2-differentiation of CD4+ T cells: In contrast to WT animals Scurfy mice show high
TSLP-serum levels measured by ELISA. We analyzed TSLP expression in inflamed Scurfy skin by
immunohistochemistry since TSLP is secreted by epithelial cells under stress-conditions. We found
strong TSLP expression in Scurfy epidermis in contrast to WT epidermis. To determine if skin-infil-
trating CD4+ T cells can respond to TSLP we analyzed TSLP-receptor-expression by FACS. CD4+ T
cells in Scurfy but not WT skin show high TSLP-receptor expression. In summary we show that
skin-infiltrating CD4+ T cells in Scurfy mice spontaneously develop a Th2-phenotype with overex-
pression of the Th2-differentiation factor TSLP in Scurfy epidermis and serum as potential driving
force for this Th2-differentiation.
047
Benefits of psychological stress in inflammatory dermatoses explain conservation of this com-
ponent of the stress response during evolution
T Lin,1,2 M Man,1 J Santiago,1,3 M Hupe,1 G Martin-Ezquerra,4 J Youm,1 C Trullas5 and K Feingold6
1 Derm, VA Med Ctr/UCSF, San Francisco, CA, 2 Derm, Natl Cheng Kung Univ Hosp, Tainan,
Taiwan, 3 Derm, Hosp Genl Univ de Ciudad Real, Cuidad Real, Spain, 4 Derm, Hosp del Mar-
IMIM/Univ Auto de Barcelona, Barcelona, Spain, 5 R&D, ISDIN, Barcelona, Spain and 6 Med,
VA Med Ctr/UCSF, San Francisco, CA
Psychological stress (PS) is widely assumed to exacerbate many systemic and cutaneous inflam-
matory disorders. PS also compromises multiple functions in normal skin, including permeability
barrier homeostasis, wound healing, and epidermal innate immunity, effects that have been linked
to increased production of endogenous glucocorticoids (GC). Accordingly, systemic or topical GC
replicate all of these PS-provoked alterations in cutaneous function. Because of the associated ele-
vation in endogenous GC, we hypothesized that PS instead could exert beneficial, anti-inflamma-
tory effects, rather than exacerbating disease. We assessed this hypothesis in three immunologically-
diverse, mouse models of cutaneous inflammation: i) single-hapten challenge-induced, acute allergic
contact dermatitis [ACD]; ii) repeated hapten (x3) challenges, producing a subacute allergic con-
tact dermatitis [SACD]; and iii) a phorbol ester-induced, acute irritant contact dermatitis [ICD] model.
Sustained, motion-restricted PS induced the expected increase in endogenous GC, which was par-
alleled by a reduction in inflammation, improved permeability barrier homeostasis, and normal-
ization of serum IgE levels in the three models. Since the seemingly-paradoxical benefits of PS in
these models were reversed by systemic co-administration of the GC receptor antagonist, mifepro-
stone (Ru486), the PS-induced improvement can be attributed to the PS-induced increase in endoge-
nous GC. Thus, in contrast to current dogma, PS could benefit rather than aggravate, established
cutaneous inflammatory dermatoses, due to the anti-inflammatory activity of increased endogenous
GC. If benefits of PS are verified for extracutaneous tissues, this observation could explain why this
component of the stress response has been conserved during human evolution.
048
Meta-analysis reveals ‘global’ psoriasis transcriptome with links to cardiovascular, metabolic
and other comorbidities
S Tian,1 JG Krueger,1 A Jabbari,1 K Li,2 C Brodmerkel,2 M Lowes1 and M Suarez-Farinas1 1
Laboratory for Investigative Dermatology, Rockefeller University, New York, NY and 2 Janssen,
Radnor, PA
Psoriasis transcriptomes create a molecular disease definition and provide biological insights into
pathogenesis. In this regard, one needs to establish a disease profile consistent across different
studies/patients. However, many variables influence microarray results, and an intersection of 5 pub-
lished studies yielded only 78 (22) up (down) regulated genes. In order to establish a robust molec-
ular definition of psoriasis, a meta-analytic approach was conducted. Raw data from 5 microarray
experiments of 386 paired samples was uniformly preprocessed using bias-reducing techniques. A
random-effect meta-analysis model was used to assess differences between LS and NL samples.
Among genes present in hgu133a2 chips, our model detects 677 (443) genes that were up (down)
regulated in psoriasis lesions across 5 studies simultaneously. When only 3 studies using hgu133plus2
chips were considered 1111 (764) up (down) regulated genes were identified. Pathway analysis
revealed key cytokines (not directly detected on microarrays) such as IL-17A, IFNγ and TNF as cen-
tral nodes in the most over-expressed networks. Interestingly, top canonical pathways included
Atherosclerosis Signaling and Fatty Acid Metabolism, which highlight the relationship between pso-
riasis and systemic manifestations such as metabolic syndrome. Comparison of the global tran-
scriptome with sequencing data (n=3) and/or psoriasis DEGs detected in skin-specific layers (col-
lected by LCM), have higher agreement than individual studies. 11 previously unidentified genes
were confirmed by RT-PCR. This metanalysis yields patient-specific profiles (normalized across stud-
ies) that can be mined in several ways. Psoriatic biomarkers were identified using Meta Threshold
Gradient Directed Regularization. In addition, heterogeneity of important psoriasis pathways was
explored in this large population. This global transcriptome represents a robust pool of candidate
genes for further discovery of pathogenesis and treatment evaluation.
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Myeloid-derived suppressor cells (MDSC) regulate autoimmunity via the DC-HIL receptor
J Chung, K Tamura, PD Cruz and K Ariizumi Dermatology, UT Southwestern, Dallas, TX
Whereas regulatory T cells (Treg) prevent autoimmune disease by suppressing activation of autore-
active T cells, a role for MDSC (the most potent regulator of T cell function) remains unclear. Hav-
ing discovered DC-HIL to mediate MDSC’s suppressor function, we asked whether DC-HIL+ MDSC
participate in autoimmune regulation. Experimental autoimmune encephalomyelitis (EAE) was
induced in B6 wild-type (WT) mice by immunizing with MOG peptide, and their myeloid cells in
spleen analyzed for DC-HIL expression. EAE increased frequency of: dendritic cells (DC) and
macrophages (MΦ) from 3% to 10%; Treg from 10% to 15%; and most dramatically, MDSC from
2% to 45%. In unimmunized mice, DC-HIL was expressed constitutively by DC and MΦ but not at
all by Treg nor MDSC. EAE stimulated MDSC to express DC-HIL (80%), but not Treg (0%). We
assessed effects of these cells from EAE mice on T cell activation. DC or MΦ stimulated naive T cell
proliferation, with no effect on pre-activated T cells. Conversely, MDSC had no effect on naive T
cells, but inhibited proliferation of pre-activated T cells 5-fold greater than Treg. Ab blockade of
DC-HIL function did not alter DC/MΦ’s stimulatory function but completely abolished MDSC’s sup-
pressor effect. We also examined effects of DC-HIL knockout (KO) on EAE. WT or KO mice (n=11)
were immunized and scored for clinical severity (0-5). WT mice manifested EAE (score = 1) by 12
days, peaked (2.5 ± 0.4) at 20 days, and remitted (1.5 ± 0.7) in 30 days. By contrast, KO mice had
earlier onset (6 days), higher peak response (4 ± 0.7) and slower remission (3.4 ± 0.5) by 30 days
(p<0.001). Hyperactivation of T cells was shown by more leukocytes in spinal cord and rise in IL-
17/IFN-γ-secreting T cells. Finally, injection of MDSC from EAE-WT (but not EAE-KO) mice ame-
liorated EAE in (mature T cell-lacking) Rag2-/- mice infused with MDSC-depleted WT splenocytes
(3.5 ± 0.9 vs. 2.0 ± 0.5, p<0.001). Because DC-HIL+ MDSC regulate activation of autoreactive T
cells as crucially as Treg, it may be possible to treat autoimmune diseases using DC-HIL+ MDSC-
based modalities.
051
Epiplakin is the major autoantigen in paraneoplastic pemphigus and is related to bronchioli-
tis obliterans
A Tsuchisaka,1 Y Natsuaki,1 T Kawakami,1 N Ishii,1 D Tsuruta,1 S Fujihara2 and T Hashimoto1 1
Department of Dermatology, Kurume University School of Medicine and Kurume University
Institute of Cutaneous Cell Biology, Kurume, Japan and 2 Department of Dermatology, Oita
University School of Medicine, Yufu, Japan
Most autoantigens in paraneoplastic pemphigus (PNP) are plakin family proteins. We previously
identified epiplakin using a patient serum, which was recently proved to be a plakin family protein.
In this study, we examined whether the 48 PNP sera also react with epiplakin by various methods
including immunoprecipitation-immunoblot (IP-IB). We first confirmed that KU-8 cells, human SCC
cell line, expressed strongly epiplakin by immunofluorescence. By IB analyses using extracts of both
normal human epidermis and cultured KU-8 cells, anti-epiplakin antibody detected the 450 kDa
epiplakin band, which disappeared by pre-absorption of the antibody with recombinant epiplakin
protein. However, by the two IB studies, no PNP sera detected epiplakin, while all PNP sera reacted
with both envoplakin and periplakin. To detect conformational epitope, we performed IP-IB with
KU-8 cell extracts, which showed that 35 (72.9%) of the 48 PNP sera reacted with epiplakin, whereas
13 PNP sera were negative. The reactivity was very strong in 19 PNP sera and relatively weak in 16
PNP sera. Epiplakin was not detected by any of 10 pemphigus vulgaris, 10 pemphigus foliaceus,
10 bullous pemphigoid and 20 normal sera, except for two normal sera with a faint reactivity. In
addition, we obtained all clinical and immunological data for the 48 PNP cases, which were sta-
tistically analyzed in terms of relationship to the presence of anti-epiplakin autoantibodies. The asso-
ciation to bronchiolitis obliterans (p=0.0425, X2=4.11) and the mortality (p=0.0341, X2=4.49) were
significantly higher in the group with anti-epiplakin antibodies. Strikingly, none of epiplakin-nega-
tive PNP cases showed the lung disease. Thus, this study indicated that epiplakin is one of the
major PNP antigens, and is related to bronchiolitis obliterans, the fatal condition in PNP.
053
Mechanisms of resistance of L-CTCL patients to alemtuzumab: What failure can teach us
R Watanabe, E Guenova, C Schlapbach, M Tawa, J Desimone, N Adams, A Dorosario, DC Fisher,
TS Kupper and RA Clark The Dana Farber/Brigham and Women’s Cancer Center, Boston, MA
We previously reported that low dose alemtuzumab (Campath) is effective in the treatment of leukemic
CTCL (L-CTCL) but not mycosis fungoides (MF). In 18 L-CTCL patients, blood disease improved in
100% and completely cleared in 89%. Skin disease partially cleared in 89% of patients and cleared
completely in 50%. Despite the fact that alemtuzumab penetrated into skin and bound to CD52 on
both benign and malignant skin T cells, it did not deplete T cells in skin. We used humanized mice
to demonstrate that neutrophils were required for alemtuzumab mediated T cell depletion. We
observed three separate mechanisms of alemtuzumab resistance in L-CTCL patients. T cells lost
expression of CD52 in two patients and one patient developed a neutralizing antibody that blocked
alemtuzumab binding to T cells. Finally, we observed emergence of skin resident, non-recirculat-
ing clonal malignant T cells in patients who previously had diffuse erythema and circulating malig-
nant T cells. These patients experienced clearing of their diffuse erythema but subsequent devel-
opment of fixed inflammatory skin lesions. In these patients, additional skin directed therapies
induced full remission. Highly migratory central memory T cells (TCM) are known to differentiate
into sessile skin resident effector memory T cells (TEM) and this ability appears to be preserved in
the malignant T cells of at least some patients with L-CTCL. In summary, low dose alemtuzumab
depletes T cells in blood but not in skin likely because neutrophils, which are rare in normal skin,
are required for T cell depletion. Patients developed resistance to alemtuzumab by down regula-
tion of CD52 on T cells, development of blocking antibodies, or differentiation of the malignant T
cells into skin resident TEM. Careful study of our L-CTCL patients is providing insights into the mech-
anism of action of alemtuzumab and the differential biology of TCM and TEM.
052
Expanding the psoriasis disease profile: Risk pathways for cardiovascular and metabolic dis-
eases are expressed in psoriasis skin lesions
K Li,1 M Suarez-Farinas,2 J Fuentes-Duculan,2 K Hayden,1 C Brodmerkel1 and JG Krueger2 1
Immunology & Biomarkers, Janssen Research & Development, Radnor, PA and 2 Laboratory
of Investigative Dermatology, Rockefeller University, New York, NY
Psoriasis is a complex disease with an expanding definition of its pathological features. We sought
to expand/refine the psoriasis transcriptome using 85 paired lesional and non-lesional samples from
a cohort of patients with moderate-to-severe psoriasis vulgaris who were not receiving active pso-
riasis therapy. This new analysis identified 4175 probe-sets (representing 2725 unique known genes)
as being differentially expressed in psoriasis lesions compared with matched biopsies of non-lesional
skin (FDR<0.05; FCH>2). These represent the largest and most comprehensive set of genes defin-
ing psoriasis at the molecular level and within the newly-identified genes, links to functional path-
ways associated with metabolic diseases/diabetes and to cardiovascular risk pathways are identi-
fied. Interestingly renin, a molecule regulating blood pressure, was shown to be over-produced in
skin lesions at mRNA and protein levels. In addition, we profiled the serum of moderate-to-severe
psoriatics compared with healthy controls to assess the overlap of over-expressed lesional genes
with over-expressed systemic proteins. We identified linkage of the functional pathways in lesional
skin associated with metabolic diseases/diabetes and cardiovascular risk with those pathways over-
expressed in the serum, suggesting a potential linkage between altered gene transcription in the skin
and comorbidities commonly seen in patients with moderate-to-severe psoriasis.
050
Soluble adenylyl cyclase is necessary for IL-22-dependent keratinocyte proliferation
A Diaz,2 L Levin,2 J Buck2 and J Zippin1 1 Dermatology, Weill Cornell Medical College of Cornell
University, New York, NY and 2 Pharmacology, Weill Cornell Medical College of Cornell
University, New York, NY
The pathogenesis of psoriasis has been a hotly debated topic for decades. Initial research focused
on a keratinocyte role in the disease; in fact, until the early 1980s, psoriasis was treated as a dis-
ease primarily of keratinocytes. Early work also suggested that second messenger signaling path-
ways, namely cAMP, were important, but a clear source or role for cAMP was never firmly estab-
lished. We study a distinct source of cAMP in mammalian cells called soluble adenylyl cyclase
(sAC). Unlike transmembrane adenylyl cyclases (tmACs), sAC is not responsive to G proteins, and
instead is regulated by calcium, bicarbonate ions, and ATP. In addition, sAC is present in the nucleus,
mitochondria, and cytoplasm. We previously published that sAC is normally present throughout
the cytoplasm in keratinocytes, but in psoriatic lesions, sAC is present in the nucleus and is associ-
ated with activated CREB protein. This suggested that sAC may be involved in psoriasis pathogen-
esis. We examined the role of sAC in keratinocyte proliferation downstream of the cytokine IL-22.
We measured cAMP production in human keratinocytes downstream of IL-22 in the presence and
absence of sAC inhibitors. To explore the role of sAC in vivo, we injected IL-22 into mouse ears and
measured acanthosis in the presence or absence of sAC inhibitor or in sAC KO mice. In a human
keratinocyte cell line, IL-22 increased the cellular cAMP level in a dose-dependent manner, and
this effect was completely inhibited by KH7 (a specific inhibitor of sAC). Injection of IL-22 induces
both acanthosis and parakeratosis in mouse epidermis and inflammation in the dermis. The effects
of IL-22 are reduced in sAC KO mice or following topical application or intradermal injection of
KH7. These data suggest that sAC activity is essential for IL-22-dependent cAMP production and
psoriasis-like pathogenesis in mouse skin.
054
Anti-Desmoglein 1 autoantibodies from Fogo Selvagem recognize LJM11, a member of the
“yellow” family of salivary proteins from Lutzomyia longipalpis
Y Qian,1 JS Jeong,1 M Maldonado,1 F Evangelista,1 BF Qaqish,1 V Aoki,2 G Hans-Filhio,3
EA Rivitti,2 JG Valenzuela4 and LA Diaz1 1 University of North Carolina, Chapel Hill, NC, 2
University of Sao Paulo, Sao Paulo, Brazil, 3 University of Mato Grosso do Sul, Mato Grosso
do Sul, Brazil and 4 NIAID, NIH, Rockville, MD
It has been hypothesized that hematophagous insect bites may initiate the autoantibody response
in Fogo Selvagem (FS). Lutzomyia longipalpis (LL) is prevalent in endemic regions of FS in Brazil,
where inhabitants are constantly bitten; hence salivary gland proteins (SGLL) may be the sensitiz-
ing antigen(s) in FS. In this study we found by ELISA that FS sera (n=45) have high levels of IgG4
and IgE anti-SGLL antibodies than healthy US controls (hUSc) (n=43) (p<0.001), the levels of which
are significantly correlated (r=0.58, p<0.0001). The IgG4 anti-Dsg1 and anti-SGLL also correlate
(r=0.56, p<0.0001). Two IgG4 monoclonal anti-Dsg1 antibodies derived from FS also recognized
SGLL antigens, a reaction which is inhibited by human recombinant Dsg1 (hrDsg1). Additionally,
sera of FS patients (n=10), hUSc (n=10) and controls from endemic areas of Brazil (n=10) were tested
for their reactivity with LJM11, a member of the “yellow” protein family of SGLL known to be
highly immunogenic to humans. We found that FS sera and the two IgG4 monoclonal antibodies
recognize LJM11. Furthermore, the binding of IgG4 monoclonal antibodies to LJM11 is Ca2+ depend-
ent, and is substantially inhibited by hrDsg1. A representative FS serum and an IgG4 monoclonal
anti-Dsg1 antibody bound LJM11 by immunoprecipitation (IP). Finally, mice immunized with LJM11
produced antibodies that recognize not only LJM11, but also hrDsg1 by ELISA and IP. These find-
ings strongly suggest that insect bites may deliver salivary antigens that drive the production of cross-
reactive anti-Dsg1 antibodies in humans and hence FS. This data provides further evidence that envi-
ronmental factors contribute to the development of this autoimmune disease.
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CD200, a molecule that can suppress T cell responses, is expressed on human Merkel cell car-
cinomas
M Dowlatshahi, T Hollmann, J Scanlon, L Wang, Q Zhan, G Murphy, A Gehad, J Teague and
RA Clark Brigham and Women’s Hospital, Boston, MA
Merkel cell carcinomas (MCC) are rare, highly malignant polyomavirus-associated skin cancers that
are infiltrated by tumor-specific T cells with suppressed activation. Signals provided by CD200, the
ligand for the inhibitory immunoreceptor CD200R, suppress T cell anti-tumor response in vitro.
CD200 expression is an independent prognostic factor for reduced overall survival in various
leukemias and anti-CD200 antibodies are in clinical trials for treatment of CLL and multiple myeloma.
CD200 is also expressed in touch dome progenitor cells (TDPCs), the epidermal progenitor of the
Merkel cell. We studied expression of CD200 on 70 MCC samples from 55 patients by immuno-
histochemistry. All 70 (100%) showed CD200 staining on at least a portion of the malignant cells.
Two independent, blinded observers semi-quantitatively scored CD200 expression using both the
intensity of staining and the percentage of positive cells. The agreement rate of 79% and the weighted
kappa coefficient of 0.73 indicate substantial interobserver agreement. Cox regression analyses were
used to determine correlation between CD200 score and disease specific survival indicators, e.g.
time to first recurrence or survival time. Univariate and multivariate analyses failed to establish any
significant correlation between CD200 scores and patient outcomes. Multivariate models included
disease stage, treatment, age, immunosuppressed state, and primary site of tumor. CD200 was
expressed on 4/4 validated human MCC cell lines. MCC cell lines suppressed the activation and
proliferation of human skin T cells in vitro but neutralizing antibodies to CD200 had no effect. In
summary, we report that CD200 is strongly expressed on MCC tumors but does not confer a worse
prognosis and does not suppress T cell activation in vitro. Therefore, although CD200 may play an
immunosuppressive role in the other malignancies, it does not appear to affect immune responses
to MCC.
056
The pro-fibrotic cytokines IL-33 and IL-13 modulate dermal fibrosis via the A2A adenosine
receptor
RC Radusky, L Franks, J Feig, P Fernandez, AG Franks, BN Cronstein and ES Chan New York
University School of Medicine, New York, NY
We have previously demonstrated that the nucleoside adenosine mediates collage production and
induces dermal fibrosis in in vitro and in vivo models. IL–13 expression is upregulated in tissues
characterized by high levels of adenosine (adenosine deaminase-deficient mice). However, the
receptor(s) and mechanism involved in this upregulation are unknown. Here, we further charac-
terize the contributions of endogenous adenosine and adenosine A2A and A2B receptors in skin
fibrosis via IL-33 and IL-13 signaling. Human dermal fibroblasts were treated with A2A receptor
agonist (CGS-21680), A2A antagonist (ZM241385); A2B agonist (BAY606583), and A2B antagonist
(MRS1706). Fold changes in the expression of IL-13 and associated receptors were analyzed after
2 hours. Message for IL-33 and three IL-13 receptor proteins – IL-13Rα1, IL-13Rα2 and IL-4R, were
assessed using quantitative real-time PCR and compared to untreated controls. Stimulation of the
A2A receptor with CGS-21680 induces expression of IL-33 and three IL-13 receptors: IL-13Rα1, IL-
13Rα2, and IL-4R. A 2.8x increase in expression was found for IL-13Rα1 (p<0.05), 3.4x increase
for IL-13Rα2 (p<0.05), and 3.9x increase for IL-4R (p<0.05) was seen. IL-33 expression was increased
by 8.6x (p<0.05). These elevations were all blocked by the A2A receptor antagonist. Stimulation of
the A2B receptor alone does not cause significant changes in the expression of the receptors stud-
ied. Despite efforts at investigating the mechanisms underlying fibrogenesis in the skin of patients
with scleroderma, no effective antifibrotic therapy exists. The nucleoside adenosine induces expres-
sion of pro-fibrotic cytokine IL-13 and particularly its cognate receptors IL-13Rα1, IL-13Rα2, and
IL-4. Furthermore, upregulation of IL-33 may in part contribute to the induction of IL-13 expression
by A2A receptors. These findings suggest that blockade of the A2A receptor may be useful as a
novel therapeutic modality to prevent dermal fibrosis in scleroderma.
057
A role for IgE receptor expression on eosinophils in BP
KN Messingham,2 A Frydman,2 RJ Roewe2 and JA Fairley1,2 1 VA Medical Center, Iowa City, IA
and 2 Dermatology, University of Iowa, Iowa City, IA
We examined a role for IgE-mediated activation of eosinophils in the pathogenesis of bullous pem-
phigoid (BP). High affinity IgE receptor (FcεRI) expression was examined on eosinophils in the per-
ilesional skin or circulation of BP patients. Cryosections of diagnostic biopsies (n=4) or skin from
age-matched controls (n=6) were stained using major basic protein (MBP) and FcεRI-specific anti-
bodies. MBP+ cells were observed in all BP skin and 10-50% of these cells were also positive for
FcεRI. Control skin (6/6) had fewer MBP+ cells and no co-localization with FcεRI was observed.
Blood was collected from 29 BP patients and 11 controls, granulocytes were isolated, adhered to
glass slides, and MBP and FcεRI expression was evaluated. Disease severity was assessed on a
scale of 1-4; 4=active, new blisters/erosions over >10% of total body surface area; 3=active, local-
ized disease with <10% involvement; 2=remission with immunosuppressive medications; 1=dis-
ease remission in the absence of medications. When stratified by disease score, 71% patients with
a score =4, 56% of the patients with a score=3 and 50% of the patients with a score=2 had
MBP+FcεRI+ cells in their circulation. Similar findings were observed when FcεRI expression was
evaluated on peripheral eosinophils (CD49d+CD9+) by flow cytometry. In 5 patients for whom serial
samples were available, flow cytometry studies suggest that disease remission results in a loss of
FcεRI expression on circulating eosinophils. We determined if BP autoantibodies could stimulate
BP180 specific degranulation using an eosinophil line, 15HL-60. 15HL-60 cells were incubated
with BP or control antibodies, degranulation was triggered by adding the immunodominant region
of the BP180 protein, NC16A, and supernatants were collected and assayed by ELISA for the gran-
ule protein eosinophil derived neurotoxin (EDN). Incubation of cells with BP IgE caused BP180
specific release of EDN compared to incubation with control IgE or addition of a control protein.
These results suggest that FcεRI expression by eosinophils may contribute to BP pathogenesis.
058
Functional regulation of IL-31 production by its genetic polymorphism in patients with extrin-
sic atopic dermatitis
C Hong,1,5 H Yu,2,5 Y Ko,3 W Chang,4 H Chuang,3 G Chen2 and C Lee2,6 1 Dermatology,
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 2 Dermatology, Kaohsiung Medical
University, Kaohsiung, Taiwan, 3 Graduate Institute of Public Health, Kaohsiung Medical
University, Kaohsiung, Taiwan, 4 Graduate Institute of Genomic Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan, 5 Graduate Institute of Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan and 6 Dermatology, Kaohsiung Municipal Hsiao-Kang Hospital,
Kaohsiung, Taiwan
IL-31 blood level is known to correlate to disease severity in patients with AD. The IL-31 single
nucleotide polymorphism (SNP) was reported to associate with an intrinsic form of AD. However,
how IL-31 SNPs are associated with blood IL-31 level or disease severity in AD, particularly in extrin-
sic AD, in not known. We recruited 105 patients with AD (age 52.2 ± 22.4 years) and 210 controls
(age 55.2 ± 18.4 year) and measured blood level of IL-31 and determined two of IL-31 SNPs,
rs10847385 and rs7974857 chosen based on previous literatures and its prevalence in Han-Chi-
nese population, respectively. The result showed there were no associations between two selected
IL-31 SNPs and the occurrence of AD. However, the rs10847385 minor allele C was associated with
decreased blood IL-31 level, IgE, and less disease severity in patients with extrinsic AD. In vitro pro-
motor study in Jurkat cells showed the baseline expression of luciferase activity was similar in trans-
fected cells containing either allele A or C. However, when activated by anti-CD3/CD28 antibod-
ies, allele A-transfected cells had significantly higher luciferase activity than those transfected with
allele-C, indicating that C allele could cause lower transactivation. In summary, IL-31-rs10847385
polymorphism was significantly associated with IL-31 blood level, IgE level, and severity in extrin-
sic AD patients of Han Chinese origin in Taiwan, but not with their susceptibility to AD. The
rs10847385 C allele contributed to inadequate function of IL-31 promotor. We conclude that IL-31
genetic polymorphism might determine disease severity of AD rather than disease susceptibility to
AD in this population.
059
Studies using newly developed Dsg1/Dsg2 swapped molecules showed unique epitopes on
Dsg1 in five Japanese cases of oral pemphigus foliaceus, possibly new disease entity, which
showed oral mucosal lesion and reacted with Dsg1 but not Dsg3
H Koga,1,2 B Ohyama,1,2 N Ishii,1,2 T Hamada,1,2 T Dainichi,1,2 D Tsuruta1,2 and T Hashimoto1,2 1
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan and 2
Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan
Oral mucosal lesions developed in pemphigus vulgaris but not in pemphigus foliaceus (PF). This is
explained by Dsg-compensation theory; thus, in PF, Dsg3 over-expressed on the oral mucosa can
compensate the function of Dsg1 depleted by anti-Dsg1 antibodies and prevent oral lesion. We
collected five Japanese cases showing oral lesions, who reacted with Dsg1 but not Dsg3 by enzyme-
linked immunosorbent assay (ELISA). These cases were never reported and cannot be explained by
Dsg-compensation theory. We tentatively designated these cases as oral PF. Cases 1 and 2 showed
only oral lesions, and cases 3-5 additionally showed skin lesions. Histology showed suprabasal
acantholytic bulla in oral mucosal biopsy of case 1, and subcorneal acantholysis in skin biopsies
of cases 3 and 4. Direct immunofluorescence (IF) showed cell surface (CS) deposition of IgG in cases
1 and 4, and IgG and IgA in case 3. Indirect IF detected IgG anti-CS antibodies in cases 3-5.
Immunoblotting using human epidermal extract showed no reactivity to any known autoantigens
including Dsg1. IgA ELISA for Dsg1/Dsg3 showed IgA anti-Dsg1 antibodies in case 3. Desmo-
collins 1-3 (Dsc1-3) cDNA transfection method for both IgG and IgA showed only IgG anti-Dsc3
antibodies in case 4. By newly developed immunoprecipitation-IB analysis using five Dsg1/Dsg2
domain swapped molecules, cases 3-5 reacted with EC1and EC2, pathogenic domains of Dsg1. In
contrast, case 1 reacted with EC5 and EC3, and case 2 reacted only with EC5, which were consid-
ered non-pathogenic in classical PF. These results may indicate that the oral mucosal lesions in our
oral PF cases developed through antibodies to EC3-EC5 of Dsg1. Alternatively, the oral lesions might
be induced by IgA anti-Dsg1 antibodies or IgG antibodies to non-Dsg proteins, such as Dsc3.
060
Measurement of skin surface S100A7 / psoriasin amount in psoriasis patients during the bio-
logics treatment
M Karakawa, M Komine, S Hosoda, J Meephansan, H Tsuda, J Sugai and M Ohtsuki Department
of Dermatology, Jichi Medical University, Shimotsuke, Japan
S100A7/psoriasin is one of S100 protein family members discovered from psoriatic lesion. It is
reported that S100A7 is also involved in skin inflammation and keratinocyte proliferation espe-
cially in psoriasis. To investigated the S100A7 expression on the skin surface during the treatment
with biologics, and to evaluate the potential of skin surface S100A7 concentration as non-invasive
marker of psoriasis disease activity. we measured S100A7 expression on the skin surface using
skin-derived washing fluids collected by washing standardized area of the lesional and non-lesional
skin of the psoriasis patient by phosphate buffered saline (Harder; 2010). Skin-derived washing flu-
ids (SWF) were collected chronologically from patients during biologics treatment. S100A7 con-
centration in SWF was measured using enzyme linked immuno-sorbent assay (ELISA). Clinical course
of the treatment is evaluated and followed-up using psoriasis area and severity index (PASI) score.
We classified cases into three groups, i.e. generalized pustular psoriasis, atypical plaque psoriasis
with diffuse erythema, and typical plaque psoriasis. S100A7 concentration in lesional SWF was high
in each group, but was not correlated with PASI score. S100A7 concentration in non-lesional SWF
was high in generalized pustular psoriasis and atypical plaque psoriasis, and correlated with PASI
score. S100A7 concentration in blood samples and S100A7 expression in skin biopsy specimens
were also investigated. These results suggest that there is weak inflammation dependent on total
psoriasis activity on non-lesional skin in pustular and atypical plaque psoriasis patients, which was
reflected by S100A7 concentration in non-lesional SWF. S100A7 concentration in non-lesional SWF
is a possible disease activity marker of psoriasis.
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Next generation sequencing technology to explore anti-inflammatory activity of IKKa in pso-
riasis
G Spallone, E Botti, M Talamonti, B Marinari, V Pinetti, S Chimenti and A Costanzo Dermatology,
University of Rome “Tor Vergata”, Rome, Italy
Epidermal cell hyperproliferation and inflammation are key features of psoriatic skin. Inflammatory
cytokines such as TNFα and INFγ are important factors contributing to the maintenance of psori-
atic plaque phenotype and TNFα is target of effective biologic therapies. Psoriatic keratinocytes have
been shown to be hypersensitive to inflammatory stimuli, overproducing inflammatory cytokines
and chemokines. IKKα is a component of the IkappaB kinase complex, which is activated by sev-
eral inflammatory stimuli, including TNFa, and leads to the nuclear translocation of NFκB tran-
scription factors. In addition, IKKα has a totally different function, being necessary for the definite
exit of keratinocytes from the cell cycle and for the termination of NFκB-dependent transcription
of inflammatory genes. Both of these new functions are dependent on the nuclear fraction of IKKα.
We have hypothesized that IKKα may be defective in psoriatic skin, favoring hyperproliferation and
keratinocytes hypersensitivity to inflammation. Therefore, in this study we have examined IKKα
expression in normal and psoriatic skin observing a strong downregulation in psoriatic plaques that
correlated with increased NFκB activation. To determine at least in part the molecular mechanisms
responsible for nuclear IKKa anti-inflammatory activity, we performed ChIP-seq experiment on pri-
mary keratinocytes identifying several inflammatory genes involved in psoriasis pathogenesis (e.g.
IL23R, IL20RB, IL6R) as directly bound and repressed by IKKa. To confirm the anti-inflammatory
activity of IKKa in psoriasis, we downregulated its expression by specific siRNA and observed
increased IL-6 production in IKKa-depleted keratinocytes in esponse to TNFa. Treatment of patients
with the TNFa blocking agent etanercept induced re-expression of IKKα in keratinocyte nuclei that
correlated with decreased prolifartion and NFκB activation. These data suggest that IKKα molecule
may contribute to keratinocyte sensitivity to inflammatory stimuli in psoriasis.
063
TREM-1 is present on inflammatory antigen presenting cells in psoriasis
LA Hyder, J Fuentes-Duculan, LC Zaba, KC Pierson, N Eungdamrong, L Johnson-Huang,
M Suarez-Farinas and MA Lowes Laboratory for Investigative Dermatology, Rockefeller
University, New York, NY
Psoriasis is a chronic and debilitating skin disease with a global prevalence of 2%. Our group recently
described a population of antigen presenting cells that appear to be critical in the pathogenesis of
psoriasis, termed inflammatory myeloid dendritic cells (CD11c+ BDCA1-). To further characterize
these cells, we analyzed the published transcriptome of psoriatic lesional inflammatory myeloid
dendritic cells using Ingenuity Pathway Analysis. This analysis indicated that Triggering receptor
expressed on myeloid cells type-1 (TREM-1) signaling was a major canonical pathway. TREM-1 is
a member of the immunoglobin superfamily, active through the DAP12 signaling pathway, with an
unknown ligand. Activation through TREM-1 amplifies production of inflammatory cytokines, par-
ticularly in response to bacterial and fungal infections. TREM-1 immunohistochemistry was per-
formed to investigate the presence of TREM-1+ cells in a group of psoriatic patients who were treated
with narrow-band UVB therapy (non-lesional and lesional, and post-treatment skin samples, n=8).
TREM-1 was abundant in lesional samples, and decreased only in patients who responded to NB-
UVB. TREM-1 was co-localized with both psoriatic CD11c+ dendritic cells and CD163+
macrophages, but not with CD3+ T cells. The TREM-1 signaling pathway was also significant in the
transcriptome of monocytes treated overnight with TLR2 agonists, heat killed listeria monocytogenes
and peptidoglycan. Monocytes treated with these agents resemble psoriatic inflammatory myeloid
dendritic cells as they induce double positive IL-17/IFNγ T cells in an allogenic mixed leukocyte
reaction. Together, these data suggest that the TREM-1 signaling pathway offers a novel therapeutic
target to prevent the induction of inflammatory myeloid DCs and their pathogenic role in psoria-
sis.
065
Granular C3 dermatosis, a possibly new disease entity
D Tsuruta, N Ishii, H Koga, T Hamada, T Dainichi, C Ohata, M Furumura and T Hashimoto
Dermatology, Kurume University School of Medicine, and Kurume Institute of Cutaneous Cell
Biology, Fukuoka, Japan
Dermatitis herpetiformis (DH) is characterized by papulovesicular skin lesions, and neutrophilic
microabscesses and granular deposits of IgA (and/or C3) at the papillary dermis. On search of more
than 4000 cases of various autoimmune bullous diseases examined at our institute, we found 20
bullous disease cases, in which direct immunofluorescence (IF) detected granular deposits of only
C3 (no IgA) below basement membrane zone. These 20 patients showed several common features;
1) clinical features were DH-like eczematous vesicular lesions, bullous pemphigoid (BP)-like tense
blisters, or exsudative erythemas without blisters, 2) histopathological features were subepidermal
edema or blisters with mainly lymphocytic and partially eosinophilic or neutrophilic infiltrations,
and 3) dapsone or oral/topical steroid was effective. Studies using various indirect IF, immunoblot
and ELISA for both IgG and IgA failed to detect any antigens, including BP230, BP180, type VII col-
lagen, laminin 332, laminin gamma 1, LAD-1, Dsg1, Dsg3, epidermal transglutaminase (eTG),
tTG, gliadin, tTG/deamidated gliadin peptide (DGP), EMA and F-actin. By direct IF of frozen biopsy
skin sections from representative 6 patients using antibodies specific to various complement com-
ponents, while control BP skins were positive for C1q, C4 and factor B, these components for clas-
sical and alternative pathways were completely negative in all 6 patients. Components for lectin
pathway, including mannose binding lectin A (MBL) and H-, M-, L-focolins, were also negative in
all cases. These results indicated that the C3 deposits in our cases were not activated via any of
classical, alternative or lectin pathways of complement activation. We propose a putative name,
granular C3 dermatosis, for these cases, in which complements may be activated without binding
of autoantibodies and via possibly novel pathway. Or, the deposited C3 was produced by ker-
atinocytes, as reported by previous in vitro studies.
064
Agonistic binding of neurokinin 1 receptor is necessary for the development of cutaneous
effector Th1 and Th2 immunity
CH Ho,1 TL Sumpter,1 OA Tkacheva,1 WJ Shufesky,3 AE Morelli2,3 and AT Larregina1,2,4 1
Dermatology, University of Pittsburgh Sch. of Med., Pittsburgh, PA, 2 Immunology, University
of Pittsburgh Sch. of Med., Pittsburgh, PA, 3 Surgery, University of Pittsburgh Sch. of Med.,
Pittsburgh, PA and 4 The McGowan Institute for Regenerative Medicine, University of
Pittsburgh Sch. of Med., Pittsburgh, PA
Inability to resolve cutaneous inflammation accounts for the development of skin chronic inflam-
matory and autoimmune disorders such as contact and atopic dermatitis caused by pathogenic Th1
and Th2 responses, respectively. Resolution of cutaneous inflammation depends on a delicate
interaction between the immune and nervous systems. In spite of the facts that pro-and anti-inflam-
matory neuropeptides are secreted in the skin and skin draining lymph nodes, and that immune
cells secrete neuropeptides and express their receptors, the role of these mediators on Th1 and Th2
biased immunity is ill understood. It has been postulated that substance P and hemokinin-1, the
prototype pro-inflammatory neuropeptides, promote Th1 biased autoimmunity by agonistically bind-
ing the neurokinin 1 receptor (NK1R). We hypothesized that agonistic binding of NK1R favors Th1
as well as Th2 mediated immunity. To test our hypothesis we compared delayed type hypersensi-
tivity responses following in vivo treatment of C57BL/6 wild type (WT) or NK1RKO mice with either
Th1 (2-4-dinitrochlorobenzene) or Th2 (fluorescein isothiocyanate) sensitizers. We show that NK1RKO
mice had impaired development of both Th1 and Th2 immunity. Our results were further confirmed
in WT mice treated with either NK1R antagonists L760,330 or RP67,580 prior to sensitization. Mech-
anistic analyses demonstrated that NK1R signaling was necessary to promote acute inflammation
in skin and skin draining lymph nodes after sensitization as well as for the recall of effector immu-
nity to the skin following elicitation. We conclude that NK1R signaling is required for efficient devel-
opment of both Th1 and Th2 cutaneous effector immunity.
062
Comprehensive analysis of psoriatic skin and blood microarray datasets highlights novel
genomic “hot spots” of differential gene expression
A Coda, M Icen and A Sinha Dermatology, University at Buffalo and Roswell Park Cancer
Institute, Buffalo, NY
Although microarray technology has been a powerful tool to explore the psoriatic ‘transcriptome’,
there remain major gaps in our knowledge regarding the exact mechanisms and genetic basis of
disease. The goals of this study were to 1) define the differentially expressed genes (DEGs) between
lesional and nonlesional psoriatic skin and perform a comprehensive comparison of similar pub-
lished microarray datasets, 2) explore differential gene expression in the blood of psoriatic sub-
jects, and 3) evaluate the distribution of DEGs across the genome to identify the overlap with reported
susceptibility loci and illuminate the regions with over-represented DEG frequency (genomic ‘hot
spots’). We examined gene expression in 10 skin (5 lesional, 5 nonlesional) and 11 blood (6 psori-
atic, 5 non-psoriatic) samples using Affymetrix HG-U95A microarrays. Paired (skin) and unpaired
(blood) t tests and Benjamini-Hochberg method were used to evaluate differential gene expression.
We detected 535 (425 upregulated, 110 downregulated) DEGs in lesional skin at the 1% false dis-
covery rate (FDR) level. Evaluating nine microarray studies that have compared lesional and non-
lesional psoriatic skin, 34.5% of dysregulated genes were reported by more than one study. Our
group also identified 32 (7 upregulated, 25 downregulated) DEGs in the blood at 1% FDR. At 5%
FDR, 159 of 1529 skin (11.8%) and 18 of 153 blood (10.4%) DEGs mapped to one of the 12
PSORS loci. There were 20 skin and 2 blood-associated genomic ‘hot spots’ at 5% FDR for our
data, and 6 ‘hot spots’ for the replicated DEGs. Despite moderate consensus across microarray stud-
ies, merging of transcriptional data may help in emphasizing significant genes. DEGs that overlap
with PSORS loci may offer prioritized targets for downstream genetic fine mapping studies. Novel
DEG genomic ‘hot spots’ may provide new targets for defining susceptibility loci in future studies.
066
Evaluation of differential gene expression in Alopecia areata patients with concurrent autoim-
mune and nail disease
A Coda and AA Sinha Dermatology, University at Buffalo and Roswell Park Cancer Institute,
Buffalo, NY
To gain further insight into the genetic basic of clinical heterogeneity in Alopecia areata (AA), we
examined global gene expression patterns in the blood of AA patients with and without a history of
autoimmune disease (AI) {with AI, n=2; without AI, n=4}, and with and without a history of nail dis-
ease {with, n=2; without, n=4} utilizing Affymetrix U133 Plus 2.0 microarrays. A set of differen-
tially expressed genes (1% false discovery rate, Benjamini-Hochberg method with a +/- 2.5 fold-
change threshold) was generated for both analyses. We found 129 genes were up-regulated and 182
genes were down-regulated in patients with coexisting AI disease vs. AA patients without coexist-
ing AI disease. The majority of these genes are involved in cytokine signaling and immune cell traf-
ficking, antigen processing and presentation, and protein modification. A subset of 30 DEGs within
this list has been strongly implicated in the pathogenesis of various autoimmune diseases in previ-
ous work. In mapping the top 200 DEGs, we found two transcriptional “hot spots” at 5q23-q31 and
6p21, with 7 of the AA with AI-associated DEGs localizing to these regions. In comparing AA patients
with and without nail disease, 129 up-regulated genes and 117 down-regulated genes differentiate
these two groups. Ontologic analysis revealed dysregulation of PPAR alpha/RXR alpha signaling,
glycosaminoglycan (GAG) synthesis, Th2-related expression, and structural proteins including KRT40
in AA patients with nail disease. While the interpretation of these data is not fully clear, our find-
ings illuminate a number of genes/pathways of potential disease relevance.
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High degree of reproducibility in psoriasis gene expression analysis of two independent patient
populations
D Aires,1 A Menter,2 G Rockwell,3 P Prath,1 S Sedivy,4 O Tawfik,5 A Bowcock6 and AA Sinha7 1
Dermatology, University of Kansas School of Medicine, Kansas City, KS, 2 Dermatology, Baylor
University Medical Center, Dallas, TX, 3 Bioinformatics, Boston University, Boston, MA, 4
Dermatopathology, Physician’s Reference Laboratory, Overland Park, KS, 5 Pathology and
Laboratory Medicine, University of Kansas School of Medicine, Kansas City, KS, 6 Human
Genetics, Washington University, St. Louis, MO and 7 Dermatology, University at Buffalo and
Roswell Park Cancer Institute, Buffalo, NY
The molecular basis of psoriasis, a common but complex chronic inflammatory skin disease, remains
to be fully understood. Recent array-based studies have reported sets of disease associated tran-
scriptionally dysregulated genes. However, there is limited consensus across studies. While gene
set enrichment analysis (GSEA) uses complex algorithms and multi-gene pathways to address lack
of reproducibility, unfortunately GSEA does not address the impact of single genes. To fill this gap,
we evaluated 210 top candidate genes from an initial study (population 1), and then confirmed dif-
ferential expression in a second validation group (population 2). We found 138 genes replicated in
both groups, strengthening their likely relevance to disease processes. Of these, 71 have not previ-
ously been associated with psoriasis, and further work is required to define their potential role in
disease pathology and value as future therapeutic targets. Comparing uninvolved vs lesional skin,
our analysis highlights changes in pathways related to inflammation, cell regulation, neoplasia and
anti-neoplasia, and skin structure. These data support the multifactorial basis of psoriasis and our
validation studies help allay doubts about single-gene array / in-silico findings.
068
Delphinidin induces epidermal differentiation and inhibits proliferation and inflammation in
a three dimensional reconstituted skin model of psoriasis
HC Pal,1 S Sharma,1 S Ayehunie2 and F Afaq1 1 Dermatology, University of Alabama at
Birmingham, Birmingham, AL and 2 MatTek Corporation, Ashland, MA
Psoriasis is a chronic, inflammatory skin disease characterized by epidermal hyperproliferation and
aberrant keratinocyte differentiation. Several lines of evidence suggest that intrinsic alterations of
the epidermis may play an important role in the pathogenesis of psoriasis. Identification of natural
agents that possess the ability to abrogate these effects could be useful for the treatment of this dis-
ease. Delphinidin, present in pigmented fruits and vegetables, possesses potent antioxidant and anti-
inflammatory activities. In this study, we examined the effect of delphinidin on markers of epider-
mal differentiation, proliferation and inflammation by employing three dimensional models of normal
human reconstituted and psoriatic skin. Delphinidin (5-20 μM; 2-8 days) treatment of human recon-
stituted skin increased the processing of caspase-14, protein expression of transglutaminase-1, involu-
crin, loricrin and filaggrin in a dose- and time-dependent manner. In addition, delphinidin treat-
ment induced terminal differentiation resulting in more rapid formation of cornified envelopes
without inducing apoptosis. Next, studies were performed to establish the significance of these find-
ings by employing a three dimensional reconstituted skin model of psoriasis. Psoriasis is charac-
terized by down-regulation of differentiation markers, including caspase-14 and filaggrin, and by
upregulation of markers of proliferation (Ki67 and PCNA) and inflammation (iNOS) in the epider-
mis. Employing immunohistochemistry and western blot analyses, we found that treatment of pso-
riatic tissues with delphinidin (5-20 μM; 24-72 hrs) resulted in an increased expression of caspase-
14 and filaggrin. In addition, delphinidin treatment reduced these markers of cell proliferation and
inflammation. Under identical treatment conditions delphinidin had no effect on apoptosis. We sug-
gest that delphinidin could be a promising agent for treatment of psoriasis.
069
The presence of anti-type VII collagen antibodies in the patients with dystrophic epidermol-
ysis bullosa
D Woodley,1 X Wang,1 J Cogan,1 D Keene,2 Y Hou,1 M Amir1 and M Chen1 1 Dermatology,
University of Southern California, Los Angeles, CA and 2 Shriners Hospital for Children,
Portland, OR
Type VII collagen (C7) is the major component of anchoring fibrils that mediate epidermal-dermal
adherence. Mutations in the gene, COL7A1, encoding for C7 cause an inherited skin disease DEB,
while autoantibodies to C7 cause an acquired autoimmune disease epidermolysis bullosa acquisita
(EBA). In this study, we screened 20 patients with recessive DEB (RDEB) and characterized their
mutations and disease phenotype immunologically and ultrastructurally. Eleven mutations created
premature termination codons and consisted of nonsense mutations, small insertions, deletions, and
splice-site mutations. The other 9 RDEB patients had missense mutations. We tested 20 RDEB patients
for expression of C7 at their cutaneous basement membrane zone (BMZ) by immunofluorescence.
Seven patients had normal C7 expression, 8 had reduced expression while 5 showed no detectable
C7 expression. Nevertheless, by transmission electron microscopy, all of these patients had signif-
icantly reduced, complete absence or abnormal anchoring fibrils. In these 20 RDEB patients we
tested for circulating anti-C7 antibodies in their plasma by ELISA and indirect immunofluorescence
(IIF). We detected anti-C7 antibodies in 12 out of 20 patients by ELISA and 6 out of 20 patients by
IIF on salt-split normal human skin substrate. The presence of anti-C7 antibodies was not depend-
ent upon the expression of C7 protein within the BMZ or the nature or the position of COL7A1 muta-
tions. All of the RDEB patients tested had negative direct immunofluorscence showing that anti-C7
antibody deposits were not present in their skin and that they did not have EBA. We conclude that
with the chronic wounding and healing of their skin, RDEB patients may have low level anti-C7
antibodies, but they are non-pathogenic and do not contribute to skin fragility or poor epidermal-
dermal adherence. These data will be useful for selecting and monitoring RDEB patients involved
in clinical trials designed to replace C7 in RDEB patients.
070
Use of constitutively active STAT6 transgenic mice to characterize calcipotriene-mediated
worsening of atopic dermatitis
MJ Turner, S Da Silva, MH Kaplan and JB Travers Indiana University, Indianapolis, IN
A 2 year old boy presented with abrupt onset of a severe flare of atopic dermatitis (AD) at applica-
tion sites of calcipotriene 0.005% solution and cream for presumed psoriasis. The flare significantly
improved 3 days after discontinuing calcipotriene and starting low potency topical corticosteroids.
Patch testing was negative at 48 and 120 hours for both calcipotriene formulations. To investigate
the mechanism by which calcipotriene aggravated this patient’s AD, we used Stat6VT transgenic
mice, a new model of AD (J. Immunol. 2010 v184 p3186-3189). These mice express a constitutively
active STAT6 protein, causing polarization towards Th2 cell development and a spontaneous AD-
like phenotype. Originally on the C57BL/6 background, this model was bred to the SKH1 hairless
background (Stat6VT.SKH1) to further investigate the cutaneous phenotype. Seventy percent of these
mice spontaneously developed the AD-like phenotype, with an onset between approximately 2-4
months of age. To determine if topical calcipotriene could trigger the AD-like phenotype, SKH1
(wild type) and Stat6VT.SKH1 mice were treated for seven days with daily application of calcipotriene
0.005% solution to the right upper back or 51% isopropanol vehicle to the left upper back. Vehi-
cle-treated skin appeared unaffected, while both groups of mice developed an eczematous erup-
tion on the calcipotriene-treated side. This eruption persisted only in the Stat6VT.SKH1 group after
discontinuation of calcipotriene. Analyses of this calcipotriene-induced eruption and spontaneously-
developed AD-like lesions in Stat6VT.SKH1 mice revealed similar histologic features including acan-
thosis and spongiosis and increased levels of transcripts for Th2 cytokines. These findings provide
the first known report that calcipotriene can worsen human AD, and that calcipotriene application
offers a reliable means to induce an AD-like phenotype in Stat6VT.SKH1 mice, thus providing a
means to investigate the mechanism underlying calcipotriene-mediated worsening of AD.
071
IKKi/IKKε mediates inflammatory induction of DEFB4 in keratinocytes
S Lambert,1 SW Stoll,1 M Uhm,2 AR Saltiel2 and JT Elder1 1 Dermatology, University of
Michigan, Ann Arbor, MI and 2 Life Science Institute, Ann Arbor, MI
TRAF3IP2 is one of at least 18 psoriasis susceptibility loci and has also been implicated in psoriatic
arthritis, with a known disease-associated missense polymorphism (D10N). TRAF3IP2 encodes Act1,
an adapter protein with ubiquitin ligase activity that connects the IL-17 receptor to NFkB, p38 and
ERK pathways. In cultured keratinocytes (KC) treated with both IL17 and TNF-α, we have shown
that Act1 mediates the synergistic induction of defensin hBD2 (DEFB4), as well as other key cytokines,
chemokines and innate defense genes which are upregulated in psoriasis lesions. Recently, the
IKK-related kinase IKKi/IKKε has been shown to phosphorylate Act1, favoring the binding of
TRAF2/TRAF5 over TRAF6 to Act1, and subsequently increasing chemokine mRNA stability by
removing the RNA-destabilizing protein ASF from target mRNAs such as CXCL1 (Nat Immunol
12:813, 2011). However, the activating stimulus for IKKi is presently unclear. Our data suggest that
the TLR3 ligand poly(I:C), which activates interferon-dependent antiviral responses in an IKKi-depend-
ent fashion in HEK293 cells (Nat Immunol 4:491, 2003), markedly induces DEFB4 mRNA under
basal, IL-17, and IL-17+TNF-α stimulated conditions in KC (3-fold, 10-fold, and 3-fold at 30 h,
respectively, n = 6, p < 0.03 for all). TNF-α induces IKKi mRNA expression by 3-fold at 30 h (p =
6.9e-08, n = 6), whereas IL-17 is ineffective. Consistent with an effect of this induction on Act-1-
mediated responses, shRNA-mediated silencing of TRAF3IP2 blocked induction of DEFB4 mRNA
by TNF-α and by IL-17+TNF-α, but surprisingly not by IL-17 alone. Finally, inhibition of IKKi using
the anti-inflammatory drug Amlexanox reduces DEFB4 expression, further suggesting that IKKi may
be involved in an Act-1-dependent signaling cascade. Sources of double-stranded RNA such as
viruses may potentiate these responses in vivo.
072
Differential activation of the inflammasome in loaded skin of young and elderly individuals
O Stojadinovic,1 J Minkiewicz,2 A Sawaya,1 J De Rivero Vaccari,2 RW Keane2 and M Tomic-Canic1
1 Dermatology and Cutaneous Surgery, University of Miami, Miami, FL and 2 Physiology &
Biophysics Dept, University of Miami, Miami, FL
Approximately 1.3 to 3 million Americans suffer from pressure ulcers (PUs) with mortality rates as
high as 68% in advanced cases. It has been suggested that development of PUs involves an inflam-
matory response, but the underlying mechanisms remain undefined. Inflammasomes are large, intra-
cellular multiprotein complexes that play a central role in innate immunity and participate in the
development of various inflammatory diseases. Although PU affect bedridden and wheelchair bound
individuals of all ages, they are more frequent among the elderly. We hypothesized that both age
and mechanical load affect inflammasome activation and contribute to inhibition of healing. We
utilized a newly-developed bio-mechanical model and subjected human skin specimens to a con-
fined compression load of 300 KPa for 30 minutes, 1, 2, and 4 hours. Pressure-plate measurements
determined this load to be the maximum on sacral skin when a person is lying on their back. To test
the contribution of age we analyzed skin from three “young” (32.5 y.o.) and three “aged” (57.5 y.o.)
Caucasian female patients. Specimen morphology was analyzed by histology, collagen orientation
was evaluated using polarized light, and inflammasome components were quantified by immunoblot-
ting. We found focal disruption along the epidermal–dermal junction and altered orientation of
collagen fibers in aged skin 2 hours after loading when compared to skin derived from young indi-
viduals. In both unloaded and loaded skin of elderly individuals we found decreased inflamma-
some proteins (caspase-1,IL-1β and ASC) with aged skin showing significantly lower levels when
compared to young skin. In conclusion, our findings support the concept that aging contributes to
the degree of morphological change and decrease in inflammasome activation seen in response to
load, suggesting that in the elderly, a decline in the innate inflammatory response may play an impor-
tant role in the pathogenesis of PU.
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Direct recruitment of slan (6-sulfo LacNAc) dendritic cells to immune complexes in a model
of physiologically relevant fluid shear stress
T Döbel, A Lonsdorf, A Hänsel, A Enk and K Schäkel Dermatology, University Hospital
Heidelberg, Heidelberg, Germany
The recognition of immune complexes (ICs) by dendritic cells (DCs) is regarded as important path-
ogenic event in autoimmune diseases. Among the distinct subsets of blood DCs we previously
identified the population of slanDCs, a human DC subset characterized by pronounced expression
of the low affinity Fcγ receptor III (CD16). SlanDCs are highly proinflammatory and serve as a
major and early source of IL-12 and TNF-α. We show that expression of CD16 equips slanDCs with
a unique capacity to capture soluble ICs. In addition, we asked whether immobilized ICs, as found
in the vasculature in autoimmune diseases, can serve as an early signal to recruit proinflammatory
slanDCs. To this end we applied a flow chamber adhesion assay to measure the arrest function of
slanDCs to ICs. Interestingly, we could show that surface-coated ICs alone are highly efficient in
mediating the arrest of slanDCs under conditions that match venous blood flow. By specifically
blocking the FcγRs of slanDCs, we were able to show that adherence to immobilized ICs is largely
dependent on CD16. In contrast, blocking CD32 (FcγRII) only slightly inhibited the adherence of
slanDCs and blocking both CD16 and CD32 did not further increase arrest compared to blocking
of CD16 alone. To extend these findings, we employed a second model. Here, microslides were
seeded with human endothelial cells and incubated with anti-endothelial IgG antibodies prior to
measuring the arrest function of slanDCs under physiologic shear stress. These studies confirmed
our hypotheses that slanDC can be recruited under physiologic shear stress to antibodies or ICs
deposited on endothelial cells. Taken together, we identified CD16 as the critical structure for the
capture of soluble ICs and reveal that immobilized ICs can recruit slanDCs under defined shear
stress conditions. Our data provide first evidence for slanDCs as being a cell type that meets impor-
tant functional criteria for an involvement in the initiation of IC-mediated inflammation.
075
Organotypic in vitro human epithelial models with engineered gene knockdown or mecha-
nistic reporter functions
P Hayden,1 CE Mankus,1 P Lei,2 GR Jackson,1 J Bolmarcich,1 A Armento,1 S Andreadis2 and
M Klausner1 1 MatTek Corporation, Ashland, MA and 2 State University of New York, Amherst,
NY
In vitro human 3D epithelial models including skin (e.g. EpiDerm, EpiDerm-FT) and airway (e.g.
EpiAirway, EpiAirway-FT) are important advances over traditional monolayer cell cultures. These
models provide more realistic, in vivo-like structure, barrier properties, metabolic functions and dos-
ing capabilities compared to monolayer cultures. Here we describe development of organotypic
3D epithelial models with added features of engineered gene knockdown or toxicologic reporter
functions. To create NFkB and Nrf2 reporter models, early passage normal human epidermal ker-
atinocytes and dermal fibroblasts were transduced with lentiviral vectors containing the respective
transcription factor (TF) response elements linked to either GFP or luciferase. To create gene knock-
down models of NFkB, IL-1α, MMP-1 and MMP-7, lentiviral vectors containing tetracycline (Tet)
inducible shRNA and RFP were utilized. Stably transduced cells were selected by puromycin resist-
ance, expanded several passages and cyropreserved to produce large pools of cells for organotypic
epithelial model production. Organotypic structure and barrier properties of models produced from
the transduced cells were similar to models produced from untransduced cells, as determined by
histological assessment and barrier function measurements. NFkB and Nrf2 reporter models read-
ily responded to positive control treatments, TNFα and t-butylhydroquinone, respectively. GFP was
detected in fixed paraffin sections by fluorescence microscopy. Luciferase activity in tissue extracts
was quantified by microplate luminometer. In gene knockdown models, exposure of models to Tet
induced robust RFP expression and >70% knockdown of IL-1α gene and protein expression. These
gene knockdown and TF reporter models, together with additional in vitro human models that may
be produced by the methods demonstrated in the current work, will provide important new tools
for conducting mechanistic human toxicological studies.
077
The role of the IL12B associated psoriasis risk allele in the pathogenesis of psoriasis
X Xing, M Riblett, JJ Kochkodan, RP Nair, JJ Voorhees, JT Elder, A Johnston and JE Gudjonsson
Dermatology, University of Michigan, Ann Arbor, MI
The pathologic role of the psoriasis associated risk allele of the IL12B gene (defined by rs6887695
G) has been unclear. IL12B encodes the common p40 subunit of IL-12 and IL-23, cytokines with
key roles in Th1 and Th17 biology respectively. As we have previously shown, IFN-γ pre-stimula-
tion of peripheral blood-derived monocytes enhances the mRNA expression of IL12B, IL12A, IL23A
and IL1B in a stimulation (LPS) dependent manner (3-140-fold, p<0.001) and increases secretion
of both IL-12 and IL-23 (p<0.001) with IFN-γ pretreatment having greater effect on IL-12 produc-
tion. Using this approach, we found that homozygous rs6887695G carriers had increased expres-
sion of IL12B compared to individuals lacking this allele (P<0.01, n=29 and n=15) and a slight
increase in IL12A expression with LPS stimulation (p<0.05) whereas there was no change in IL23A
and IL1B expression. Serum IL-12p70 levels were increased in risk compared to non-carriers (p<0.05)
whereas IL-23p19 levels were decreased (p<0.001), whereas there was no difference in IL-22 lev-
els. QRT-PCR confirmed previously published findings of increased expression of IL12B and IL23A
in psoriatic skin (p<0.01) and decreased IL12A expression (p<0.05). However, measurements of
tissue lysates revealed increased levels of both IL-12p70 and IL-12p40 in psoriatic skin (p<0.01).
Global gene expression in psoriatic skin from 58 patients was correlated with IL12B risk allele dose
(0, 1 or 2 alleles). Five transcripts were enriched in risk allele carriers (p<0.01) and four of those
were specifically induced by IFN-γ in normal human keratinocytes (KC). In contrast, no effect was
seen after TNF-α or IL-17A treatment (n=3). Our findings demonstrate that the risk variant in IL12B
leads to its increased expression and, in the IFN-γ rich environment of psoriatic lesion, this leads to
increased IL-12 production, which may further amplify the IFN-γ signature thereby creating a pos-
itive feedback loop.
076
IL-13 is a pro-inflammatory cytokine active in psoriasis
JJ Kochkodan, X Xing, M Riblett, R Jan, A Johnston and JE Gudjonsson Dermatology, University
of Michigan, Ann Arbor, MI
Recent genetic studies have shown that a genetic risk variant (rs20541) in the IL13 gene on chro-
mosome 5 contributes to increased risk of psoriasis. However, the pathologic role of IL-13, which
traditionally has been classified as a Th2 cytokine, has remained unknown. To address this we first
measured IL-13 expression in psoriasis skin and observed increased levels of both IL-13 mRNA and
protein in lesional compared to uninvolved skin (3.1-fold and 2.4-fold respectively, p<0.01 and
p<0.001, n=38 and n=12 respectively). Flow cytometric analysis from lesional skin demonstrated
that IL-13 was primarily derived from CD4 and CD8+ T-cells (2-3% of total). There was increased
expression of both chains of the IL-13 receptor (IL4R and IL13RA1) in lesional compared to unin-
volved psoriatic skin (1.6-fold and 1.3-fold, p<0.0001 and p<0.05, respectively, n=38) whereas
IL13RA2, a soluble inhibitor of IL-13, was decreased (1.3-fold). IL13RA1 and IL4R expression by
cultured normal keratinocytes was induced by IFNg and IL-22 whereas TNFa and IL-17 promoted
expression of IL13RA2. Consistent with previously published findings, IL-13 with IFNg induced
increased expression of the monocyte attractants CCL2 and CCL5 (p<0.01 and p<0.05 respectively).
Immunohistochemistry and fluorescent microscopy revealed staining for IL-4R and IL-13Ra1 in pso-
riatic epidermis with intense foci of co-localization limited to few cells within the inflammatory
infiltrate. These cells corresponded to monocytes as confirmed by fluorescent microscopy and flow
cytometry. These cells showed dose-dependent increases in pSTAT6 phosphorylation to IL-13 whereas
T-cells were unresponsive. Using IFNg pre-stimulated monocytes in the presence of TNFa we observed
dose-dependent increase in IL12B, TNFA and TGFB1 expression by IL-13 with increase in IL-23
secretion (3-fold, p<0.05 respectively). These data suggest that IL-13 is an active participant in the
inflammatory network in psoriasis and acts on both the epidermis as well as the inflammatory infil-
trate to participate in and amplify Th17 responses.
074
Keratinocyte specific inactivation of Sharpin is critical in the mouse chronic proliferative
dermatitis (Sharpin<cpdm>) phenotype
CS Potter,1 KA Silva,1 V Kennedy,1 Z Wang,2 H HogenEsch2,1 and JP Sundberg1,2 1 Research and
Development, The Jackson Laboratory, Bar Harbor, ME and 2 Department of Comparative
Pathobiology, Purdue University, West Lafayette, IN
Two spontaneous allelic mutations arose in the mouse Sharpin gene resulting in the chronic prolif-
erative dermatitis (Sharpin<cpdm>) phenotype. These mutant mice develop severe and progressive
epidermal hyperplasia, apoptosis, dermal and visceral inflammation, and hypoplasia of secondary
lymphoid organs. Studies using in vivo full thickness skin yielded results different from those focus-
ing on in vitro mouse embryonic fibroblast cultures. Immunohistochemical localization of SHARPIN
protein was limited to the epidermis not dermal fibroblasts in the skin. This was confirmed by pro-
ducing a conditional Sharpin null allele (B6(Cg)-Tyrc<2J> Sharpin<tm1Sun>/Sun) when these mice
were crossed with a keratin 14 specific cre-recombinase (STOCK-Tg(KRT14-cre)1Amc/J) which reca-
pitulated the cutaneous phenotype. Furthermore, full thickness skin grafts from normal C57BL/6-
Tg(UBC-GFP)30Scha/J mice partially corrected the cutaneous phenotype of the spontaneous Sharpin
null mice (C57BL/KaLawRij-Sharpin<cpdm>/RijSunJ). These and other cre-recombinase studies with
our conditional Sharpin null mice demonstrate that fibroblasts may not be the cell type of choice
for defining the mechanisms by which SHARPIN regulates the NFKB and ubiquitinization pathways.
078
Th2 and Th22 mediators initiate and maintain progression of atopic dermatitis
JK Gittler,1,2 A Shemer,3 M Suarez-Farinas,2 I Cardinale,2 JG Krueger2 and E Guttman-Yassky1,2 1
Department of Dermatology, Mount Sinai School of Medicine, New York, NY, 2 Laboratory for
Investigative Dermatology, The Rockefeller University, New York, NY and 3 Department of
Dermatology, Tel-Hashomer Hospital and Tel-Aviv University, Tel Aviv, Israel
Atopic dermatitis (AD) is a common chronic inflammatory disease. Identification of the factors that
initiate and maintain skin inflammation in AD is critical in the development of new therapeutic
approaches. We sought to characterize the progression of AD from non-lesional (ANL) through acute
(ALS) and chronic (CLS) AD and determine the factors that initiate and sustain inflammation. We
performed genomic and histologic profiling of ANL, ALS and CLS skin lesions (n=10). Th2 and Th22
inflammatory mediators (IL-4, IL-10, IL-31, and IL-22), as well as several antimicrobial proteins
(AMPs), specifically the IL-22-regulated S100A7, S100A8, S100A9 and elafin, were significantly
upregulated in ALS (p<0.05), compared with ANL, while their expression levels slightly increased
from ALS to CLS. Th1 immune activation (IFN-gamma, IL-1B, IL-8, and MX-1) was gradually upreg-
ulated from ANL through CLS, although the increase was more evident between ALS and CLS. We
also found an upregulation of the Th17 axis (IL-17A, CCL20, and p40) in ALS, as compared to ANL.
The epidermal hyperplasia (measured by K16, thickness, and Ki67) significantly increased from ANL
through CLS. We also found significantly increased inflammatory cells, including T-cells (CD3+),
langerhans cells (CD1a+), inflammatory dendritic epidermal cells (IDECs), quantified by CD206+
and FCεR1+, and myeloid (CD11c+) and plasmacytoid (BDCA2+) dendritic cells, from ANL through
CLS. Our data shows that initiation of AD is mainly associated with an activation of Th2 and Th22
inflammatory responses and AMPs in ALS that continue to gradually increase through CLS. Thus,
gradual progression of immune responses through its chronic stage, rather than a Th2 to Th1 switch,
as was previously suggested, characterizes the AD immune phenotype, with important mechanis-
tic and therapeutic implications.
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Persistence of identical anti-Dsg 3 B cell clones in a pemphigus vulgaris (PV) patient for 4
years
CM Hammers,1 S Kacir,2 C Lin,1 AS Payne,1 D Siegel2 and JR Stanley1 1 Derm, Univ of Penn,
Philadelphia, PA and 2 Path Lab Med, Univ of Penn, Philadelphia, PA
PV is caused by anti-desmoglein 3 (Dsg3) antibodies. To determine whether there is an ongoing
loss of B cell tolerance to Dsg3 or if the same anti-Dsg3 clones persist, we used phage display to
characterize the anti-Dsg3 response from a PV patient at presentation and 4 years later at relapse
after remission induced by prednisone and mycophenolate. Antibodies and the B cells that pro-
duce them are considered clonal (i.e. from the same parent) if variable heavy chains (HCs) have the
same CDR3 sequence (i.e. have undergone identical VH-D-JH gene rearrangements). The entire HCs
were also completely sequenced to determine if they were identical or differed by somatic muta-
tions. We found an oligoclonal autoantibody response, with 5 clones at presentation and 4 clones
in relapse. Interestingly, 3 of the 4 clones in relapse were of the same clonal origin (i.e. had the same
CDR3 sequence) as clones found at presentation. Even more strikingly, these 3 clones had mem-
bers in which the entire HC sequences matched perfectly those in the initial library, indicating that
identical antibody HCs persisted over 4 years. One of the three clones had additional members in
which the HCs differed by somatic mutations from those found in the initial library. Though origi-
nal HC and light chain (LC) pairings are not necessarily preserved using the phage display approach,
LC gene usage was nearly 100% conserved between the repertoires of anti-Dsg3 antibodies ana-
lyzed at the 2 time points, although all 4 antibody clones in relapse had unique LC sequences in
their phage clones (showing these were not contaminating phage between libraries). These data
indicate that at least some PV patients do not have an ongoing loss of B cell tolerance to Dsg3 with
continual production of new autoantibody-producing clones, but most likely have had some event
that has caused loss of tolerance of a few B cells whose clones persist over time, which suggests
why aggressive initial therapy (e.g. with rituximab) that can eliminate the aberrant B cell clones is
so effective.
080
Carbon monoxide releasing molecule-2 inhibits the inflammatory response induced by tumor
necrosis factor-α in dermal fibroblasts
S Ward and D Yager Surgery, Virgina Commonwealth University, Richmond, VA
Wound pathologies such as chronic wounds are frequently associated with a persistent inflamma-
tory response. This is reflected by the accumulation of large numbers of inflammatory cells and ele-
vated levels of proinflammatory cytokines. The migration and infiltration of inflammatory cells is
partly dependent on the presence of cell-surface adhesion molecules such as ICAM-1 and VCAM-
1. In response to proinflammatory cytokines such as IL-1β and TNF-α, dermal fibroblasts abundantly
express ICAM-1 and VCAM-1. These cell adhesion markers very likely play an important role in the
recruitment and retainment of inflammatory cells. This study has begun to examine the effect of
carbon monoxide (CO) on the proinflammatory responses to TNF-α in these cells. Tricar-
bonyldichlororuthenium(II) dimer (CORM-2) is a metal-centered carbonyl that rapidly liberates CO.
Pretreatment of neonatal dermal fibroblasts with 250μM CORM-2 efficiently inhibited the TNF-α
induction of both ICAM-1 and VCAM-1 protein to less than 25% of the levels expressed by cells
treated with TNF-α only. Even addition of CORM-2 as much as 2 hr after induction with TNF-α
resulted in some inhibition of ICAM-1 expression (75% of levels expressed by cells treated with
TNF-α only). Pretreatment with CORM-2 significantly inhibited the TNF-α induction of IL-8 (30%
of the levels generated by cells treated with TNF-α only). This was also associated with an almost
complete abrogation in the levels of the gelatinase, MMP-2, that was released into the medium. Pre-
liminary evidence also indicates that CO may be acting by inhibiting signaling through the p38
mitogen-activated protein kinase. Together, these results indicate that a small, highly diffusible sig-
naling molecule has potential for ameliorating pathological inflammatory responses.
081
CD11c+ inflammatory dendritic cells and CD163+ macrophages are the main source of
TNF-alpha in chronic plaque-type psoriasis
PM Brunner, F Koszik, ML Kalb, B Reininger and G Stingl Dpt. of Dermatology, Medical
University of Vienna, Vienna, Austria
The spectrum of tumor necrosis factor (TNF)-alpha-producing cells as well as their fate during treat-
ment with TNF-alpha-antagonists is not clearly defined in psoriasis. The elucidation of these ques-
tions should allow us to better understand the mode of action, efficacy and, perhaps, also the risks
of an anti-psoriatic treatment with TNF-alpha-blockers. Using a tyramide signal amplification sys-
tem for anti-TNF-alpha labeling, we found TNF-alpha exclusively on dermal leukocytes co-express-
ing CD11c and HLA-DR and, to a much lesser extent, CD163. This marker profile is consistent with
that of mDCs and macrophages. Strikingly, we did not find TNF-alpha on keratinocytes or T cells.
Up to 16 hours after the intravenous administration of the TNF-alpha-antagonist infliximab, we found
no overt changes in the numbers of TNF-alpha-reactive cells, nor could we detect signs of com-
plement killing or apoptosis. Yet, we observed a rapid decrease of levels of mRNA encoding the
proinflammatory molecules IL-12p40, IL-1beta and CCL20 as well as IL12RB1, the common sub-
set of the IL-12 and the IL-23 receptor. It has to be determined whether these effects of anti-TNF-
alpha antagonists are due to an interference with either paracrine or even autocrine/juxtacrine
TNF-alpha signaling. Our data suggest that anti-TNF-alpha treatment not only results in decreased
tissue inflammation, but also in a down regulation of the pathogenic IL-12-/IL-23-driven immune
response.
082
Evaluation of the immunotoxicological potential of small molecular weight compounds in
THP-1 cells and primary monocyte-derived dendritic cells
K Sebastian,1 C Skazik-Voogt,1 H Ott,3 Y Marquardt,1 K Czaja,1 G Zwadlo-Klarwasser,2 JM Baron1
and HF Merk1 1 Dermatology and Allergology, University Hospital RWTH Aachen, Aachen,
Germany, 2 IZKF (BIOMAT), University Hospital RWTH Aachen, Aachen, Germany and 3
Pediatric Dermatology, Catholic Children Hospital Wilhelmstift, Hamburg, Germany
Skin is a major target organ for allergic reactions to small molecular weight compounds such as
contact allergic dermatitis or drug allergy. The aim of the study was to investigate the immunotox-
icological potential of small molecular weight compounds on gene expression alterations in human
antigen-presenting cells. Small molecular weight compounds such as antibiotics and strong con-
tact sensitizers were co-incubated with THP-1 cells and primary monocyte-derived dendritic cells
(moDCs) and subsequently expression of selected marker genes (cytokines IL-8 and IL-1β, enzymes
CES1, NQO1 and GCLM, transcription factors PIR and TRIM16) was studied by real-time PCR. We
determined that benzylpenicillin and phenoxymethylpenicillin are capable to induce the mRNA
expression of these genes in moDCs and except for IL-8 in THP-1 cells. However, we observed that
the pro-hapten sulfamethoxazol without metabolic activation is not able to induce gene expression
changes. Furthermore, we demonstrated that dimethylfumarate, which has become known as a
potent contact sensitizer, however without inducing delayed type allergic reactions after oral admin-
istration – e.g. in patients with psoriasis – inhibits the TNBS-, as well as the cinnamic aldehyde-
stimulated IL-8 and TRIM16 expression in moDCs. Here we demonstrate that the sensitizing poten-
tial of small molecular weight compounds can be measured in vitro using myeloid-/DC-like cells.
These in vitro methods could be helpful to predict the immunotoxicological potential of small molec-
ular weight compounds.
083
Hyaluronan small oligosaccharides regulate TLR3-dependent autoimmune inflammatory
responses
M Kim, J Muto and RL Gallo Division of Dermatology, University of California San Diego, San
Diego, CA
Fragments of Hyaluronan (HA) that are generated after injury have been proposed to be immunomod-
ulatory and active in regulation of inflammation. Previous studies have found that some of the pro-
inflammatory signals of injury are mediated by self-RNA through activation of TLR3. Conversely,
HA fragments released after injury may be immunosuppressive, since addition of HA to macrophages
before LPS (a ligand for TLR4) significantly decreased IL-6 and TNFα as well as suppressed the sep-
sis response in mice. In this study we investigated how HA may influence inflammation initiated by
TLR3 ligands. A pure, synthetic small MW form of HA (oHA) was added to MHS cells (mouse alve-
olar macrophage cell line) that were then activated by poly(I:C). ELISA analysis of culture super-
natants showed that when oHA was present with a TLR3 ligand, the presence of oHA suppressed
IL-6 (69.5%, p<0.01) and TNFα (53.36%, p<0.05) in comparison to poly(I:C) alone. IL-6 mRNA
expression was also suppressed (72.62%, p<0.001) as measured by qPCR. To determine how oHA
acts on macrophages, WT, TLR2 or TLR4 deficient mouse-derived macrophages were similarly treated
with oHA and poly(I:C). TLR2 deficient macrophages responded identically to wild-type (WT) cells
and still had suppression of inflammatory cytokines. However, TLR4 deficient macrophages were
no longer suppressed by oHA. The mechanism for inhibition by oHA involved molecules in the
downstream signaling pathway of TLR4. An increase in Traf1 mRNA was observed after oHA treat-
ment of WT cells but not in TLR4 deficient mice macrophages, and oHA did not inhibit cytokine
responsiveness in Traf1 deficient macrophages. Therefore, our results show that oHA that is released
after injury is an immunosuppressant that acts through TLR4 and TRAF1 to inhibit TLR3 dependent
inflammation. This observation illustrates the complex immunomodulatory action of innate immune
signaling systems and suggests novel approaches for influencing autoimmune disease.
084
Investigating the role of the transcriptional repressor Blimp1 in the interplay between adult
epithelial cells and the immune system
NA Roberts,1 W Cui2 and V Horsley1 1 Molecular, Cellular and Developmental Biology, Yale
University, New Haven, CT and 2 Immunobiology, Yale University, New Haven, CT
Immune cells play and important role in the regulation of skin biology during homeostasis and repair.
We have identified an inflammatory phenotype in mice that constitutively lack B lymphocyte induced
maturation protein 1 (Blimp1), a transcriptional repressor, in K14+ epithelial cells. We hypothesize
that this phenotype results from defects in the adult epidermis or in a role for Blimp1 in the devel-
opment, maintenance or function of medullary thymic epithelial cells, which also express K14. To
test these possibilities, we have examined the expression and function of Blimp1 in thymic epithe-
lial cells and the skin epithelium using mouse genetics, biochemistry and cell isolation techniques.
These studies will identify a novel role for Blimp1 in the interplay between adult epithelial cells
and the immune system.
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Oxidized fatty acids and inflammatory response in acne: A potential therapeutic role for
apolipoprotein A-I (apoA-I) mimetic peptide 4F as an anti-inflammatory agent
A Pirouz,1,2 M Qin,1,2 AM Fogelman1 and J Kim1,2,3 1 Medicine, David Geffen School of
Medicine at UCLA, Los Angeles, CA, 2 Dermatology, David Geffen School of Medicine at
UCLA, Los Angeles, CA and 3 Dermatology, Greater Los Angeles Healthcare System Veterans
Affairs, Los Angeles, CA
Lipid peroxidation products have been shown to play an important role in variety of inflammatory
conditions such as atherosclerosis, Alzheimer’s disease and pulmonary fibrosis. Lipid oxidation
resulting from oxidative stress has been also implicated in several dermatologic diseases including
acne. Oxidized lipids have been thought to contribute to pathogenesis of acne by inducing pro-
duction of pro-inflammatory cytokines through activation of peroxisome proliferators-activated
receptors (PPARs), augmenting P. acnes’ induction of inflammatory responses. To date, there is com-
pelling evidence that the ApoA-I mimetic 4F, whose structure is based on the helical repeating
domains of apoA-I has anti-inflammatory properties. 4F, an 18 amino acid amphipathic peptide,
has been shown to remodel high-density lipoprotein, sequester oxidized lipids, and activate an anti-
inflammatory process in macrophages. In this study we investigated the in-vitro effects of 4F on the
inflammatory response human peripheral blood mononuclear cells (PBMCs) and skin innate cells
when infected with P. acnes. Treatment of sebocytes and keratinocytes with 4F significantly reduced
the production of proinflammatory lipids, arachidonic acid and its downstream products, 9-HODE
and 15- HETE in response to infection with P. acnes. Pretreatment of PBMCs with 4F one hour prior
to infection potently suppressed P. acnes induced IL-1β secretion by 90% (p<0.01). There was no
significant suppression of other inflammatory cytokines including IL-6, IL-8, IL-12 or TNF-α, sug-
gesting a specific mechanism involving IL-1β. Our results demonstrate a promising anti-inflamma-
tory potential of 4F and point toward a novel approach in the treatment of acne as well as of vari-
ous other dermatologic diseases in which oxidized lipids promote inflammatory responses.
087
CD103-positive CD4+Foxp3+ T regulatory cells are necessary for optimal suppression of cuta-
neous inflammation
J Yoo,1 J McGuire,2 A Manicone,3 X Zhu,2 P Treuting,4 E Landis,1 T Birkland,3 L Johnston,3 V Lee,2,3
C Rims,2 Y Wang3 and W Parks3 1 Medicine (Dermatology), University of Washington, Seattle,
WA, 2 Pediatrics, University of Washington, Seattle, WA, 3 Medicine (Pulmonary and Critical
Care Medicine), University of Washington, Seattle, WA and 4 Comparative Medicine,
University of Washington, Seattle, WA
CD4+Foxp3+ T regulatory cells (Tregs) are critical suppressive cells of the immune system, pre-
venting autoimmunity and controlling inflammation. CD4+Foxp3+ Tregs that express the αE (aka
CD103) β7 integrin demonstrate a highly activated and suppressive phenotype and are relatively
abundant in the skin. We hypothesized that CD103-positive CD4+Foxp3+ Tregs are critical for the
optimal regulation of skin inflammation and sought to evaluate their importance and function
using CD103-deficient (Cd103-/-) mice. We observed Cd103-/- mice to have increased suscepti-
bility to both an ulcerative dermatitis seen spontaneously in C57BL/6J strains as well as an experi-
mentally induced contact hypersensitivity. Accounting for these phenotypes, we showed CD4+Foxp3+
Tregs from Cd103-/- mice to be functionally compromised as a function of age, with a nadir coin-
ciding in time with the onset of spontaneous dermatitis (around 4-6 months of age), as well as dur-
ing the sensitization phase of contact hypersensitivity. Finally, we observed that in vitro cross-link-
ing of CD103 directly promoted the activation and maturation of CD103-positive CD4+Foxp3+
Tregs, both alone and additive with TCR- and IL-2-mediated effects, via a mechanism that appears
to involve modulation of the JAK/STAT signaling pathway. We conclude that CD103 plays an early
and important costimulatory role in promoting cutaneous CD4+Foxp3+ Treg function and that
CD103-positive CD4+Foxp3+ Tregs are indeed a critical immunoregulatory population in cutaneous
immunity.
089
Comparison of the expression of cytokeratin 19, integrin α6 and β1 in normal and psoriatic
skin
M Zheng, W Li, X Man, J Zhou, J Chen and S Cai Dermatology, Second Affiliated Hospital,
Zhejiang University School of Medicine, Hangzhou, China
Epidermal stem cells are thought to be localized in the basal layer of epidermis and possess focally
expression. Up to date, many efforts have been devoted to explore reliable markers for epidermal
stem cells and many potential candidates are reported, including cytokeratin 19, integrin α6 and
β1. After defining the expression of cytokeratin 19, integrin α6 and β1 in normal and psoriatic skin
by immunofluorescence, we found that these proteins were widely expressed in normal and psori-
atic epidermis. Cytokeratin 19 and integrin α6 were detected in the whole basal layer and adjacent
suprabasal layers in healthy and psoriatic conditions, and integrin β1was stained in the whole basal
keratinocytes. Furthermore, cytokeratin 19, integrin α6 and β1 were all present in normal hair fol-
licular outer root sheath (ORS). In normal eccrine glands, cytokeatin 19 and integrin β1 were pos-
itive while integrin α6 not detectable. In addition, cytokeratin 19, integrin α6 and β1 were detected
nearly in all cultured normal human keratinocytes in vitro. Western blot also confirmed the expres-
sion of these three proteins in normal keratinocytes and there was no significant difference between
normal and psoriatic keratinocytes. Cytokeratin 19 and integrin α6, not β1, were also detected in
cultured dermal fibroblasts isolated from the same donors as keratinocytes. These data collectively
identify that the comprehensive distribution of cytokeratin 19, integrin α6 and β1 may not be spe-
cific epidermal stem cell markers.
088
Regulation of integrin α6 in scleroderma keratinocytes
W Li, X Man, J Chen, J Zhou, S Cai and M Zheng Dermatology, Second Affiliated Hospital,
Zhejiang University School of Medicine, Hangzhou, China
Scleroderma is a life-threatening autoimmune disease characterized by extensive fibrosis. This study
investigated the expression of integrin α6 in scleroderma epidermis. The localization and expres-
sion of integrin α6 were determined by immunofluorescence and Western blot separately. Our results
showed that integrin α6 was widely expressed in both normal and scleroderma epidermis, but the
distribution pattern was different. In normal epidermis, integrin α6 was mainly located on the basal
and suprabasal prickle layers, while in scleroderma epidermis, integrin α6 was mainly distributed
on granular layer and upper stratum spinosum, indicating that the scleroderma keratinocytes may
undergo a different process from normal keratinocytes. No difference of integrin α6 between healthy
and scleroderma keratinocytes was found by Western blot. In addition, the response of normal and
scleroderma keratinocytes to same cytokines were different. In normal keratinocytes, integrin α6
was highly upregulated by TGF-β1, endothelin-1(ET-1), interferon γ (IFN-γ), vascular endothelial
growth factor165 (VEGF165) and platelet-derived growth factor-BB (PDGF-BB). However, in scle-
roderma keratinocytes, integrin α6 was downregulated by these cytokines, except for IFN-γ. Inter-
estingly, tumor necrosis factor-α (TNF-α), which decreased integrin α6 in normal keratinocytes,
increased integrin α6 in scleroderma keratinocytes. IL-1β slightly promoted integrin α6 in normal
keratinocytes, but increased integrin α6 highly in scleroderma keratinocytes. IL-6 downregulated
integrin α6 in both normal and scleroderma keratinocytes. It seems that there is a cytokine network
to keep the balance of production of integrin α6 to maintain the homeostasis of epidermal ker-
atinocytes, both in normal and scleroderma keratinocytes, but they respond differently to the same
exogenous cytokine. The underlying mechanism needs further investigations.
086
Discoid lupus exhibits a weaker Th17- and stronger Th1- molecular signature when compared
with psoriasis
M Suarez-Farinas,2,3 J Duculan,3 J Gonzalez,4 AG Franks,5 JG Krueger2,3 and A Jabbari1 1
Dermatology, Columbia University, New York, NY, 2 CTSA, Rockefeller, New York, NY, 3
Laboratory for Investigative Dermatology, Rockefeller, New York, NY, 4 Translation Technology
Core, Rockefeller, New York, NY and 5 Dermatology, NYU, New York, NY
Discoid lupus erythematosus (DLE) represents a cutaneous form of lupus characterized by atrophic,
scaly plaques that can cause disfiguring scars and alopecia. Although the majority of patients with
DLE do not develop the progressive multi-system findings observed in systemic lupus (SLE), approx-
imately 25% of patients with SLE develop DLE. It is unclear whether DLE lesions are representative
of the pathologic dysfunction seen in other organ systems. Recent studies have focused on the role
of IL-17-producing Th17 cells in SLE. Elevated IL-17 levels and increased numbers of Th17 cells in
the serum/blood of SLE patients have been reported. Reduced autoimmune stigmata in animal lupus
models have been observed after ablation of IL-17-mediated signaling. We postulated that Th17
cells were present in DLE skin lesions and play a central role in the pathogenesis of DLE. We col-
lected biopsies from affected skin from 7 DLE patients. Psoriatic skin was used for comparison
because psoriasis is relatively well-characterized on a molecular level and because Th17 cells are
known to be present in the disease. Microarray and qPCR studies identified a diminished IL-17 sig-
nature in DLE lesions. Rather, a strong Th1 signature was identified, and infiltrating T cells (from 4
additional patient samples) were heavily skewed towards the Th1 subset. Furthermore, trends towards
increased Th1-associated CXCL9, 10 and 11, consistent with a strong type I interferon signature in
DLE, and diminished Th17-associated CCL20 were identified when compared with psoriasis. These
preliminary studies indicate that Th1, rather than Th17, cells are the predominant T cell population
in DLE lesions. We are currently conducting testing in mouse models to assess the efficacy of inter-
fering with Th1-associated pathways in the treatment of cutaneous lupus.
090
Differential regulation of Integrin α5 and β4 in normal and psoriatic epidermal keratinocytes
J Zhou, X Man, J Chen, W Li, S Cai and M Zheng Dermatology, Second Affiliated Hospital,
Zhejiang University School of Medicine, Hangzhou, China
Psoriasis is a common, chronic skin inflammation, characterized by impaired differentiation, hyper-
proliferation of epidermal keratinocytes. Integrins, a large group of adhesion molecules, play impor-
tant roles in proliferation, differentiation and adhesion of cells, and are associated with inflamma-
tion. The immunohistochemical analysis revealed that integrin α5 localized in the whole skin, except
for squamous layer in both normal and psoriatic epidermis. In normal epidermis, the expression of
α5 was very weak, but showed a relative concentration at the basal layer. In psoriasis, the distribu-
tion of α5 was almost homogenous in basal and prickle keratinocytes, and the immunoreaction
was much stronger than that in normal epidermis. Integrin β4 was detected in the membrane of
normal epidermal keratinocytes from basal to granular layers, while β4 being absent in the basal
and parakeratosis layer of psoriatic epidermis. Our results demonstrated that α5 in normal ker-
atinocytes was much less than in psoriatic keratinocytes (p<0.05). In normal keratinocytes, α5 was
upregulated by interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α) and interferon- γ (IFN-γ),
and β4 by IL-13 and IFN-γ. However, in psoriatic keratinocytes, α5 was decreased by these cytokines,
especially IL-17A. β4 was decreased by IL-13, IL-17A, TNF-α and IFN-γ, but increased by endothe-
lin-1 (ET-1). Furthermore, after incubated with U0126, expression of α5 was enhanced by these
cytokines in normal keratinocytes; while β4 decreased by IL-13, IL-17A and IFN-γ, but increased
by ET-1 and TNF-α. In psoriatic keratinocytes, with U0126, α5 was increased by IL-13, IL-17A and
ET-1, not altered by TNF-α, but decreased by IFN-γ. β4 was increased by IL-13, IL-17A and IFN-γ,
not altered by ET-1 and TNF-α. Our results suggest that IL-13, IL-17A, ET-1, TNF-α and IFN- γ may
regulate expression of α5 and β4 through ERK pathway in normal and psoriatic keratinocytes. The
same kind of cells under physiological or pathological conditions, may respond differently to the
same cytokines.
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Maximal TNFα-induced interleukin-8 in keratinocytes requires EGFR activation
VJ Maffei,1 KJ White1 and RA Swerlick1,2 1 Dermatology, Emory University School of Medicine,
Atlanta, GA and 2 Dermatology, Atlanta Veterans Affairs Medical Center, Decatur, GA
Tumor necrosis factor-α (TNFα) targeting antibodies yield remarkable clearance of the psoriatic phe-
notype. Mechanisms behind this response may involve targeting bone marrow derived immune cells
or involve direct effects on resident skin cells such as keratinocytes. Keratinocyte activation by TNFα
results in transactivation of the epidermal growth factor receptor (EGFR), activation of downstream
kinases, and keratinocyte cytokine expression that may drive psoriatic inflammation. Treatment of
HaCaT cells or primary human keratinocytes with TNFα rapidly induces interleukin (IL)-8 mRNA.
Co-treatment with TNFα and TGFα augments IL-8 induction. Blockade of EGFR members ErbB1
and ErbB2 by cetuximab and trastuzumab, respectively, inhibited TNFα-induced IL-8 mRNA and
protein upregulation supporting the role of EGFR activation in IL-8 expression. IL-8 mRNA inhibi-
tion via EGFR neutralization was a product of both reduced de novo transcription, as measured by
qPCR of IL-8 heteronuclear RNA, and IL-8 mRNA stability. TNFα-induced IL-8 expression was probed
for dependence on EGFR-mediated kinases extracellular release kinase 1 & 2 (ERK1/2) and p38
kinase. PD98059, a small molecule inhibitor of ERK1/2, dramatically reduced TNFα-stimulated IL-
8 mRNA whereas the p38 inhibitor SB203580 failed to block TNFα-induced IL-8 mRNA upregula-
tion. TNFα and TGFα also rapidly induced expression of activator protein-1 nuclear transcription
factors cFos and cJun that may bind to relevant enhancer elements of the IL-8 promoter. Inhibition
of ERK1/2 activation blunted TNFα-induced cFos and cJun expression. Furthermore, knockdown of
cJun via RNAi led to a 30-50% decrease in TNFα-induced IL-8 mRNA upregulation while cFos
knockdown had no effect. These data support a role for EGFR activation involving ErbB1, ErbB2
and ERK1/2 in TNFα-dependent expression of IL-8 in keratinocytes.
092
Involucrin in scleroderma epidermal keratinocytes
J Chen, X Man, W Li, J Zhou, S Cai and M Zheng Dermatology, Second Affiliated Hospital,
Zhejiang University School of Medicine, Hangzhou, China
Scleroderma (systemic sclerosis, SSc) is a complex disease featured with extensive fibrosis, vascu-
lar alterations and autoantibodies against various cellular antigens. The differentiation of scleoderma
epidermal keratinocytes is altered and results in a delay in maturation. Involucrin was identified as
a protein precursor of the cross-linked envelope which turns out to be an early differentiation marker
of the epidermal keratinocytes. In normal epidermis, involucrin locates in the upper spinous and
granular layers. In this study, we compared the expression of involucrin between scleroderma epi-
dermis and normal epidermis by using immunofluorescence(IF) assay and western blotting. In
addition, we investigate whether Inflammatory cytokines such as interleukins, transforming growth
factor(TGF)-β1, endothelin(ET)-1, interferon(IFN)-γ, vascular endothelial growth factor(VEGF) and
platelet-derived growth factor(PDGF)-BB, which up-regulated in scleroderma as reported, could
influence involucrin expression in both normal and scleroderma epidermal keratinocytes. We found
that no difference of the location of involucrin between scleroderma and normal epidermis. How-
ever, the protein level of involucrin from cultured scleroderma keratinocytes were much lower than
that in normal keratinocytes. Furthermore, IL-4, IL-6, IL-10, TGF-β, ET-1, IFN-γ, VEGF and PDGF-
BB (25 ng/ml) down-regulated involucrin at protein level after 24 hours in scleroderma keratinocytes,
while in normal keratinocytes, these cytokines up-regulated the involucrin protein level. In con-
clusion, the epidermal differentiation of scleroderma is abnormal, and this may be linked with inflam-
matory cytokines, such as IL-4, IL-6, IL-10, TGF-β1, ET-1, IFN-γ, VEGF and PDGF-BB.
093
Mast cells and neuropeptide expression are increased in erythematotelangiectatic rosacea in
comparison to telangiectatic photoaging
YR Helfrich,1 J Varani,1 G Fisher,1 C Hammerberg,1 A Bruce,2 A Lin,1 L Maier,1 D Sachs1 and
J Voorhees1 1 Dermatology, University of Michigan Medical School, Ann Arbor, MI and 2
Dermatology Associates, Portland, ME
Erythematotelangiectatic rosacea (ETR) and telangiectatic photoaging (TP) are both characterized
by facial erythema and telangiectasia, more on the central face in ETR and more lateral in TP. ETR
subjects also may complain of symptomatic flushing. We examined molecular differences between
ETR and TP to better understand these two conditions. Twenty-six subjects with ETR, 20 with TP,
and 11 controls were entered into the study. Punch biopsies were taken from involved facial skin
and from the lateral cheek of controls. We utilized immunohistochemistry, quantitative real-time
RT-PCR, light and electron microscopy. Mast cell tryptase was over 4-fold higher in ETR vs TP
(p=0.033) and control (p<0.0001). CXCR4, a receptor for mast cell chemoattractant CXCL12, was
4-fold higher in ETR vs TP(p=0.001). We also noted elevation of neuropeptides in ETR. Calcitonin
gene related peptide-α (CGRP-α ) was nearly 10-fold higher in ETR vs TP (p<0.0001); substance P
was nearly 5-fold higher (p=0.01). Both play a key role in perception of itching and pain in humans.
We also noted upregulation of matrix remodeling genes in ETR vs TP. We did not detect increased
mRNA for antimicrobial peptides LL-37 or human beta defensins-2 or -3 in ETR vs TP or control.
On light microscopy, we noted significantly greater actinic damage in TP(p=0.001). We also saw a
greater inflammatory infiltrate in ETR vs TP (p=0.016). Finally, we noted more sebaceous glands in
both ETR and TP than in controls (p<0.035). In conclusion, definite molecular distinctions exist
between ETR and TP. The symptomatic flushing that characterizes ETR may be related to increased
mast cells and increased neuropeptides such as CGRP-α and substance P. Our findings support
recent data showing increased matrix remodeling in various forms of rosacea and highlight the
importance of mast cells and neuropeptides in rosacea.
094
TGFβ1-dependent ERK activation through Smads signaling in Scleroderma dermal fibrob-
lasts
H Cao, X Man, J Zhou, J Chen, W Li, Q Lei, S Cai and M Zheng Dermatology, Second Affiliated
Hospital, Zhejiang University School of Medicine, Hangzhou, China
Transforming Growth Factor-beta1 (TGFβ1) plays a critical role in the processes of the skin dermal
fibrosis and ECM deposition in systemic sclerosis (SSc) via both canonical Smad and Smad-inde-
pendent pathways. It has been shown that extracellular signal-regulated kinases (ERK) is among
one of the most important Smad-independent signaling pathways. Despite recent advances in under-
standing the mechanism of fibrosis, the molecular mechanisms between TGFβ1 dependent ERK acti-
vation and Smad signaling have not been thoroughly elucidated. In this study, we found that the
basal level of phosphorylation of Smad1/2/3 and ERK was significantly increased in cultured SSc
fibroblasts than in normal control fibroblasts, indicating that both Smad and ERK are activated in
SSc fibroblasts. Furthermore, the Western blot results revealed increased level of connective tissue
growth factor (CTGF) and type I collagen (COL-I) in SSc fibroblasts could be decreased by activin-
receptor like kinases 5 (ALK5) inhibitor SB431542 and MER/ERK inhibitor U0126. Notably, either
pretreatment with U0126 or not before exogenously adding TGFβ1 did not affect TGFβ1-induced
phosphorylation of Smad1/2/3, whereas pretreatment with SB431542 increased ERK phosphoryla-
tion after TGFβ was added. These data support the hypothesis that Smads may act on upstream of
ERK or in a parallel pathway, ALK5 inhibitor may increase ERK phosphorylation by a negative feed-
back system in dermal fibroblasts. Accordingly, we try to clarify the mechanisms of this negative
feedback system, and provide a more selective way in blocking the profibrotic effects of TGFβ1
dependent Smad pathway while preventing ERK phosphorylation.
095
Increased depression in cutaneous lupus erythematosus compared to the general population
and dermatomyositis
ER Ghazi,1,2,3 MA Kling,1,4 K Propert,5 J Okawa1,2 and VP Werth1,2 1 Philadelphia VA Medical
Center, Philadelphia, PA, 2 Dermatology, University of Pennsylvania, Philadelphia, PA, 3
UMDNJ-RWJMS, Piscataway, NJ, 4 Psychiatry, University of Pennsylvania, Philadelphia, PA
and 5 Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
The aim of this cross-sectional study was to compare depression and anxiety between cutaneous
lupus erythematosus (CLE) and the general population, and between CLE and dermatomyositis (DM).
52 CLE and 43 DM participants were enrolled. The Patient Health Questionnaire 9 (PHQ-9) deter-
mined major depressive symptoms, with ≥5 indicating at least mild depression and ≥10 indicating
at least moderate depression. The Depression Anxiety and Stress Scale 21 (DASS), with depression
(DASS-D) and anxiety (DASS-A) subscales, captured these mood dimensions. The PHQ-9 and DASS-
D assess overlapping but not identical depressive features. The median PHQ-9 score for CLE [6.5,
Interquartile range (IQR) =8] was significantly greater than DM’s median [3, IQR=5; Wilcoxon rank
sum (WRS) P=0.02]. 57.7% of CLE patients had at least mild depression, vs. 37.2% of DM and
21.6% of the general population. 34.6% of CLE had at least moderate depression, vs. 16.3% of DM
and 6.9% of the general population. CLE had significantly higher rates for both mild and moderate
PHQ-9 cutoffs vs. the general population (χ2=40.0, P=0.0001 for ≥5; χ2=61.9, P=0.0001 for ≥10).
The CLE medians for the DASS-D (4, IQR=11) and DASS-A (5, IQR=8) were higher than historic
controls (DASS- D and A medians=2.0; Wilcoxon signed ranks P=<0.001 for both). The medians
for the DM DASS-D (2, IQR=8) and A (4, IQR=10) did not differ from CLE (WRS P value for DASS-
D= 0.34; DASS-A= 0.45). This may reflect the PHQ-9’s focus on diagnostic criteria and inclusion
of somatic symptoms vs. the DASS-D’s focus on emotion and cognitive distortions. There was no
difference in PHQ-9 scores between CLE only and CLE/systemic lupus erythematosus groups (WRS
P=0.11). In conclusion, CLE patients have more depression and anxiety compared to controls and
more depression than DM on PHQ-9 testing.
096
Slow clinical response to combined treatment with rituximab and low dose steroid in two
cases of recalcitrant epidermolysis bullosa acquisita
W Fujimoto, H Hayashi and S Sasaoka Dermatology, Kawasaki Medical School, Kurashiki,
Japan
Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal bullous disease of the skin
and mucous membrane characterized by the presence of autoantibodies against type VII collagen.
We report clinical response and autoantibody profiles in 2 patients with mechanobullous EBA treated
with rituximab and low dose steroid. Autoantibodies against type VII collagen were examined by
Anti Type VII collagen ELISA kit (MBL. Co., Ltd. Tokyo). Case 1, a 60-year-old Japanese man with
diabetes mellitus diagnosed with EBA 4 years previously and case 2, a 73-year-old Japanese man
diagnosed with EBA 1.5 years previously. Both patients had bullous and erosive lesions of the oral
mucosa and esophagus. The hands, elbows, shins, buttocks, and feet showed skin fragility with
flaccid blisters and erosions. With a history of non-response to several long-term immunosuppres-
sive treatment regimens, both patients received 4 courses of intravenous rituximab therapy (375
mg/m2 of body surface) in biweekly intervals. Treatment with low dose prednisolone (10mg/d) or
betamethasone (1mg/d) with colchicine (1mg/d) was continued. Skin and oral lesions improved
quite slowly after 67 weeks in case 1, while oral lesions and the lesions on hands and face showed
slight improvement after 37 weeks in case 2. Anti-type VII collagen antibody ELISA index values
declined consecutively from 106.3 to 20.0 in case 1 and from 125.4 to 26.5 in case 2, respectively.
Levels of serum IgG were maintained over 750 mg/dl and no adverse effect was observed in both
patients. Although skin fragility still remains in both patients, the rituximab treatment combined with
low dose steroid may be a safe, valuable adjuvant treatment regimen for recalcitrant mechanobul-
lous EBA. Slow response in both patients irrespective of consecutive decline of anti-type VII colla-
gen autoantibody titers might suggests strong affinity of low-titer autoantibodies for type VII colla-
gen in the epidermal basement membrane of cases with mechanobullous EBA.
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Human epidermal Langerhans cells replenishing skin xenografts are depleted by alloreactive
T cells in vivo
RE Schopf,1 J Hemmerling,2 J Wegner-Kops,1 E von Stebut-Borschitz,1 EM Wagner,2 UF Hartwig,2
MC André2 and RG Meyer2 1 Dermatology, Johannes Gutenberg Univ., Mainz, Germany and
2 Hematology, Johannes Gutenberg Univ., Mainz, Germany
Epidermal Langerhans cells (LC) are potent APCs surveying the skin. They are crucial regulators of
T cell activation in the context of inflammatory skin disease and graft-versus-host disease (GVHD).
In contrast to other dendritic cell subtypes, murine LC are able to reconstitute after local depletion
without the need of peripheral blood-derived precursors. Using an experimental model of human
skin grafted to NOD-SCID IL2Rγ(null) mice we have previously shown that xenografting leads to
the transient loss of LC from the human skin grafts and despite the lack of a human hematopoietic
system, human LC repopulated the xenografts 6 to 9 wk after transplantation. By staining of LC with
the proliferation marker Ki67, we show that one third of the replenishing LC exhibit proliferative
activity in vivo. We further used the skin xenograft as an in vivo model for human GVHD. HLA-dis-
parate third-party T cells stimulated with skin donor-derived dendritic cells were injected intra-
venously into NOD-SCID IL2Rγ(null) mice that had been transplanted with human skin. The appli-
cation of alloreactive T cells led to erythema and was associated with histological signs of GVHD
limited to the transplanted human skin. The inflammation also led to the depletion of LC from the
epidermis. Our data provide evidence that human LC are able to repopulate the skin independent
of blood-derived precursor cells and that this at least partly relates to their proliferative capacity.
Our data also propose xeno-transplantation of human skin as a model system for studying the role
of skin dendritic cells in the efferent arm of GVHD.
099
Rituximab decreases all anti BP180 IgG subclasses in patients with refractory bullous pem-
phigoid(BP)
A Ronaghy, RD Streilein and RP Hall Dermatology, Duke Univ, Durham, NC
BP is an autoimmune blistering disease with pathogenic IgG antibodies against the BP180 NC 16A
domain (type XVII collagen). IgG subclass analysis has revealed that IgG4 anti-BP180 is the pre-
dominant, but not the only, pathogenic autoantibody subclass. Refractory BP patients have a vari-
able response to rituximab treatment with a decrease, but not a disappearance, of total IgG anti-
BP180 antibodies. Rituximab has been reported to preferentially target IgG4 associated diseases.
We hypothesized that treatment with rituximab would result in a preferential decrease in IgG4 anti-
BP180 antibodies. Total and IgG1, 2, 3, & 4 anti-BP180 antibodies were detected by ELISA (MBL,
Woburn, MA) from the sera of 6 refractory BP patients treated with rituximab and 20 control sub-
jects (10 healthy; 10 unrelated skin disease; none with anti-BP180 antibodies). The sera were ana-
lyzed at time 0 (before treatment), day 14, months 1-6, 9, and 12. Before therapy, all 6 subjects had
total IgG anti-BP180 specific IgG antibodies (mean 739.9 U/ml, range 37-3556; normal < 9 U/ml).
Pre-treatment subclass analysis revealed 5 of 6 subjects had IgG1 (mean 135.3 U/ml, range 12.5-
384.1), 5 of 6 IgG2 (mean 1311.8 U/ml, range 8.7-6152.4), 2 of 6 had IgG3 (mean 29 U/ml, range
12.3-45.6), and 4 of 6 had IgG4 (mean 464.3 U/ml, range 29.2-950) anti-BP180 specific antibod-
ies. Total IgG anti-BP180 antibodies decreased to a mean of 23.4 U/ml (28.5% of pre-treatment (T0))
at a mean of 9.5 months post infusion (range 6–12 months). IgG1 decreased to 3.9 u/ml (13.6% T0)
at 10.2 months (range 6-12 months), for IgG2 25.2 u/ml (23.4% T0) at 8.2 months (range 5-12
months), for IgG3 1.5 u/ml (3.2% T0) at 3 months(range 3 months), and IgG4 decreased to 30.6 u/ml
(4.3%T0) at 8.3 months (range 3-12 months). The time to reach minimum antibody levels and the
amount of antibody reduction among IgG anti-BP180 subclass values was not found to be signifi-
cantly different from total IgG anti-BP180 after rituximab therapy. This study suggests that rituximab
therapy does not have a preferential effect on specific IgG subclasses of anti-BP180 antibodies.
101
Human monocytic Myeloid-Derived Suppressor Cells (MDSC) are increased in the peripheral
blood of psoriatic patients
DC Soler,1 A Young,1 J Golden,1 TS McCormick1 and KD Cooper1,2 1 Dermatology, Case Western
Reserve University, Cleveland, OH and 2 VA Medical Center, Cleveland, OH
Psoriasis appears to involve defects of regulation of immune responses, including Regulatory T
cells (Tregs). Recently, a newly discovered immuno-regulatory cell, the Myeloid Derived Suppres-
sor Cell (MDSC), first described in cancer patients and belonging to the myeloid arm of the immune
system, have been shown to possess T-cell suppressive mechanisms and the ability to induce Tregs.
Using fresh peripheral blood mononuclear cells from either psoriasis patients or non-psoriatic con-
trol volunteer subjects, we noted a trend toward reduction in Mean Fluorescence Intensity of HLA-
DR on CD14+ monocytes from psoriatic individuals, suggesting that psoriasis patients may have a
higher proportion of MDSCs. Indeed, we observed a statistically higher proportion of CD14+HLA-
DRlow cells in psoriatic patient peripheral blood compared to non-psoriatic controls (26% vs 13%,
n=6, p=0.04). To verify that CD14+ HLA-DRlow cells (bottom 10%) were MDSCs, we added either
psoriatic or non-psoriatic control CD14+ HLA-DRlow cells to anti-CD2/CD3/CD28 bead-stimu-
lated CD8 cells previously labeled with the cell proliferation dye eFluor® 670. The percentage of
T cells proliferating without MDSC’s was 42%, whereas addition of either normal or psoriatic MDSC’s
resulted in 17% and 28% proliferation, respectively. These results suggest that immunoregulatory
monocytic CD14+ HLA-DRlow MDSC are increased in psoriatic patients compared to healthy
controls, raising the possibility of multiple regulatory cellular components that might influence the
psoriatic immunologic milieu.
100
Spectratype analysis of Alopecia Areata T cells identifies an oligoclonal population of CD8
effector T cells
A de Jong,1 J O’Malley,1 Z Dai,1 M Kurban,1 A Jabbari,1 J Mackay-Wiggan,1 AM Christiano1 and
R Clynes2 1 Dermatology, Columbia University Medical Center, New York, NY and 2 Medicine,
Columbia University Medical Center, New York, NY
Alopecia Areata (AA) is a common organ-specific autoimmune disease that is characterized by non-
scarring hair loss. T cells are thought to be the main pathogenic effectors in AA, since they infiltrate
the hair follicles in active disease and can transfer disease in mouse models of AA. In contrast to
other human autoimmune diseases, the target organ is highly accessible in AA, yet no studies of
hair follicle infiltrating T cells have been undertaken. To gain more insight into AA immunopatho-
genesis, we isolated infiltrating T cells from microdissected perilesional AA hair follicles, and ana-
lyzed the T cell receptor (TCR) repertoire by a combination of CDR3 length analysis and high through-
put sequencing. Preliminary analysis shows that follicular T cell populations are highly oligoclonal,
expressing only a limited set of TCRs. This oliclonality suggests an antigen driven component in AA,
which will be further assessed by the analysis of TCR specificity of infiltrating T cell clones, using
autologous dendritic cells and hair follicle lysate. Ultimately, these approaches are aimed at iden-
tification of specific AA autoantigens. Our preliminary studies in C3H-HeJ mice have shown that
the majority of TCR Vβ expansions detected in alopecic skin are contained in the NKG2D+ CD8+
T cell population of skin draining lymph nodes, supporting the notion that this circulating T cell sub-
set harbors pathogenic effector cells. In human AA, similar comparisons of TCRs from hair follicle
infiltrating T cells and peripheral blood T cell subsets will allow us to pinpoint circulating effector
cells for use as a biomarker during the clinical course of disease, as well as for immunomonitoring
during clinical trials.
098
The up-regulation of cyclic AMP in monocytes inhibit the differentiation to multinualeated
giant cells
K Mizuno, M Osawa, H Tanimura, F Yamazaki and H Okamoto Department of Dermatology,
Kansai Medical University, Moriguchi, Japan
Multinucleated giant cells (MGC) are characteristic cells in granulomatous disorders and derived
from monocyte-macrophage lineage cells. The exact mechanisms of the formation and the func-
tional significance of MGC are not determined. Cyclic adenosine monophosphate (cAMP) is the
intracellular second messenger for various immunoregulatory mediators and plays a key role in
regulation of monocyte-macrophage-mediated inflammatory responses. Here we examined the
effects of cAMP on in vitro formation of MGC from human monocytes. When monocytes were cul-
tured with concanavalin A-stimulated mononuclear cell supernatants (conditioned medium), Lang-
hans-type and foreign body-type MGC were formed on day 3. When a phosphodiesterase inhibitor,
forskolin, was added, the MGC formation was significantly suppressed. MGC formation is a com-
plex event involving plasma membrane receptors that are responsible for adhesion, activation and
the actual fusion process. Monocytes cultured with conditioned medium highly expressed CD11a
and CD54. The addition of forskolin decreased the expression of these adhesion molecules. P2X7
receptor belongs to the purinergic receptor family and is supposed to play a central role in the last
step of MGC formation. Forskolin also inhibited the expression of P2X7 receptor on monocytes cul-
tured with conditioned medium. These findings indicate that up-regulation of cAMP in human mono-
cytes directly inhibited the MGC formation, suggesting that cAMP is a mediator of the granuloma
formation.
102
Epidermal control of psoriasis like skin inflammation by a TNF-α and IL-24 dependent mech-
anism
S Kumari,1 M Pasparakis,2 R Sabat3 and I Haase1 1 Dept. of Dermatology, University of Cologne,
Cologne, Germany, 2 Institute of Genetics, University of Cologne, Cologne, Germany and 3
Institute of Immunology, Humboldt- University Berlin, Berlin, Germany
TNF-α is a key cytokine in the pathogenesis of psoriasis and polymorphisms within the TNF-α /
NFκB signaling pathway are known to be associated with this disease. Mice with epidermis spe-
cific deletion of I kappa B Kinase 2 (IKK2), a kinase essential for normal activation of NFκB signal-
ing, develop a severe, psoriasis like inflammatory skin disease shortly after birth. Here we demon-
strate that in these mice epidermal keratinocytes initiate the psoriasis like inflammatory skin disease
by producing large amounts of IL- 19 and IL- 24 in a TNF-α dependent manner. This is followed by
the sequential expression of various cytokines and chemokines in the epidermis and dermis thus
directing inflammation specifically towards an innate immune response of the skin. Comparison of
the pattern of epidermis derived cytokines between inflamed murine skin and human psoriatic skin
revealed a high degree of similarity. Inhibition of IL- 19 signaling by targeted deletion of the IL20
receptor chain I attenuates the inflammatory skin phenotype; inhibition of IL- 24 signaling by dele-
tion of the IL22 receptor chain I abrogates it. In vitro studies with IKK2 deficient epidermal ker-
atinocytes revealed that the absence of IKK2 results in an augmented production of IL-24 and other
cytokines in response to TNF-α, but not IL-1β. Our results unequivocally demonstrate that the pso-
riasis like skin disease in our model is the consequence of an altered response of epidermal ker-
atinocytes to TNF-α which involves IL-24 as a central pathogenic cytokine.
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Ceramide deficiency in the epidermis leads to development of psoriasis-like lesions associ-
ated with IL-23-dependent proliferation of γδ-17 cells
K Nakajima,1 S Kataoka,1 N Goto-Inoue,2 M Terao,3 H Murota,3 H Azukizawa,3 M Setou,4
I Katayama,3 J Takeda5 and S Sano1 1 Department of Dermatology, Kochi University, Kochi,
Japan, 2 Grad. Sch. Health Promotion Sciences, Tokyo Metropolitan University, Tokyo, Japan,
3 Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan,
4 Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine,
Hamamatsu, Japan and 5 Department of Social and Environmental Medicine, Osaka
University Graduate School of Medicine, Osaka, Japan
It has been recognized that ceramide levels are decreased in the epidermis of patients with atopic
dermatitis and psoriasis. However, the underlying mechanism by which ceramide deficiency leads
to skin inflammation still remains unclear. Here, we generated Sptlc2 targeted mice under control
of the keratin 5 promoter (referred to as K5-SPT-KO mice), by which their keratinocytes were devoid
of serine palmitoyltransferase (SPT), the rate-limiting enzyme for de novo sphingolipid synthesis.
K5-SPT-KO mice have decreased levels of ceramide in the epidermis, with aberration of lamellar
bodies, and these mice demonstrate lower water-holding capacity and barrier dysfunction. From 2
weeks of age, they develop skin inflammation, showing psoriasis-like histopathologic changes,
including hyperkeratosis, acanthosis, and inflammatory cell infiltrates in the dermis. While expres-
sion of IFN-γ was not observed in the inflamed skin and draining lymph nodes, increased levels of
IL-17 and IL-22 were detected. Strikingly, K5-SPT-KO mice showed increased numbers of γδ-T cells
that produce IL-17 (γδ-17) in the skin lesion and lymph nodes and most of them also produce IL-
22, similar to Th17 cells. However, much fewer γδ-17 cells are detected in the skin and lymph nodes
of wild-type mice. In vivo administration of anti-IL-12/23p40 antibody ameliorated the skin lesions
and reduced the number of γδ-17 cells in K5-SPT-KO mice. Therefore, we conclude that ceramide
deficiency in the epidermis results in the development of psoriasis-like lesions, likely mediated by
IL-23-dependent γδ-17 cells in mice.
104
IL-15 is a therapeutic target in human alopecia areata
L Xing,2 Z Dai,1 W Gong,1 A Jabbari,1 A de Jong,1 S Harel,1 AM Christiano1 and R Clynes2 1
Dermatology, Columbia University, New York, NY and 2 Immunology, Columbia University,
New York, NY
Alopecia areata (AA) results from autoimmune attack by T cells that invade the hair follicle (HF).
The local factors that drive the activation of self-reactive T cells remain unknown and identification
of these end-organ precipitants would define new therapeutic opportunities. Given our recent
identification of CD8+NKG2Dhi T cells as key effectors in the HF infiltrate in human AA, here we
have investigated the role of IL-15, a well-known driver of CD8 killer T cell activation and expan-
sion. Using human skin biopsies from AA subjects, we determined that IL-15 and its obligate chap-
erone IL-15Rα are both massively upregulated in the outer root sheaths of AA HFs, where their co-
expression provides direct engagement of dermal IL-15β receptor-bearing CD8 T cells. Moreover,
we identified IL-15 as a novel serum biomarker in AA subjects. The identical situation was seen in
the C3H/HeJ AA mouse model, in which IL-15 production was found together with NKG2DhiCD8+
T cells in HF infiltrates. Spectratype analysis of the NKG2D+CD8+ T cell population in draining
lymph nodes defined an oligoclonal population that encompassed the entire TCR repertoire seen
in lesional skin, identifying these cells as the dominant HF-specific pathogenic T cell subset. To
investigate the therapeutic relevance of these findings, we evaluated two distinct IL-15 targeted
approaches in the AA graft model. Treatment of AA graft recipients with either anti-IL-15Rβ mAb
blockade or a small molecule inhibitor of the JAK3 kinase, tofacitinib, completely prevented hair
loss in all treated mice (n=8 mice/group). Moreover, anti-IL-15 treatment eliminated the pathogenic
CD8+NKG2Dhi cells from the circulation and dramatically down-regulated inflammatory biomarkers
in the skin, including MHC molecules and the AA-associated IFN signature. Thus our studies demon-
strate, for the first time, a critical role for local production of IL-15 in AA pathogenesis in driving
the activation of alopecic T cells and provide proof-of-concept data for these targets in the treat-
ment of human AA.
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The role of ALK5 in production of CTGF in psoriatic dermal fibroblasts
Q Lei, X Man, J Zhou, W Li and M Zheng Dermatology, Second Affiliated Hospital, Zhejiang
University School of Medicine, Hangzhou, China
Psoriasis is a common, chronic inflammatory and proliferative skin disease. Previous studies focus
on the keratinocytes of psoriatic epidermis, but recent studies indicated that dermal fibroblasts
(Fibroblasts, FB) are also abnormal during the pathogenesis of psoriasis, which may be one impor-
tant factor in initiating psoriasis. Transforming growth factor beta 1 (TGFβ1) is a multifunctional
cytokine that regulates cell growth, differentiation and extracellular matrix formation. TGFβ1 play
a key role during fibrosis. Numerous studies have demonstrated overexpression of TGFβ1 in skin
lesions and serum of psoriatic patients, suggesting that TGFβ1 signal pathway involved in the
pathogenesis of psoriasis. In this study, we cultured dermal fibroblasts of normal and psoriatic skin.
The results showed that in normal and psoriatic fibroblasts, TGFβ1 significantly induced phospho-
rylation of Smad1 and Smad2. The ALK5 inhibitor, SB431542, and MEK inhibitor, U0126, abolished
TGF-β1-induced phosphorylation. The signal of pSmad1 and pSmad2 were significantly stronger in
psoriatic fibroblasts than in normal fibroblasts, suggesting that TGF-β1/smads signal in psoriatic
fibroblasts undergo abnormalities. Connective tissue growth factor (CTGF) is known to play an impor-
tant role in fibrosis. Our results showed that TGF-β1 significantly upregulated the production of
CTGF in psoriatic fibroblasts. ALK5 inhibitor, SB431542, abated TGF-β1-induced upregulation of
CTGF, while MEK inhibitor, U0126, showed no effect, indicating that TGF-β Type I receptor (TGF-
RI/ALK5) kinase is essential for the TGFβ1-induced upregulaton of CTGF in psoriatic fibroblasts.
Based on above, we concluded that psoriatic dermal fibroblasts may also play a role in the patho-
genesis of psoriasis. TGF-β1-induced fibrosis in psoriasis is mediated via TGFRI/smads signaling
pathway.
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Glucocorticoid receptor localizes to adherens junctions at the plasma membrane of ker-
atinocytes
I Pastar, O Stojadinovic, A Shawaya and M Tomic-Canic Dermatology, University of Miami
Miller School of Medicine, Miami, FL
Recently, we demonstrated constitutive epidermal cortisol synthesis that is induced by various stress
and tissue injury. Glucocorticoids are important regulators of epidermal tissue homeostasis that exert
their effect by binding to glucocorticoid receptor (GR), which directly regulates gene expression
(genomic effect) or mediates effects via cell signaling that do not involve gene transcription (non-
genomic). Although genomic effects of GR in the epidermis are well documented, the non-genomic
effects are not completely understood. Therefore, we utilized immunostaining and immunoprecip-
itations to determine specific localization of the GR in human keratinocytes that may contribute to
non-genomic effects of GR action. Unexpectedly, we found that GR localizes to the plasma mem-
brane of keratinocytes. Immunocytochemistry showed co-localization of GR with E-cadherin, and
immunoprecipitation of the membranous fraction revealed an association of GR with alpha-catenin,
confirming its localization to adherens junctions. We conclude that GR localization to adherens
junctions of keratinocytes may provide a new mechanism of non-genomic signaling by glucocorti-
coids which has significant biological and clinical impact.
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Response to self antigen imprints regulatory memory in the skin
M Rosenblum,1 I Gratz,2 J Paw,1 H Truong1 and A Abbas2 1 Dermatology, UCSF, San Francisco,
CA and 2 Pathology, UCSF, San Francisco, CA
The mammalian immune system exists in a state of balance in which responses to an array of
microbial antigens are permitted but reactions against self antigens are suppressed. In large part,
the establishment and maintenance of this balance is the result of a finely tuned equilibrium between
effector T lymphocytes and regulatory T lymphocytes (Tregs). Understanding how this equilibrium
is maintained and why it fails is central to understanding the pathogenesis of autoimmunity. We
established a novel mouse model of skin inflammation in which tissue antigen is expressed consti-
tutively in the thymus and inducibly in the skin, allowing us to closely study immune responses in
the skin upon induction of ‘self antigen’ expression. We show that exposure of antigen-specific
CD4+ T cells to self antigen expressed in the thymus results in ~40% of the T-cells developing into
Tregs. When antigen is induced in the skin, a severe inflammatory dermatitis develops which resolves
spontaneously. Resolution is mediated by Tregs being activated in response to recognition of self
antigen expressed in the skin, resulting in a marked increase in their regulatory function. Some of
the Tregs survive in the skin as a population of memory Tregs (mTregs), which protect against inju-
rious responses upon subsequent exposures to the antigen. The establishment and maintenance of
mTregs may be a fundamental mechanism by which tissues such as the skin regulate inflammatory
reactions, and understanding how these cells are generated and maintained might provide new ther-
apeutic approaches for human autoimmune and inflammatory diseases.
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